View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($) $ in Billions	12 Months Ended
Document and Entity Information - USD ($) $ in Billions	Dec. 31, 2017	Feb. 15, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Trading Symbol	XON
Entity Registrant Name	INTREXON CORP
Entity Central Index Key	0001356090
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		129,066,114
Entity Public Float			$ 1.4

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets
Cash and cash equivalents	$ 68,111	$ 62,607
Restricted cash	6,987	6,987
Short-term investments	6,273	174,602
Equity securities	5,285	0
Receivables
Trade, net	19,775	21,637
Related parties, net	17,913	16,793
Notes, net	0	1,500
Other	2,153	2,555
Inventory	20,493	21,139
Prepaid expenses and other	7,057	7,361
Total current assets	154,047	315,181
Long-term investments	0	5,993
Equity securities, noncurrent	9,815	23,522
Investments in preferred stock	161,225	129,545
Property, plant and equipment, net	112,674	64,672
Intangible assets, net	232,877	225,615
Goodwill	153,289	157,175
Investments in affiliates	18,870	23,655
Other assets	4,054	3,710
Total assets	846,851	949,068
Current liabilities
Accounts payable	8,701	8,478
Accrued compensation and benefits	6,474	6,540
Other accrued liabilities	21,080	15,776
Deferred revenue	42,870	53,364
Lines of credit	233	820
Current portion of long term debt	502	386
Deferred consideration	0	8,801
Related party payables	313	440
Total current liabilities	80,173	94,605
Long term debt, net of current portion	7,535	7,562
Deferred revenue, net of current portion	193,527	256,778
Deferred tax liabilities, net	15,620	17,007
Other long term liabilities	3,451	3,868
Total liabilities	300,306	379,820
Commitments and contingencies (Note 17)
Total equity
Common stock, no par value, 200,000,000 shares authorized as of December 31, 2017 and 2016; and 122,087,040 shares and 118,688,770 shares issued and outstanding as of December 31, 2017 and 2016, respectively	0	0
Additional paid-in capital	1,397,005	1,325,780
Accumulated deficit	(847,820)	(729,341)
Accumulated other comprehensive loss	(15,554)	(36,202)
Total Intrexon shareholders' equity	533,631	560,237
Noncontrolling interests	12,914	9,011
Total equity	546,545	569,248
Total liabilities and total equity	$ 846,851	$ 949,068

Consolidated Balance Sheets (Parenthetical) - shares	Dec. 31, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	122,087,040	118,688,770
Common stock, shares outstanding	122,087,040	118,688,770

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues
Collaboration and licensing revenues, including $130,670, $93,792, and $77,354 from related parties in 2017, 2016, and 2015, respectively	$ 145,579	$ 109,871	$ 87,821
Product revenues	33,589	36,958	41,879
Service revenues	50,611	43,049	42,923
Other revenues	1,202	1,048	982
Total revenues	230,981	190,926	173,605
Operating Expenses
Cost of products	33,263	37,709	40,746
Cost of services	29,525	23,930	23,183
Research and development	143,207	112,135	147,483
Selling, general and administrative	146,103	142,318	109,057
Impairment loss	16,773	0	0
Total operating expenses	368,871	316,092	320,469
Operating loss	(137,890)	(125,166)	(146,864)
Other Income (Expense), Net
Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock	2,586	(58,894)	66,876
Interest expense	(611)	(861)	(1,244)
Interest and dividend income	19,485	10,190	1,884
Other income, net	1,013	1,700	1,314
Total other income (expense), net	22,473	(47,865)	68,830
Equity in net loss of affiliates	(14,283)	(21,120)	(8,944)
Loss before income taxes	(129,700)	(194,151)	(86,978)
Income tax benefit (expense)	2,880	3,877	(1,016)
Net loss	(126,820)	(190,274)	(87,994)
Net loss attributable to the noncontrolling interests	9,802	3,662	3,501
Net loss attributable to Intrexon	$ (117,018)	$ (186,612)	$ (84,493)
Net loss attributable to Intrexon per share, basic and diluted	$ (0.98)	$ (1.58)	$ (0.76)
Weighted average shares outstanding, basic and diluted	119,998,826	117,983,836	111,066,352

Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Collaboration and licensing revenues	$ 145,579	$ 109,871	$ 87,821
Related Parties, Aggregated
Related Party Transaction [Line Items]
Collaboration and licensing revenues	$ 130,670	$ 93,792	$ 77,354

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement of Comprehensive Income [Abstract]
Net loss	$ (126,820)	$ (190,274)	$ (87,994)
Other comprehensive income (loss):
Unrealized gain (loss) on investments	87	430	(561)
Gain (loss) on foreign currency translation adjustments	20,599	(23,901)	(12,108)
Comprehensive loss	(106,134)	(213,745)	(100,663)
Comprehensive loss attributable to the noncontrolling interests	9,764	3,683	3,422
Comprehensive loss attributable to Intrexon	$ (96,370)	$ (210,062)	$ (97,241)

Consolidated Statements of Shareholders' and Total Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total Intrexon Shareholders' Equity	Noncontrolling Interests
Beginning balance at Dec. 31, 2014	$ 409,289	$ 0	$ 843,001	$ (4)	$ (458,236)	$ 384,761	$ 24,528
Beginning balance, shares at Dec. 31, 2014		100,557,932
Changes in Stockholders' Equity
Stock-based compensation expense	38,688		38,507			38,507	181
Exercises of stock options and warrants	14,462		14,462			14,462	0
Exercises of stock options and warrants, shares		1,148,463
Shares issued as payment for services	2,169		2,169			2,169	0
Shares issued as payment for services, shares		70,925
Shares issued in public or private offerings, net of issuance costs	328,234		328,234			328,234	0
Shares issued in public or private offerings, net of issuance costs, shares		9,922,256
Shares issued as consideration for license agreement	59,579		59,579			59,579	0
Shares issued as consideration for license agreement, shares		2,100,085
Shares issued in business combinations	126,863		126,863			126,863	0
Shares issued in business combinations, shares		2,552,151
Shares and warrants issued in business combination	126,863
Shares issued in asset acquisition	0
Shares issued as payment for contingent consideration	0
Acquisition of noncontrolling interest	$ (1,566)		9,412			9,412	(10,978)
Acquisition of noncontrolling interest, shares	307,074
Adjustments for noncontrolling interests	$ 250		(249)			(249)	499
Noncash dividend	(172,419)		(172,419)			(172,419)	0
Net loss	(87,994)				(84,493)	(84,493)	(3,501)
Other comprehensive income (loss)	(12,669)			(12,748)		(12,748)	79
Ending balance at Dec. 31, 2015	704,886		1,249,559	(12,752)	(542,729)	694,078	10,808
Ending balance, shares at Dec. 31, 2015		116,658,886
Changes in Stockholders' Equity
Stock-based compensation expense	42,181		42,108			42,108	73
Exercises of stock options and warrants	19,165		19,165			19,165	0
Exercises of stock options and warrants, shares		1,400,146
Shares issued as payment for services	10,777		10,777			10,777	0
Shares issued as payment for services, shares		434,061
Shares and warrants issued in business combination	0
Shares issued in asset acquisition	4,401		4,401			4,401	0
Shares issued in asset acquisition, shares		136,340
Shares issued as payment for contingent consideration	1,583		1,583			1,583	0
Shares issued as payment for contingent consideration, shares		59,337
Acquisition of noncontrolling interest	0		(1,813)			(1,813)	1,813
Acquisition of noncontrolling interest, shares		0
Net loss	(190,274)				(186,612)	(186,612)	(3,662)
Other comprehensive income (loss)	(23,471)			(23,450)		(23,450)	(21)
Ending balance at Dec. 31, 2016	$ 569,248	$ 0	1,325,780	(36,202)	(729,341)	560,237	9,011
Ending balance, shares at Dec. 31, 2016	118,688,770	118,688,770
Changes in Stockholders' Equity
Cumulative effect of adoption of ASU 2016-09	$ 0		1,461		(1,461)	0	0
Stock-based compensation expense	41,576		41,525			41,525	51
Exercises of stock options and warrants	980		952			952	28
Exercises of stock options and warrants, shares		149,429
Shares issued as payment for services	11,118		11,118			11,118	0
Shares issued as payment for services, shares		654,456
Shares issued in public or private offerings, net of issuance costs	13,686		13,686			13,686	0
Shares issued in public or private offerings, net of issuance costs, shares		1,207,980
Shares issued in business combinations, shares		684,240
Shares and warrants issued in business combination	16,997		16,997			16,997	0
Shares issued in asset acquisition	0
Shares issued as payment for contingent consideration	0		0			0	0
Shares issued as payment for contingent consideration, shares		480,422
Acquisition of noncontrolling interest	(913)		5,082			5,082	(5,995)
Acquisition of noncontrolling interest, shares		221,743
Adjustments for noncontrolling interests	(13)		2,789			2,789	(2,802)
Noncash dividend	0		(22,385)			(22,385)	22,385
Net loss	(126,820)				(117,018)	(117,018)	(9,802)
Other comprehensive income (loss)	20,686			20,648		20,648	38
Ending balance at Dec. 31, 2017	$ 546,545		$ 1,397,005	$ (15,554)	$ (847,820)	$ 533,631	$ 12,914
Ending balance, shares at Dec. 31, 2017	122,087,040	122,087,040

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities
Net loss	$ (126,820)	$ (190,274)	$ (87,994)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	31,145	24,572	17,743
Loss on disposal of long-lived assets	3,124	666	633
Impairment loss	16,773	0	0
Unrealized and realized (appreciation) depreciation on equity securities and preferred stock	(2,586)	58,894	(66,876)
Noncash dividend income	(16,756)	(7,421)	0
Amortization of premiums on investments	411	1,070	642
Equity in net loss of affiliates	14,283	21,120	8,944
Stock-based compensation expense	41,576	42,202	38,667
Shares issued as payment for services	11,118	10,777	2,169
Shares issued as consideration for license agreement	0	0	59,579
Provision for bad debts	1,217	1,963	1,757
Deferred income taxes	(2,528)	(3,467)	1,117
Other noncash items	(517)	1,662	460
Changes in operating assets and liabilities:
Restricted cash	0	(6,987)	0
Receivables:
Trade	740	2,588	(12,138)
Related parties	631	6,804	(11,042)
Notes	0	(42)	0
Other	661	271	5,286
Inventory	663	3,807	(774)
Prepaid expenses and other	492	(932)	(2,729)
Other assets	(1,436)	2,189	(2,119)
Accounts payable	(3,402)	3,618	(3,263)
Accrued compensation and benefits	(1,466)	(12,402)	10,491
Other accrued liabilities	3,007	9,002	1,593
Deferred revenue	(75,337)	(25,481)	74,434
Deferred consideration	(313)	(630)	(943)
Related party payables	(147)	310	(64)
Other long term liabilities	1,328	146	96
Net cash provided by (used in) operating activities	(104,139)	(55,975)	35,669
Cash flows from investing activities
Purchases of investments	0	(75,246)	(181,572)
Maturities of investments	174,542	101,987	88,000
Purchases of equity securities, preferred stock, and warrants	(1,161)	(2,308)	(17,080)
Proceeds from sales of equity securities	235	280	0
Acquisitions of businesses, net of cash received	2,054	0	(123,928)
Investments in affiliates	(11,189)	(11,542)	(13,442)
Cash paid in asset acquisition	(14,219)	(7,244)	0
Purchases of property, plant and equipment	(46,666)	(31,629)	(12,749)
Proceeds from sale of property, plant and equipment	1,636	274	626
Issuances of notes receivable	(2,400)	(2,964)	(600)
Proceeds from repayment of notes receivable	1,500	0	1,500
Net cash provided by (used in) investing activities	104,332	(28,392)	(259,245)
Cash flows from financing activities
Proceeds from issuance of shares in a private placement	13,686	0	0
Proceeds from issuance of shares in public offerings, net of issuance costs	0	0	328,234
Acquisitions of noncontrolling interests	(913)	0	(1,566)
Advances from lines of credit	5,906	5,075	15,232
Repayments of advances from lines of credit	(6,493)	(4,816)	(16,944)
Proceeds from long term debt	325	547	81
Payments of long term debt	(519)	(1,201)	(1,564)
Payments of deferred consideration for acquisitions	(8,678)	(6,705)	(6,252)
Proceeds from stock option exercises	980	19,165	14,462
Payment of stock issuance costs	(10)	0	0
Net cash provided by financing activities	4,284	12,065	331,683
Effect of exchange rate changes on cash and cash equivalents	1,027	(873)	209
Net increase (decrease) in cash and cash equivalents	5,504	(73,175)	108,316
Cash and cash equivalents
Beginning of period	62,607	135,782	27,466
End of period	68,111	62,607	135,782
Supplemental disclosure of cash flow information
Cash paid during the period for interest	617	964	1,195
Cash paid during the period for income taxes	566	10	1,165
Significant noncash financing and investing activities
Stock received as consideration for collaboration agreements	0	18,766	9,149
Preferred stock received as consideration for collaboration amendments	0	120,000	0
Receivables converted to preferred stock	3,385	0	0
Stock and warrants issued in business combinations	16,997	0	126,863
Stock issued to acquire noncontrolling interests	5,082	0	9,412
Stock issued in asset acquisition	0	4,401	0
Contingent consideration assumed in asset acquisition	0	3,660	0
Stock issued as payment for contingent consideration	0	1,583	0
Noncash dividend to shareholders	22,385	0	172,419
Deferred consideration payable related to acquisition	0	0	1,992
Purchases of equipment included in accounts payable and other accrued liabilities	2,257	652	782
Receivable recorded in anticipation of dissolution of affiliate	2,598	0	0
Transfer of inventory to breeding stock	$ 0	$ 1,191	$ 0

Organization and Basis of Presentation	12 Months Ended
Organization and Basis of Presentation	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Organization and Basis of Presentation Intrexon Corporation ("Intrexon"), a Virginia corporation, uses synthetic biology to focus on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals, which may be accomplished through collaborations and joint ventures. Intrexon's primary domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. There have been no commercialized products derived from Intrexon's collaborations to date. Trans Ova Genetics, L.C. ("Trans Ova"), a provider of advanced reproductive technologies and other genetic processes to cattle breeders and other producers, is a wholly owned subsidiary of Intrexon with primary operations in Iowa, Maryland, Missouri, Oklahoma and Texas. Oxitec Limited ("Oxitec"), a pioneering company in biological insect control solutions, is a wholly owned subsidiary of Intrexon with primary operations in England and Brazil. Intrexon Produce Holdings, Inc. ("IPHI") is a wholly owned subsidiary of Intrexon. Okanagan Specialty Fruits, Inc. ("Okanagan"), a company which developed and received regulatory approval for the world's first non-browning apple without the use of any flavor-altering chemical or antioxidant additives, is a wholly owned subsidiary of IPHI with primary operations in Canada. Fruit Orchard Holdings, Inc. ("FOHI") is a wholly owned subsidiary of IPHI with primary operations in Washington. ViaGen, L.C. ("ViaGen"), a provider of genetic preservation and cloning technologies, and Exemplar Genetics, LLC ("Exemplar"), a provider of genetically engineered swine for medical and genetic research, are wholly owned subsidiaries with primary operations in Texas and Iowa, respectively. In March 2017, Intrexon acquired the remaining 49% of the equity of Biological & Popular Culture, Inc. ("BioPop"), a California company developing artwork, children's toys and novelty goods that are derived from living organisms or enabled by synthetic biology for $900 in cash and 221,743 shares of Intrexon common stock valued at $5,082. Upon closing this transaction, BioPop became a wholly owned subsidiary of Intrexon. As of December 31, 2017, Intrexon owned approximately 58% of AquaBounty Technologies, Inc. ("AquaBounty"), a company focused on improving productivity in commercial aquaculture. In January 2017, in conjunction with the listing by AquaBounty of their common stock on the NASDAQ Stock Market, Intrexon purchased $25,000 of additional AquaBounty common stock and subsequently distributed shares of AquaBounty common stock as a dividend to Intrexon shareholders. See Notes 14 and 22 for additional discussion. Intrexon Corporation and its consolidated subsidiaries are hereinafter referred to as the "Company." These consolidated financial statements are presented in United States dollars and are prepared under accounting principles generally accepted in the United States of America ("U.S. GAAP").

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.

Revenue Recognition

The Company generates collaboration and licensing revenue through the execution of agreements with collaborators (known as exclusive channel collaborations, "ECC" or "ECCs") and licensing agreements whereby the collaborators or the licensee obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Generally, the terms of these agreements provide that the Company receives some or all of the following: (i) upfront payments upon consummation of the agreement, (ii) reimbursements for costs incurred by the Company for research and development and/or manufacturing efforts related to specific applications provided for in the agreement, (iii) milestone payments upon the achievement of specified development, regulatory and commercial activities, and (iv) royalties on sales of products arising from the collaboration or licensing agreement.

The Company's collaboration and licensing agreements typically contain multiple elements, or deliverables, including technology licenses, research and development services, and in certain cases manufacturing services. The Company identifies the deliverables within the agreements and evaluates which deliverables represent separate units of accounting. Analyzing the agreements to identify deliverables requires the use of judgment. A deliverable is considered a separate unit of accounting when the deliverable has value to the collaborator or licensee on a standalone basis based on the consideration of the relevant facts and circumstances for each agreement.

Consideration received is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. When available, the relative selling price for each deliverable is determined using vendor specific objective evidence ("VSOE") of the selling price or third-party evidence of the selling price, if VSOE does not exist. If neither VSOE nor third-party evidence of the selling price exists, the Company uses its best estimate of the selling price for the deliverable. The amount of allocable consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. The Company recognizes the revenue allocated to each unit of accounting as the Company delivers the related goods or services. If the Company determines that certain deliverables should be treated as a single unit of accounting, then the revenue is recognized using either a proportional performance or straight-line method, depending on whether the Company can reasonably estimate the level of effort required to complete its performance obligations under an arrangement and whether such performance obligations are provided on a best-efforts basis. As the Company cannot reasonably estimate its performance obligations related to its collaborators or licensees, the Company recognizes revenue on a straight-line basis over the period it expects to complete its performance obligations, which is reevaluated each reporting period.

The terms of the Company's agreements may provide for milestone payments upon achievement of certain defined events. The Company applies the Milestone Method for recognizing milestone payments. Under the Milestone Method, the Company recognizes consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:


(1)	The consideration is commensurate with either the entity's performance to achieve the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the entity's performance to achieve the milestone;


(2)	The consideration relates solely to past performance; and


(3)	The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.

In the event that a milestone is not considered substantive, the Company recognizes the milestone consideration as revenue using the same method applied to upfront payments.

Research and development services are a deliverable satisfied by the Company in accordance with the terms of the collaboration and licensing agreements and the Company considers these services to be inseparable from the license to the core technology; therefore, reimbursements of services performed are recognized as revenue. Because reimbursement (i) is contingent upon performance of the services by the Company, (ii) does not include a profit component, and (iii) does not relate to any future deliverable, the revenue is recognized during the period in which the related services are performed and collection of such amounts is reasonably assured. Payments received for manufacturing services will be recognized when the earnings process related to the manufactured materials has been completed. Royalties to be received under the agreements will be recognized as earned.

From time to time, the Company and certain collaborators may cancel their agreements, relieving the Company of any further performance obligations under the agreement. When no further performance obligations are required of the Company under an agreement, the Company recognizes any remaining deferred revenue.

The Company generates product and service revenues primarily through sales of products and services which are created from technologies developed or owned by the Company. The Company's current offerings include sales of advanced reproductive technologies, including the Company's bovine embryo transfer and in vitro fertilization processes and from genetic preservation and sexed semen processes and applications of such processes to other livestock, as well as sales of livestock and embryos produced using these processes and used in production. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) services have been rendered or delivery has occurred such that risk of loss has passed to the customer, (iii) the price is fixed or determinable, and (iv) collection from the customer is reasonably assured.

Research and Development

The Company considers that regulatory requirements inherent in the research and development of new products preclude it from capitalizing such costs. Research and development expenses include salaries and related costs of research and development personnel, including stock-based compensation expense, and the costs of consultants, certain in-licensed technology rights, facilities, materials and supplies associated with research and development projects as well as various laboratory studies. Indirect research and development costs include depreciation, amortization and other indirect overhead expenses.

The Company has research and development arrangements with third parties that include upfront and milestone payments. As of December 31, 2017 and 2016, the Company had research and development commitments with third parties that had not yet been incurred totaling $10,682 and $10,631, respectively. The commitments are generally cancellable by the Company at any time upon written notice.

Cash and Cash Equivalents

All highly liquid investments with an original maturity of three months or less at the date of purchase are considered to be cash equivalents. Cash balances at a limited number of banks may periodically exceed insurable amounts. The Company believes that it mitigates its risk by investing in or through major financial institutions with high quality credit ratings. Recoverability of investments is dependent upon the performance of the issuer. As of December 31, 2017 and 2016, the Company had cash equivalent investments in highly liquid money market accounts at major financial institutions of $43,012 and $43,808, respectively.

Restricted Cash

Restricted cash represents funds deposited with the U.S. Treasury, as required by a court decision resulting from litigation against Trans Ova (Note 17).

Short-term and Long-term Investments

As of December 31, 2017, short-term investments include U.S. government debt securities and certificates of deposit. The Company determines the appropriate classification as short-term or long-term at the time of purchase based on original maturities and management's reasonable expectation of sales and redemption. The Company reevaluates such classification at each balance sheet date. The Company's written investment policy requires investments to be explicitly rated by two of the three following rating services: Standard & Poor's, Moody's and/or Fitch and to have a minimum rating of A1, P1 and/or F-1, respectively, from those agencies. In addition, the investment policy limits the amount of credit exposure to any one issuer.

Equity Securities

The Company holds equity securities received and/or purchased from certain collaborators. Other than investments accounted for using the equity method, the Company elected the fair value option to account for its equity securities held in these collaborators. These equity securities are recorded at fair value at each reporting date and are subject to market price volatility. Unrealized gains and losses resulting from fair value adjustments are reported in the consolidated statement of operations. The fair value of these equity securities is subject to fluctuation in the future due to the volatility of the stock market, changes in general economic conditions and changes in the financial conditions of these collaborators. Equity securities that the Company does not intend to sell within one year are classified as noncurrent in the consolidated balance sheet.

The Company records the fair value of securities received on the date the collaboration is consummated or the milestone is achieved using the closing, quoted price of the collaborator's security on that date, assuming the transfer of consideration is considered perfunctory. If the transfer of the consideration is not considered perfunctory, the Company considers the specific facts and circumstances to determine the appropriate date on which to evaluate fair value. The Company also evaluates whether any discounts for trading restrictions or other basis for lack of marketability should be applied to the fair value of the securities at inception of the collaboration. In the event the Company concludes that a discount should be applied, the fair value of the securities is adjusted at inception of the collaboration and re-evaluated at each reporting period thereafter.

Investments in Preferred Stock

The Company holds preferred stock in certain of its collaborators, most of which may be converted to common stock as described in Note 7. The Company elected the fair value option to account for its investments in preferred stock whereby the value of preferred stock is adjusted to fair value as of each reporting date and unrealized gains and losses are reported in the consolidated statement of operations. These investments are subject to fluctuation in the future due to, among other things, the likelihood and timing of conversion of certain of the preferred stock into common stock, the volatility of each collaborator's common stock, and changes in general economic and financial conditions of the collaborators. The investments are classified as noncurrent in the consolidated balance sheet since the Company does not intend to sell the investments nor expect the investments that are convertible into common stock to be converted within one year.

The Company is entitled to monthly dividends and records dividend income as described in Note 7.

Fair Value of Financial Instruments

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset and liability. As a basis for considering such assumptions, the Company uses a three-tier fair value hierarchy that prioritizes the inputs used in its fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:



Level 1:	Quoted prices in active markets for identical assets and liabilities;

Level 2:	Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and

Level 3:	Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available.

Concentrations of Risk

Due to the Company's mix of fixed and variable rate securities holdings, the Company's investment portfolio is susceptible to changes in interest rates. As of December 31, 2017, gross unrealized losses on the Company's short-term investments were not material. From time to time, the Company may liquidate some or all of its investments to fund operational needs or other activities, such as capital expenditures or business acquisitions, or distribute its equity securities to shareholders as a stock dividend. Depending on which investments the Company liquidates to fund these activities, the Company could recognize a portion, or all, of the gross unrealized losses.

Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of trade and related party receivables. The Company controls credit risk through credit approvals, credit limits and monitoring procedures. The Company performs ongoing credit evaluations of its customers but generally does not require collateral to support accounts receivable.

Equity Method Investments

The Company accounts for its investments in each of its joint ventures and for its investments in start-up entities backed by the Harvest Intrexon Enterprise Fund I, LP ("Harvest"), a related party, (Note 18) using the equity method of accounting based upon relative ownership interest. The Company's investments in these entities are included in investments in affiliates in the accompanying consolidated balance sheets.

The Company accounts for its investment in Oragenics, Inc. ("Oragenics"), one of its collaborators, using the fair value option. The fair value of the Company's investment in Oragenics was $3,085 and $7,244 as of December 31, 2017 and 2016, respectively, and is included as equity securities in the accompanying consolidated balance sheets. The Company's ownership of Oragenics was 29.4% and 29.5% as of December 31, 2017 and 2016, respectively. Unrealized appreciation (depreciation) in the fair value of these securities was $(4,159), $(10,523), and $4,863 for the years ended December 31, 2017, 2016, and 2015, respectively. See Note 7 for additional discussion regarding Oragenics.

In 2015, the Company determined that ZIOPHARM Oncology, Inc. ("ZIOPHARM") met the criteria of SEC Regulation S-X Article 3-09 for inclusion of separate financial statements of an equity method investment as the Company determined it had significant influence over ZIOPHARM until the Company distributed its share of ZIOPHARM common stock to shareholders in the form of a special stock dividend (Note 14). Upon disposition, the Company realized a gain of $81,401 during the year ended December 31, 2015.

Summarized financial data as of December 31, 2017 and 2016, and for the years ended December 31, 2017, 2016, and 2015, for the Company's equity method investments for which separate financial statements are not included, pursuant to SEC Regulation S-X Article 3-09, are shown in the following tables.



	December 31,
	2017		2016
Current assets	$	61,086	$	77,761
Non-current assets	13,598		11,040
Total assets	74,684		88,801
Current liabilities	6,213		11,588
Net assets	$	68,471	$	77,213



	Year Ended December 31,
	2017			2016			2015
Revenues, net	$	254		$	417		$	1,176
Operating expenses	41,904			62,373			32,513
Operating loss	(41,650		)	(61,956		)	(31,337		)
Other, net	(8		)	1,535			(64		)
Net loss	$	(41,658	)	$	(60,421	)	$	(31,401	)

Variable Interest Entities

The Company identifies entities that (i) do not have sufficient equity investment at risk to permit the entity to finance its activities without additional subordinated financial support or (ii) in which the equity investors lack an essential characteristic of a controlling financial interest as variable interest entities ("VIE" or "VIEs"). The Company performs an initial and on-going evaluation of the entities with which the Company has variable interests to determine if any of these entities are VIEs. If an entity is identified as a VIE, the Company performs an assessment to determine whether the Company has both (i) the power to direct activities that most significantly impact the VIE's economic performance and (ii) have the obligation to absorb losses from or the right to receive benefits of the VIE that could potentially be significant to the VIE. If both of these criteria are satisfied, the Company is identified as the primary beneficiary of the VIE.

As of December 31, 2017 and 2016, the Company determined that certain of its collaborators and joint ventures as well as Harvest were VIEs. The Company was not the primary beneficiary for these entities since it did not have the power to direct the activities that most significantly impact the economic performance of the VIEs. The Company's aggregate investment balances of these VIEs as of December 31, 2017 and 2016, were $185,261 and $159,115, respectively, which represents the Company's maximum risk of loss related to the identified VIEs.

Trade Receivables

Trade receivables consist of credit extended to the Company's customers in the normal course of business and are reported net of an allowance for doubtful accounts. The Company reviews its customer accounts on a periodic basis and records bad debt expense for specific amounts the Company evaluates as uncollectible. Past due status is determined based upon contractual terms. Amounts are written off at the point when collection attempts have been exhausted. Management estimates uncollectible amounts considering such factors as current economic conditions and historic and anticipated customer performance. This estimate can fluctuate due to changes in economic, industry or specific customer conditions which may require adjustment to the allowance recorded by the Company. Management has included amounts believed to be uncollectible in the allowance for doubtful accounts.

The following table shows the activity in the allowance for doubtful receivable accounts for the years ended December 31, 2017, 2016, and 2015:



	2017			2016			2015
Beginning balance	$	3,703		$	2,081		$	565
Charged to operating expenses	1,217			1,963			1,757
Write offs of accounts receivable, net of recoveries	(289		)	(341		)	(241		)
Ending balance	$	4,631		$	3,703		$	2,081

Inventory

The Company's inventory primarily includes adult female cows which are used in certain production processes and are recorded at acquisition cost using the first-in, first-out method or at market, whichever is lower. Work-in-process inventory includes allocations of production costs and facility costs for products currently in production and is recorded at the lower of cost or market. Significant declines in the price of cows could result in unfavorable adjustments to inventory balances.

Property, Plant and Equipment

Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Major additions or betterments are capitalized and repairs and maintenance are generally expensed as incurred. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of these assets are as follows:



	Years
Land improvements	4–20
Buildings and building improvements	3–25
Furniture and fixtures	1–10
Equipment	1–10
Breeding stock	1–4
Computer hardware and software	1–7

Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally one to twenty years.

Goodwill

Goodwill represents the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Goodwill is reviewed for impairment at least annually. The Company performs a qualitative assessment to determine whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount prior to performing the goodwill impairment test. If this is the case, the goodwill impairment test is required. If it is more-likely-than-not that the fair value of a reporting unit is greater than the carrying amount, the goodwill impairment test is not required.

If the goodwill impairment test is required, first, the fair value of the reporting unit is compared with its carrying amount (including goodwill). If the fair value of the reporting unit is less than its carrying amount, an indication of goodwill impairment exists for the reporting unit and the entity must record the impairment charge for the excess carrying amount, which is limited to the amount of goodwill allocated to the reporting unit. If the fair value of the reporting unit exceeds its carrying amount, no goodwill impairment charge is necessary.

The Company performs its annual impairment review of goodwill in the fourth quarter, or sooner if a triggering event occurs prior to the annual impairment review. See Note 11 for additional discussion regarding the results of this review for the year ended December 31, 2017.

Intangible Assets

Intangible assets subject to amortization consist of patents, developed technologies and know-how; customer relationships; and trademarks acquired as a result of mergers and acquisitions. These intangible assets are subject to amortization, were recorded at fair value at the date of acquisition and are stated net of accumulated amortization. Indefinite-lived intangible assets consist of in-process research and development technologies acquired in mergers or acquisitions and were recorded at fair value at the dates of the respective acquisitions.

The Company amortizes long-lived intangible assets to reflect the pattern in which the economic benefits of the intangible asset are expected to be realized. The intangible assets are amortized over their estimated useful lives, ranging from three to twenty-one years for the patents, developed technologies and know-how; customer relationships; and trademarks.

Impairment of Long-Lived Assets

Long-lived assets to be held and used, including property, plant and equipment and intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable.

Indefinite-lived intangible assets, including in-process research and development, are tested for impairment annually, or more frequently if events or circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of their fair value to carrying value, without consideration of any recoverability test. The Company monitors the progression of its in-process research and development, as the likelihood of success is contingent upon commercial development or regulatory approval.

Self-insurance Reserves

Effective January 1, 2017, the Company commenced a self-insurance program for a significant portion of its employee health benefit programs. The Company maintains stop-loss coverage with third party insurers to limit its individual claims and total exposure under those programs. The Company estimates its accrued liability for the ultimate costs to close known claims, including claims incurred but not yet reported to the Company, as of the balance sheet date. The Company's recorded estimated liability for self-insurance is based on the insurance company's incurred loss estimates and management's judgment, including assumptions and factors related to the frequency and severity of claims and the Company's claims development history.

The assessment of self-insurance reserves is a highly subjective process that requires judgments about future events. Self-insurance reserves are reviewed at least quarterly to determine the adequacy of the accruals and related financial statement disclosure. The ultimate settlement of self-insurance reserves may differ significantly from amounts the Company has accrued in its consolidated financial statements.

Foreign Currency Translation

The assets and liabilities of foreign subsidiaries, where the local currency is the functional currency, are translated from their respective functional currencies into United States dollars at the exchange rates in effect at the balance sheet date, with resulting foreign currency translation adjustments recorded in the consolidated statement of comprehensive loss. Revenue and expense amounts are translated at average rates during the period.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to both differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases as well as operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of the change. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.

The Company identifies any uncertain income tax positions and recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest, if any, related to unrecognized tax benefits as a component of interest expense. Penalties, if any, are recorded in selling, general and administrative expenses.

On December 22, 2017, the Tax Cuts and Jobs Act (the "Tax Act") was signed into law and significantly revised U.S. corporate income tax law by, among other things, reducing the corporate income tax rate to 21% effective January 1, 2018, eliminating the corporate alternative minimum tax and implementing a modified territorial tax system that includes a one-time transition tax on deemed repatriated earnings foreign subsidiaries. The SEC Staff issued Staff Accounting Bulletin No. 118 ("SAB 118") to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed, including computations, in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. The Company has recognized provisional tax impacts related to revaluation of most of the Company's domestic deferred tax assets, the impact of revaluation of those deferred tax assets on the Company's valuation allowance and elimination of the corporate alternative minimum tax, and included those amounts in the consolidated financial statements for the year ended December 31, 2017. The actual impact of the Tax Act may differ from the Company's estimates due to, among other things, changes in interpretations and assumptions made, and guidance that may be issued as a result of the Tax Act.

In addition, the Tax Act implemented a new minimum tax on global intangible low-taxed income ("GILTI"). A company can elect an accounting policy to account for GILTI in either of the following ways:


•	As a period charge in the future period the tax arises; or


•	As part of deferred taxes related to the investment or subsidiary.

The Company is currently in the process of analyzing this provision and, as a result, is not yet able to reasonably estimate its effect. Therefore, the Company has not made any provisional adjustments related to potential GILTI tax in its consolidated financial statements and has not made a policy decision regarding whether to record deferred taxes under the GILTI regime.

The accounting is expected to be completed within the one-year measurement period as allowed by SAB 118 for items impacted or introduced by the Tax Act.

Share-Based Payments

Intrexon uses the Black-Scholes option pricing model to estimate the grant-date fair value of all stock options. The Black-Scholes option pricing model requires the use of assumptions for estimated expected volatility, estimated expected term of stock options, risk-free rate, estimated expected dividend yield, and the fair value of the underlying common stock at the date of grant. Since Intrexon does not have sufficient history to estimate the expected volatility of its common stock price, expected volatility is based on a blended approach which utilizes the volatility of Intrexon's common stock and the volatility of peer public entities that are similar in size and industry. Intrexon estimates the expected term of all options based on previous history of exercises. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for the expected term of the option. The expected dividend yield is 0% as Intrexon does not expect to declare cash dividends in the near future. The fair value of the underlying common stock is determined based on the quoted market price on the New York Stock Exchange. Forfeitures are recorded when incurred. The assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2017, 2016 and 2015 are set forth in the table below:



	2017	2016	2015
Valuation assumptions
Expected dividend yield	0%	0%	0%
Expected volatility	57%—60%	59%—60%	59%—62%
Expected term (years)	6.25	6.25	6.25
Risk-free interest rate	1.89%—2.27%	1.23%—2.17%	1.56%—1.95%

Net Loss per Share

Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, using the treasury-stock method. For purposes of the diluted net loss per share calculation, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and, therefore, basic and diluted net loss per share were the same for all periods presented.

Segment Information

While the Company generates revenues from multiple sources, including collaboration agreements, licensing, and products and services primarily associated with bovine reproduction, management is organized around a singular research and development focus to further the development of the Company's underlying synthetic biology technologies. Accordingly, the Company has determined that it operates in one segment. As of December 31, 2017 and 2016, the Company had $21,837 and $13,265, respectively, of long-lived assets in foreign countries. The Company recognized revenues derived in foreign countries totaling $17,605, $11,969, and $5,918 for the years ended December 31, 2017, 2016 and 2015, respectively.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Recently Adopted Accounting Pronouncements

In January 2017, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU 2017-04"). The provisions of ASU 2017-04 simplify how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. The Company elected to early adopt this standard in the fourth quarter of 2017 and utilized the guidance for the annual goodwill impairment test (Note 11).

In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805) - Clarifying the Definition of a Business ("ASU 2017-01"). The provisions of ASU 2017-01 clarify the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The Company adopted this standard in the second quarter of 2017, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements.

In October 2016, the FASB issued ASU 2016-17, Consolidation (Topic 810) - Interests Held through Related Parties That Are under Common Control ("ASU 2016-17"). The provisions of ASU 2016-17 amend the consolidation guidance on how a reporting entity that is the single decision maker of a VIE should treat indirect interests in the entity held through related parties that are under common control with the reporting entity when determining whether it is the primary beneficiary of that VIE. The Company adopted this standard effective January 1, 2017, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Stock Compensation (Topic 718) - Improvements to Employee Share-Based Payment Accounting ("ASU 2016-09"). The provisions of ASU 2016-09 simplify various aspects of the accounting for employee share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The Company adopted this standard effective January 1, 2017. Upon adoption in the first quarter of 2017, the Company elected to recognize forfeitures as they occur and recorded an opening adjustment to additional paid-in capital and accumulated deficit for previously unrecognized stock-based compensation costs due to estimating forfeitures on unvested shares totaling $1,461. The Company also recognized deferred tax assets of $17,843 related to the excess tax benefits that previously arose directly from tax deductions related to equity compensation greater than stock-based compensation costs recognized in the consolidated financial statements and the cumulative adjustment for forfeitures. These deferred tax assets were fully offset by a valuation allowance (Note 13). The adoption was on a modified retrospective basis and had no impact on prior periods.

In March 2016, the FASB issued ASU 2016-07, Investments-Equity Method and Joint Ventures (Topic 323) - Simplifying the Transition to the Equity Method of Accounting ("ASU 2016-07"). The provisions of ASU 2016-07 eliminate the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an adjustment must be made to the investment, results of operations, and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment had been held. The Company adopted this standard effective January 1, 2017, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements.

In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330) - Simplifying the Measurement of Inventory ("ASU 2015-11"). The provisions of ASU 2015-11 provide guidance for simplifying the calculation for subsequent measurement of inventory measured using the first-in-first-out or average cost methods. The Company adopted this standard effective January 1, 2017, and the implementation of this standard did not have a material impact on the Company's consolidated financial statements.

Recently Issued Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"). The FASB issued ASU 2014-09 to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. This guidance was originally effective for annual periods and interim periods within those annual periods beginning after December 15, 2016 and early adoption was not permitted. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606) - Deferral of the Effective Date, which deferred the effective date of the guidance in ASU 2014-09 by one year to December 15, 2017 for interim and annual reporting periods beginning after that date, and is effective for the Company for the year ending December 31, 2018. In 2016 and 2017, the FASB clarified the implementation guidance on principal versus agent, identifying performance obligations, licensing, narrow-scope improvements, practical expedients, and to expedite improvements to ASU 2014-09 by issuing ASU 2016-08, Revenue from Contracts with Customers (Topic 606) - Principal versus Agent Considerations, ASU 2016-10, Revenue from Contracts with Customers (Topic 606) - Identifying Performance Obligations and Licensing, and ASU 2016-12, Revenue from Contracts with Customers (Topic 606) - Narrow-Scope Improvements and Practical Expedients, ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers, and ASU 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842). The Company continues to progress in the evaluation of its collaborations and licensing agreements and product and service revenue arrangements to determine the impact, if any, that the implementation of this standard will have on the Company's consolidated financial statements. The Company completed its review of collaboration and licensing agreements and product and service revenue arrangements and determined that other than the cumulative catch-up adjustment and related increased deferred revenue discussed below the standard will not have a significant impact on its financial position, results of operations and disclosures for these revenue arrangements. Upon adoption using the modified retrospective approach in the first quarter of 2018, the Company expects to recognize a cumulative catch-up adjustment to increase deferred revenue and accumulated deficit in the net amount of $40,413. Under the current guidance, the Company recorded the upfront payment received from Ares Trading S.A. ("Ares Trading") net of the required payment made to ZIOPHARM as deferred revenue and is recognizing the deferred revenue over the estimated recognition period (Note 5). The new guidance requires gross presentation for these payments and would have resulted in the Company recording the full amount of the upfront payment received from Ares Trading as deferred revenue, recognizing the deferred revenue over the estimated recognition period, and immediately expensing the payment made to ZIOPHARM. As a result of this change under the new guidance, the Company expects to record $40,789 of additional deferred revenue relating to the additional unrecognized portion of the upfront payment, which will be recognized over the remainder of the expected recognition period. Additionally, the Company expects to reduce deferred revenue by $376 as a portion of the Company's previously deferred revenue related to a milestone payment received from ZIOPHARM pursuant to an ECC (Note 5) would have been recognized immediately under the new guidance. The milestone payment was received by the Company in form of the ZIOPHARM's common stock and under current guidance was valued on the date the milestone was achieved. Under the new guidance, the milestone would have been valued at contract inception with any difference in the value between contract inception and milestone achievement recorded as a gain or loss on the equity securities. Any revenue arrangements entered into subsequent to December 31, 2017 with financial or other significant terms which differ from the financial or other significant terms of the Company's existing revenue arrangements will be evaluated under this new standard.

In February 2018, the FASB issued ASU 2018-02, Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income ("ASU 2018-02"). The provisions of ASU 2018-02 allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Act. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, with early adoption permitted, and is effective for the Company for the year ending December 31, 2019. The amendments in ASU 2018-02 may be applied either in the period of adoption or retrospectively to each period (or periods) in which the effect of the change in the U.S. federal corporate income tax rate in the Tax Act is recognized. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.

In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception ("ASU 2017-11"). The amendments in Part I of ASU 2017-11 change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity's own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity-classified financial instruments, the amendments require entities that present earnings per share ("EPS") in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt-Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). The amendments in Part II of ASU 2017-11 re-characterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the FASB codification, to a scope exception. Those amendments do not have an accounting effect. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, with early adoption permitted, and is effective for the Company for the year ended December 31, 2019. The Company is currently evaluating the impact that the implementation of this standard will have on the Company's consolidated financial statements.

In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718) – Scope of Modification Accounting ("ASU 2017-09"). The provisions of ASU 2017-09 provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. An entity should account for the effects of a modification unless (a) the fair value of the modified award is the same as the fair value of the original award, (b) the vesting conditions of the modified award are the same as the vesting conditions of the original award and (c) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2017, and is effective for the Company for the year ending December 31, 2018. The amendments in ASU 2017-09 should be applied prospectively to an award modified on or after the adoption date. As this standard is prospective in nature, the impact to the Company's consolidated financial statements will depend on the nature of any future award modifications.

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230) - Restricted Cash (A Consensus of the FASB Emerging Issues Task Force) ("ASU 2016-18"). The provisions of ASU 2016-18 require amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the total beginning and ending balances for the periods presented on the statement of cash flows. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2017, and is effective for the Company for the year ending December 31, 2018. The impact of the implementation of this standard will modify the Company's current disclosures and reclassifications within the consolidated statement of cash flows.

In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740) - Intra-Entity Transfers of Assets Other Than Inventory ("ASU 2016-16"). The provisions of ASU 2016-16 remove the prohibition in ASC 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2017, and is effective for the Company for the year ending December 31, 2018. The implementation of this standard is not expected to have a material impact on the Company's consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230) - Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"). The provisions of ASU 2016-15 address eight specific cash flow issues and how those certain cash receipts and cash payments are presented and classified in the statement of cash flows under Topic 230, Statement of Cash Flows, and other Topics. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2017, and is effective for the Company for the year ending December 31, 2018. The implementation of this standard is not expected to have a material impact on the Company's consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02"). The provisions of ASU 2016-02 set out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for in a similar manner as under existing guidance for operating leases today. ASU 2016-02 supersedes the previous lease standard, Topic 840, Leases. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2018, and is effective for the Company for the year ending December 31, 2019. The Company is currently evaluating its lease agreements to determine the impact that the implementation of this standard will have on the Company's consolidated financial statements as it relates to the classification of leases under the dual approach and the recognition of a right-of-use asset and a lease liability.

In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10) - Recognition and Measurement of Financial Assets and Financial Liabilities ("ASU 2016-01"). The provisions of ASU 2016-01 make targeted improvements to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information, including certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2017, and is effective for the Company for the year ending December 31, 2018. The implementation of this standard is not expected to have a material impact on the Company's consolidated financial statements.

Reclassifications

Certain insignificant reclassifications have been made to the prior year consolidated financial statements to conform to the current year presentation.

Mergers and Acquisitions

12 Months Ended

Dec. 31, 2017

Business Combinations [Abstract]

Mergers and Acquisitions

GenVec Acquisition

In June 2017, pursuant to an Agreement and Plan of Merger (the "GenVec Merger Agreement"), the Company acquired 100% of the outstanding shares of GenVec, Inc. ("GenVec"), a clinical-stage company and pioneer in the development of AdenoVerse gene delivery technology. Pursuant to the GenVec Merger Agreement, the former shareholders of GenVec received an aggregate of 684,240 shares of the Company's common stock and have the right to receive contingent consideration equal to 50% of any milestone or royalty payments received under one of GenVec's collaboration agreements, provided such payments are received within three years after the closing of the transaction. The Company also assumed warrants held by certain former shareholders of GenVec. The results of GenVec's operations subsequent to the acquisition date have been included in the consolidated financial statements.

The fair value of the total consideration transferred was $17,582. The acquisition date fair value of each class of consideration transferred is presented below:



Common shares	$	15,616
Warrants	1,381
Contingent consideration	585
	$	17,582

The fair value of the shares of the Company's common stock issued was based on the quoted closing price of the Company's common stock immediately prior to the closing of the acquisition. The fair value of the warrants assumed was estimated using the Black-Scholes option-pricing model. The fair value of the contingent consideration was determined using a probability weighted discounted cash flows model and is considered a freestanding financial instrument and recorded at fair value each reporting period. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:



Cash and cash equivalents	$	2,054
Short term investments	542
Trade receivables	75
Other receivables	97
Prepaid expenses and other	227
Property and equipment	250
Intangible assets	14,000
Other noncurrent assets	58
Total assets acquired	17,303
Accounts payable	2,158
Accrued compensation and benefits	1,226
Other accrued expenses	856
Other long term liabilities	92
Deferred tax liabilities	239
Total liabilities assumed	4,571
Net assets acquired	12,732
Goodwill	4,850
Total consideration	$	17,582

The acquired intangible assets include developed technology, the fair value of which was determined using the multi-period excess earning method, which is a variation of the income approach that converts future cash flows to single discounted present value amounts. The intangible assets are being amortized over a useful life of eleven years. Goodwill, which is not deductible for tax purposes, represents the assembled workforce and the anticipated buyer-specific synergies arising from the combination of the Company's and GenVec's technology.

Acquisition-related costs totaling $507 and $12 are included in selling, general and administrative expenses in the accompanying consolidated statements of operations for the years ended December 31, 2017 and 2016, respectively.

Oxitec Acquisition

In September 2015, pursuant to a Stock Purchase Agreement (the "Oxitec Purchase Agreement"), the Company acquired 100% of the issued outstanding share capital of Oxitec. The aggregated consideration paid consisted of (i) 1,359,343 shares of the Company's common stock (the "Stock Consideration") and (ii) $90,199 in cash (the "Cash Consideration"), inclusive of net cash and working capital adjustments as defined in the Oxitec Purchase Agreement totaling $9,449. Stock Consideration totaling 480,422 shares and Cash Consideration totaling $1,991 were withheld as escrow at closing and were issued and paid, respectively, in March 2017. The results of Oxitec's operations subsequent to the acquisition date have been included in the consolidated financial statements.

The fair value of the total consideration transferred was $146,394. The acquisition date fair value of the Stock Consideration and Cash Consideration is presented below:



Cash	$	90,199
Common shares	56,195
	$	146,394

The fair value of the shares of the Company common stock issued was based on the quoted closing price of the Company's common stock as of the closing date of the acquisition. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:



Cash	$	3,780
Trade receivables	125
Other receivables	7,395
Prepaid expenses and other	121
Property, plant, and equipment	1,198
Intangible assets	96,854
Total assets acquired	109,473
Accounts payable	1,187
Accrued compensation and benefits	246
Other accrued liabilities	210
Deferred revenue	120
Deferred tax liabilities	12,584
Total liabilities assumed	14,347
Net assets acquired	95,126
Goodwill	51,268
Total consideration	$	146,394

The acquired intangible assets primarily include in-process research and development, the fair value of which was determined using the multi-period excess earning method, which is a variation of the income approach that converts future cash flows to single discounted present value amounts. In November 2016, the Company re-evaluated certain of the acquired in-process research and development technology and determined it was placed in service as developed technology and began amortizing the original amount capitalized using a useful life of eighteen years. Goodwill, which is not deductible for tax purposes, represents the assembled workforce and the potential for future Oxitec products and technologies.

Acquisition-related costs totaling $1,675 are included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the year ended December 31, 2015.

Okanagan Acquisition

In April 2015, pursuant to a Stock Purchase Agreement (the "Okanagan Purchase Agreement"), the Company acquired 100% of the outstanding shares of Okanagan. Pursuant to the Okanagan Purchase Agreement, the former shareholders of Okanagan received an aggregate of 707,853 shares of the Company's common stock and $10,000 cash in exchange for all shares in Okanagan. The results of Okanagan's operations subsequent to the acquisition date have been included in the consolidated financial statements.

The fair value of the total consideration transferred was $40,933. The acquisition date fair value of each class of consideration transferred is presented below:



Cash	$	10,000
Common shares	30,933
	$	40,933

The fair value of the shares of the Company's common stock issued was based on the quoted closing price of the Company's common stock as of the closing date of the acquisition. The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:



Cash	$	58
Trade receivables	16
Other receivables	49
Property, plant, and equipment	32
Intangible assets	36,500
Total assets acquired	36,655
Accounts payable	181
Deferred revenue	181
Deferred tax liabilities	8,847
Total liabilities assumed	9,209
Net assets acquired	27,446
Goodwill	13,487
Total consideration	$	40,933

The acquired intangible assets primarily include developed technology, patents and know-how and the fair values of the acquired assets were determined using the with-and-without method, which is a variation of the income approach that utilizes estimated cash flows with all assets in place at the valuation date and estimated cash flows with all assets in place except the intangible assets at the valuation date. The intangible assets are being amortized over a useful life of fourteen years. Goodwill, which is not deductible for tax purposes, represents potential future applications of Okanagan's technology to other fruits, including additional apple varietals, and anticipated buyer-specific synergies arising from the combination of the Company's and Okanagan's technologies.

Acquisition-related costs totaling $267 are included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the year ended December 31, 2015.

ActoGeniX Acquisition

In February 2015, the Company acquired 100% of the membership interests of ActoGeniX NV ("ActoGeniX"), a European biopharmaceutical company, pursuant to a Stock Purchase Agreement (the "ActoGeniX Purchase Agreement"). ActoGeniX's platform technology complements the Company's suite of proprietary technologies available for current and future collaborators. Pursuant to the ActoGeniX Purchase Agreement, the former members of ActoGeniX received an aggregate of 965,377 shares of the Company's common stock and $32,739 in cash in exchange for all membership interests of ActoGeniX. The results of ActoGeniX's operations subsequent to the acquisition date have been included in the consolidated financial statements.

The fair value of the total consideration transferred was $72,474. The acquisition date fair value of each class of consideration transferred is presented below:



Cash	$	32,739
Common shares	39,735
	$	72,474



Cash	$	3,180
Other receivables	305
Prepaid expenses and other	31
Property, plant and equipment	209
Intangible assets	68,100
Other noncurrent assets	23
Total assets acquired	71,848
Accounts payable	230
Accrued compensation and benefits	196
Other accrued liabilities	253
Deferred revenue	732
Deferred tax liabilities	612
Total liabilities assumed	2,023
Net assets acquired	69,825
Goodwill	2,649
Total consideration	$	72,474

The acquired intangible assets primarily include in-process research and development, the fair value of which was determined using the multi-period excess earnings and with-and-without methods, which are both variations of the income approach that convert future cash flows to single discounted present value amounts. In August 2015, the Company re-evaluated the acquired in-process research and development technology and determined that it was placed in service as developed technology and began amortizing the original amount capitalized using a useful life of eighteen years. Goodwill, which is not deductible for tax purposes, represents the assembled workforce and anticipated buyer-specific synergies arising from the combination of the Company's and ActoGeniX's technologies.

Acquisition-related costs totaling $381 are included in selling, general and administrative expenses in the accompanying consolidated statement of operations for the year ended December 31, 2015.

Unaudited Condensed Pro Forma Financial Information

GenVec's results of operations subsequent to the acquisition are included in the consolidated statement of operations. The following unaudited condensed pro forma financial information for the years ended December 31, 2017 and 2016, is presented as if the acquisition had been consummated on January 1, 2016:



	Year Ended December 31,
	2017			2016
	Pro Forma
Revenues	$	231,213		$	191,437
Loss before income taxes	(136,966		)	(201,210		)
Net loss	(134,275		)	(197,144		)
Net loss attributable to the noncontrolling interests	9,802			3,662
Net loss attributable to Intrexon	(124,473		)	(193,482		)

The results of operations of the 2015 acquisitions discussed above subsequent to the acquisitions are included in the consolidated statement of operations. The following unaudited condensed pro forma financial information for the year ended December 31, 2015 is presented as if the 2015 acquisitions had been consummated on January 1, 2014:



	Year Ended December 31, 2015
	Pro Forma
Revenues	$	174,558
Loss before income taxes	(99,751		)
Net loss	(99,594		)
Net loss attributable to the noncontrolling interests	3,501
Net loss attributable to Intrexon	(96,093		)

Investments in Joint Ventures	12 Months Ended
Investments in Joint Ventures	Dec. 31, 2017
Equity Method Investments and Joint Ventures [Abstract]
Investments in Joint Ventures	Investments in Joint Ventures S & I Ophthalmic In September 2013, the Company entered into a Limited Liability Company Agreement ("Sun LLC Agreement") with Sun Pharmaceutical Industries, Inc. ("Sun Pharmaceutical Subsidiary"), an indirect subsidiary of Sun Pharmaceutical Industries Ltd. ("Sun Pharmaceutical"), an international specialty pharmaceutical company focused on chronic diseases, to form S & I Ophthalmic, LLC ("S & I Ophthalmic"). The Sun LLC Agreement governs the affairs and the conduct of business of S & I Ophthalmic. S & I Ophthalmic leverages experience and technology from both the Company and Sun Pharmaceutical. Both the Company and Sun Pharmaceutical Subsidiary made an initial capital contribution of $5,000 in October 2013 for a 50% membership interest in S & I Ophthalmic. S & I Ophthalmic is governed by a board of managers which has four members, two each from the Company and Sun Pharmaceutical Subsidiary. In 2015, both the Company and Sun Pharmaceutical Subsidiary made subsequent capital contributions of $5,000. In December 2017, both the Company and Sun Pharmaceutical Subsidiary agreed to dissolve S & I Ophthalmic and terminate the related ECC agreement. The Company is entitled to receive $2,598 upon the dissolution of S & I Ophthalmic which represents the Company's portion of S & I Ophthalmic's remaining cash after all liabilities are settled and is included in related party receivables in the accompanying consolidated balance sheet as of December 31, 2017. The Company's investment in S & I Ophthalmic was $3,236 as of December 31, 2016 and is included in investments in affiliates in the accompanying consolidated balance sheet. OvaXon In December 2013, the Company and OvaScience, Inc. ("OvaScience"), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, entered into a Limited Liability Company Agreement ("OvaXon LLC Agreement") to form OvaXon, LLC ("OvaXon"), a joint venture to create new applications for improving human and animal health. Both the Company and OvaScience made an initial capital contribution of $1,500 in January 2014 for a 50% membership interest in OvaXon. OvaXon is governed by the OvaXon board of managers ("OvaXon Board") which has four members, two each from the Company and OvaScience. In cases in which the OvaXon Board determines that additional capital contributions are necessary in order for OvaXon to conduct business and comply with its obligations, each of the Company and OvaScience has the right, but not the obligation, to make additional capital contributions to OvaXon subject to the OvaXon LLC Agreement. Through December 31, 2017, both the Company and OvaScience have made subsequent capital contributions of $4,350. The Company's investment in OvaXon was $146 and $65 as of December 31, 2017 and 2016, respectively, and is included in investments in affiliates in the accompanying consolidated balance sheets. See additional discussion in Note 22. Intrexon Energy Partners In March 2014, the Company and certain investors (the "IEP Investors"), including an affiliate of Third Security, LLC ("Third Security"), entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon Energy Partners, LLC ("Intrexon Energy Partners"), a joint venture formed to optimize and scale-up the Company's methane bioconversion platform ("MBP") technology for the production of certain fuels and lubricants. The Company also entered into an ECC with Intrexon Energy Partners providing exclusive rights to the Company's technology for the use in bioconversion, as a result of which the Company received a technology access fee of $25,000 while retaining a 50% membership interest in Intrexon Energy Partners. The IEP Investors made initial capital contributions, totaling $25,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners totaling 50%. In addition, Intrexon has committed to make capital contributions of up to $25,000, and the IEP Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners, have committed to make additional capital contributions of up to $25,000, at the request of Intrexon Energy Partners' board of managers (the "Intrexon Energy Partners Board") and subject to certain limitations. As of December 31, 2017, the Company's remaining commitment was $6,011. Intrexon Energy Partners is governed by the Intrexon Energy Partners Board which has five members. Two members of the Intrexon Energy Partners Board are designated by the Company and three members are designated by a majority of the IEP Investors. The Company and the IEP Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners Board. The Company's investment in Intrexon Energy Partners was $(444) and $(477) as of December 31, 2017 and 2016, respectively, and is included in other accrued liabilities in the accompanying consolidated balance sheets. Intrexon Energy Partners II In December 2015, the Company and certain investors (the "IEPII Investors"), including Harvest, entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon Energy Partners II, LLC ("Intrexon Energy Partners II"), a joint venture formed to utilize the Company's MBP technology for the production of 1,4-butanediol, an industrial chemical used to manufacture spandex, polyurethane, plastics, and polyester. The Company also entered into an ECC with Intrexon Energy Partners II which provides exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $18,000 while retaining a 50% membership interest in Intrexon Energy Partners II. The IEPII Investors made initial capital contributions, totaling $18,000 in the aggregate, in exchange for pro rata membership interests in Intrexon Energy Partners II totaling 50%. In December 2015, the owners of Intrexon Energy Partners II made a capital contribution of $4,000, half of which was paid by the Company. Intrexon has committed to make additional capital contributions of up to $10,000, and the IEPII Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon Energy Partners II, have committed to make additional capital contributions of up to $10,000, at the request of Intrexon Energy Partners II's board of managers (the "Intrexon Energy Partners II Board") and subject to certain limitations. Intrexon Energy Partners II is governed by the Intrexon Energy Partners II Board which has five members. One member of the Intrexon Energy Partners II Board is designated by the Company and four members are designated by a majority of the IEPII Investors. The Company and the IEPII Investors have the right, but not the obligation, to make additional capital contributions above the initial limits when and if solicited by the Intrexon Energy Partners II Board. The Company's investment in Intrexon Energy Partners II was $572 and $1,414 as of December 31, 2017 and 2016, respectively, and is included in investments in affiliates in the accompanying consolidated balance sheets. EnviroFlight In February 2016, the Company entered into a series of transactions involving EnviroFlight, LLC ("Old EnviroFlight"), Darling Ingredients Inc. ("Darling") and a newly formed venture between the Company and Darling ("New EnviroFlight"). The Company determined that the series of integrated transactions to acquire substantially all of the assets of Old EnviroFlight for cash, common stock, and contingent consideration should be accounted for as a single transaction, which constituted a business, and considered New EnviroFlight to be the accounting acquirer. Consideration paid to Old EnviroFlight was $4,244 in cash, 136,340 shares of the Company's common stock valued at $4,401 and contingent consideration estimated at $3,660. Contemporaneously, all the assets acquired from Old EnviroFlight, with the exception of certain developed technology, and $3,000 of cash were contributed to New EnviroFlight in exchange for a non-controlling, 50% membership interest in New EnviroFlight. The Company's contributions to New EnviroFlight included an exclusive license to the developed technology that was retained by the Company. Darling received the remaining 50% membership interest in New EnviroFlight as consideration for terminating rights previously held in the developed technology with Old EnviroFlight. New EnviroFlight was formed to generate high-nutrition, low environmental impact animal and fish feed, as well as fertilizer products, from black soldier fly larvae. The Company and Darling as members have each agreed to make additional capital contributions of up to $5,000 to fund ongoing operations of New EnviroFlight. As of December 31, 2017, the Company's remaining commitment was $250, which was satisfied in January 2018. All of the employees of Old EnviroFlight became employees of New EnviroFlight. The Company determined that its investment in New EnviroFlight should be accounted for using the equity method of accounting. The Company recorded an estimated fair value of $5,425 for its investment in New EnviroFlight and $9,880 for the retained developed technology intangible asset. The developed technology is being amortized over a period of twenty-one years. The contingent consideration liability payable to the members of Old EnviroFlight is considered a freestanding financial instrument and is recorded at fair value each reporting period. New EnviroFlight met a regulatory milestone, as defined in the asset purchase agreement, and the members of Old EnviroFlight received a portion of the contingent consideration consisting of 59,337 shares of the Company's common stock valued at $1,583 in October 2016. The members of Old EnviroFlight may receive up to $4,000 of additional shares of the Company's common stock if certain commercial milestones are met prior to February 2019. Based upon management's assessment of the likelihood of New EnviroFlight achieving the commercial milestones, the Company wrote-off the remaining balance of its estimated liability during the year ended December 31, 2017 (Note 8). The Company's investment in New EnviroFlight was $7,092 and $4,189 as of December 31, 2017 and 2016, respectively, and is included in investments in affiliates in the accompanying consolidated balance sheets. Intrexon T1D Partners In March 2016, the Company and certain investors (the "T1D Investors"), including affiliates of Third Security, entered into a Limited Liability Company Agreement which governs the affairs and conduct of business of Intrexon T1D Partners, LLC ("Intrexon T1D Partners"), a joint venture formed to utilize the Company's proprietary ActoBiotics platform to develop and commercialize products to treat type 1 diabetes. The Company also entered into an ECC with Intrexon T1D Partners which provides the exclusive rights to the Company's technology for use in the field, as a result of which the Company received a technology access fee of $10,000 while retaining a 50% membership interest in Intrexon T1D Partners. The T1D Investors made initial capital contributions, totaling $10,000 in the aggregate, in exchange for pro rata membership interests in Intrexon T1D Partners totaling 50%. Intrexon has committed to make capital contributions of up to $5,000, and the T1D Investors, as a group and pro rata in accordance with their respective membership interests in Intrexon T1D Partners, have committed to make additional capital contributions of up to $5,000, at the request of Intrexon T1D Partners' board of managers (the "Intrexon T1D Partners Board") and subject to certain limitations. As of December 31, 2017, the Company's remaining commitment was $2,900. Intrexon T1D Partners is governed by the Intrexon T1D Partners Board, which has five members. Two members of the Intrexon T1D Partners Board are designated by the Company and three members are designated by a majority of the T1D Investors. The Company and the T1D Investors have the right, but not the obligation, to make additional capital contributions above these limits when and if solicited by the Intrexon T1D Partners Board. The Company's investment in Intrexon T1D Partners was $(943) and $806 as of December 31, 2017 and 2016, respectively, and is included in other accrued liabilities and investments in affiliates, respectively, in the accompanying consolidated balance sheets.

Collaboration and Licensing Revenue

12 Months Ended

Dec. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Collaboration and Licensing Revenue

The Company's collaborations and licensing agreements provide for multiple deliverables to be delivered by the Company and typically include a license to the Company's technology platforms, participation in collaboration committees, performance of certain research and development services and may include obligations for certain manufacturing services. The Company typically groups these deliverables into two units of accounting based on the nature of the deliverables and the separation criteria. The first deliverable ("Unit of Accounting 1") includes the license to the Company's technology platform, the Company's participation on the collaboration committees and any research and development services associated with its technology platforms. The deliverables for Unit of Accounting 1 are combined because they cannot be individually separated. If applicable, the second deliverable ("Unit of Accounting 2") includes manufacturing services to be provided for any Company materials in an approved product. These services have standalone value and are contingent due to uncertainties on whether an approved product will ever be developed thereby requiring manufacture by the Company at that time. All upfront consideration is allocated to Unit of Accounting 1. Unit of Accounting 2 is determined to be a contingent deliverable at the inception of the collaboration due to the uncertainties surrounding whether an approved product will ever be developed and require manufacturing by the Company. The upfront consideration allocated to Unit of Accounting 1 is recognized over the expected life of the Company's technology platform using a straight-line approach which approximates the period the Company expects to complete its performance obligations.

The Company recognizes the reimbursement payments received for research and development services in the period when the services are performed and collection is reasonably assured. At the inception of each collaboration, the Company determines whether any milestone payments are substantive and can be recognized when earned. The milestone payments are typically not considered substantive. Royalties related to product sales will be recognized when earned since payments relate directly to products that have been fully developed and for which the Company has satisfied all of its obligations.

The Company determines whether collaborations and licensing agreements are individually significant for disclosure based on a number of factors, including total revenue recorded by the Company pursuant to collaboration and licensing agreements, collaborators or licensees with either majority-owned subsidiaries or equity method investments, or other qualitative factors. Collaboration and licensing revenues generated from consolidated subsidiaries are eliminated in consolidation. The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant collaboration or licensing agreement for the years ended December 31, 2017, 2016 and 2015.



	Year Ended December 31, 2017
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	48,313	$	21,499	$	69,812
Oragenics, Inc.	1,047		973		2,020
Fibrocell Science, Inc.	2,419		4,925		7,344
Genopaver, LLC	273		6,417		6,690
S & I Ophthalmic, LLC	—		755		755
OvaXon, LLC	—		1,966		1,966
Intrexon Energy Partners, LLC	2,500		8,165		10,665
Persea Bio, LLC	500		446		946
Ares Trading S.A.	6,389		4,349		10,738
Intrexon Energy Partners II, LLC	2,000		1,672		3,672
Intrexon T1D Partners, LLC	1,109		4,859		5,968
Harvest start-up entities (1)	2,442		12,790		15,232
Other	4,645		5,126		9,771
Total	$	71,637	$	73,942	$	145,579


(1)	For the year ended December 31, 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.



	Year Ended December 31, 2016
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	11,529	$	22,307	$	33,836
Oragenics, Inc.	1,047		1,705		2,752
Fibrocell Science, Inc.	2,419		3,523		5,942
Genopaver, LLC	273		5,844		6,117
S & I Ophthalmic, LLC	—		6,141		6,141
OvaXon, LLC	—		2,934		2,934
Intrexon Energy Partners, LLC	2,500		15,052		17,552
Persea Bio, LLC	500		778		1,278
Ares Trading S.A.	6,389		3,803		10,192
Intrexon Energy Partners II, LLC	2,000		1,169		3,169
Intrexon T1D Partners, LLC	821		1,087		1,908
Harvest start-up entities (1)	1,383		3,591		4,974
Other	5,572		7,504		13,076
Total	$	34,433	$	75,438	$	109,871


(1)	For the year ended December 31, 2016, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.



	Year Ended December 31, 2015
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	2,855	$	16,451	$	19,306
Oragenics, Inc.	5,679		856		6,535
Fibrocell Science, Inc.	6,046		6,133		12,179
Genopaver, LLC	273		3,556		3,829
S & I Ophthalmic, LLC	—		4,115		4,115
OvaXon, LLC	—		2,540		2,540
Intrexon Energy Partners, LLC	2,500		10,947		13,447
Persea Bio, LLC	500		741		1,241
Ares Trading S.A.	3,933		795		4,728
Intrexon Energy Partners II, LLC	167		—		167
Harvest start-up entities (1)	46		220		266
Other	10,514		8,954		19,468
Total	$	32,513	$	55,308	$	87,821


(1)	For the year ended December 31, 2015, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.

The following is a summary of the terms of the Company's significant collaborations and licensing agreements.

ZIOPHARM Collaborations

In January 2011, the Company entered into an ECC with ZIOPHARM, a related party. Pursuant to the ECC, ZIOPHARM received a license to the Company's technology platform within the field of oncology as defined more specifically in the agreement. Upon execution of the ECC, the Company received 3,636,926 shares of ZIOPHARM's common stock valued at $17,457 as upfront consideration. In addition to the deliverables discussed above, the Company transferred two clinical product candidates to ZIOPHARM that resulted in a separate unit of accounting for which $1,115 of the upfront consideration was allocated and recognized as collaboration revenue in 2011. The remaining $16,342 of upfront consideration was allocated to Unit of Accounting 1 discussed above. The Company was entitled to additional shares of common stock representing the lesser of (i) the original shares received or (ii) the number of shares representing 7.495% of ZIOPHARM's outstanding shares at the date of the dosing of the first patient in a Phase II clinical trial of a product candidate created, produced or developed by ZIOPHARM using the Company's technology ("ZIOPHARM Milestone"). In October 2012, the ZIOPHARM Milestone was achieved and the Company received 3,636,926 shares of ZIOPHARM's common stock valued at $18,330 as milestone consideration. Since the ZIOPHARM Milestone was not substantive, the Company allocated the ZIOPHARM Milestone to the applicable units of accounting and is recognizing it in a manner similar to these units of accounting. The Company receives reimbursement payments for research and development services provided and manufacturing services for Company materials provided to ZIOPHARM during the ECC. Subject to certain expense allocations, ZIOPHARM will pay the Company a percentage of the quarterly net profits derived from the sale of products developed from the ECC, as defined and amended in the agreement.

ZIOPHARM is responsible for conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of product candidates. The term of the ECC commenced in January 2011 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by ZIOPHARM upon 90 days written notice to the Company. In March 2015, in conjunction with the worldwide License and Collaboration Agreement ("Merck Agreement") with Ares Trading, a subsidiary of the biopharmaceutical business of Merck KGaA, and ZIOPHARM discussed below, the Company and ZIOPHARM amended their existing ECC. The amendment modifies the scope of the ECC in connection with the Merck Agreement and provides that the Company will pay to ZIOPHARM 50% of all payments received for upfront fees, milestones and royalties under the Merck Agreement.

In September 2015, the Company entered into its second ECC with ZIOPHARM ("ZIOPHARM ECC 2"). Pursuant to the ECC, ZIOPHARM received a license to the Company's technology platform to develop and commercialize novel biotherapeutics for the treatment of patients with graft-versus-host disease, or GvHD. Upon execution of ZIOPHARM ECC 2, the Company received a technology access fee of $10,000. The Company received reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to ZIOPHARM during the ECC. In December 2017, the Company and ZIOPHARM mutually agreed to terminate ZIOPHARM ECC2 and accordingly, the Company recognized the remaining balance of the deferred revenue associated with ZIOPHARM ECC2 totaling $28,943.

In June 2016, the Company amended each of its two existing collaboration agreements with ZIOPHARM and as a result the rate of the royalty which the Company is entitled to receive on certain products commercialized pursuant to the agreements was reduced from 50% to 20%. As consideration for execution of the amendments, ZIOPHARM issued the Company 100,000 shares of ZIOPHARM's Series 1 Preferred Stock valued at $120,000. The Company allocated the consideration received to each ECC based on the cumulative value of upfront and milestone payments previously received pursuant to that ECC. Because the Company has remaining performance obligations under each of the ZIOPHARM ECCs, the Company recorded the initial fair value received as deferred revenue and recognizes this amount straight-line over the remaining performance period for each ZIOPHARM ECC. No other financially significant terms of the ZIOPHARM ECCs were changed as a result of the amendments. See Note 7 for additional discussion of the terms of the preferred stock and the accounting treatment.

Oragenics Collaborations

In June 2012, the Company entered into an ECC with Oragenics, a publicly traded company focused on becoming the world leader in novel antibiotics against infectious diseases and a related party. Pursuant to the ECC, at the transaction effective date, Oragenics received a license to the Company's technology platform within the field of lantibiotics for the treatment of infectious diseases in humans and companion animals as defined more specifically in the agreement. Upon execution of the ECC, the Company received a technology access fee of 439,243 shares of Oragenics' common stock valued at $6,588 as upfront consideration. In November 2017, the Company amended the ECC agreement with Oragenics, and as a result, the Company is entitled to up to $35,000 of potential one-time payments for certain regulatory milestones. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Oragenics during the ECC. Oragenics will pay the Company 25% of the quarterly profits derived from the sale of products developed from the ECC, as defined in the agreement.

Oragenics is responsible for funding the further development of lantibiotics toward the goal of commercialization, conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of the product candidates. The term of the ECC commenced in June 2012 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Oragenics upon 90 days written notice to the Company.

In September 2013, the Company entered into its second ECC with Oragenics ("Oragenics ECC 2"). Pursuant to Oragenics ECC 2, at the transaction effective date, Oragenics received a license to the Company's technology platform to develop and commercialize probiotics, specifically the direct administration to humans of genetically modified probiotics for the treatment of diseases of the oral cavity, throat, sinus and esophagus as defined more specifically in the agreement. Upon execution of Oragenics ECC 2, the Company received a technology access fee of 134,800 shares of Oragenics' common stock valued at $3,503 and a $1,956 convertible promissory note maturing on or before December 31, 2013 as upfront consideration. Prior to the maturity date, Oragenics had the right to convert the promissory note into shares of Oragenics' common stock subject to its shareholders' approval. The conversion price was equal to the closing price of Oragenics' common stock on the last trading day immediately prior to the date of conversion. In December 2013, Oragenics converted the promissory note into 69,824 shares of Oragenics' common stock. In September 2015, Oragenics and the Company mutually agreed to terminate Oragenics ECC 2 and accordingly, the Company recognized the remaining balance of the deferred revenue associated with the upfront payment.

In June 2015, the Company entered into its third ECC with Oragenics ("Oragenics ECC 3"). Pursuant to Oragenics ECC 3, at the transaction effective date, Oragenics received a license to the Company's technology platform within the field of biotherapeutics for use in certain treatments of oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus. Upon execution of Oragenics ECC 3, the Company received a technology access fee of a $5,000 convertible promissory note maturing on or before December 31, 2015 as upfront consideration. Prior to the maturity date, Oragenics had the right to convert the promissory note into shares of Oragenics' common stock, subject to its shareholders' approval. In December 2015, Oragenics converted the promissory note into 338,100 shares of Oragenics' common stock. The Company is also entitled to up to $22,000 of potential payments for development and commercial milestones for each Oragenics product developed from Oragenics ECC 3 and up to $10,000 of potential one-time payments for certain regulatory milestones under Oragenics ECC 3. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Oragenics during Oragenics ECC 3. Oragenics will pay the Company royalties as a percentage in the low-teens of net sales derived from the sale of products developed from Oragenics ECC 3, as defined in the agreement. In November 2017, the Company amended the Oragenics ECC 3 agreement, and as a result, the Company is entitled to an additional $5,500 of potential payments for development and commercial milestones for each Oragenics product developed from Oragenics ECC 3.

Oragenics is responsible for funding the further development of Oragenics ECC 3 products towards the goal of commercialization, conducting preclinical and clinical development of product candidates, as well as for other aspects of commercialization or manufacturing of the product candidates. The term of Oragenics ECC 3 commenced in June 2015 and may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Oragenics upon 90 days written notice to the Company.

All Oragenics share data noted above reflect a 1-for-10 reverse stock split of Oragenics' common stock effective January 19, 2018.

Fibrocell Science Collaborations

In October 2012, the Company entered into an ECC ("Fibrocell ECC 1") with Fibrocell Science, Inc. ("Fibrocell"), a publicly traded cell and gene therapy company focused on diseases affecting the skin and connective tissue and a related party. Pursuant to the ECC, at the transaction effective date, Fibrocell received a license to the Company's technology platform to develop and commercialize genetically modified and non-genetically modified autologous fibroblasts and autologous dermal cells in the United States of America. Upon execution of the ECC, the Company received a technology access fee of 439,173 shares of Fibrocell's common stock valued at $7,576 as upfront consideration. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Fibrocell during the ECC. On a quarterly basis, Fibrocell will pay the Company royalties of 7% of net sales up to $25,000 and 14% of net sales above $25,000 on each product developed from the ECC, as defined in the agreement. If Fibrocell uses the Company's technology platform to improve the production of a current or new Fibrocell product not developed from the ECC, Fibrocell will pay the Company quarterly royalties equal to 33% of the cost of goods sold savings generated by the improvement, as defined in the agreement.

Fibrocell is responsible for conducting preclinical and clinical development of product candidates associated with Fibrocell ECC 1, as well as for other aspects of commercialization and manufacturing of the product candidates. The term of the ECC commenced in October 2012 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Fibrocell upon 90 days written notice to the Company.

In June 2013, the Company and Fibrocell entered into an amendment to the Fibrocell ECC 1. The amendment expanded the field of use defined in the ECC agreement. Under the terms of the amendment to the Fibrocell ECC 1, the Company received 414,594 shares of Fibrocell's common stock valued at $7,612 as a supplemental technology access fee. The Company allocated this additional consideration to the appropriate unit of accounting and is recognizing it consistent with the unit of accounting.

In January 2014, the Company and Fibrocell entered into a second amendment to the Fibrocell ECC 1. The second amendment further expanded the field of use defined in the ECC agreement. Under the terms of the second amendment to the Fibrocell ECC 1, the Company received 341,530 shares of Fibrocell's common stock valued at $5,225 as a supplemental technology access fee. The Company allocated this additional consideration to the appropriate unit of accounting. In September 2015, Fibrocell and the Company mutually agreed to terminate the second amendment to the ECC and accordingly, the Company recognized the remaining balance of deferred revenue associated with the related upfront payment.

In December 2015, the Company entered into a second ECC with Fibrocell ("Fibrocell ECC 2"). Pursuant to the ECC, at the transaction effective date, Fibrocell received a license to the Company's technology platform to develop and commercialize genetically-modified fibroblasts to treat chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions. Upon execution of the ECC, the Company received a technology access fee of $10,000. The Company is also entitled to (i) up to $30,000 of potential one-time payments for certain development and regulatory milestones for the first product developed under Fibrocell ECC 2, (ii) up to $30,000 of potential payments for certain regulatory milestones for each additional product developed under Fibrocell ECC 2, and (iii) up to $22,500 of potential payments for certain sales milestones for each product developed under Fibrocell ECC 2. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC and manufacturing services for Company materials provided to Fibrocell during the ECC. Fibrocell will pay the Company royalties as a percentage in the low double-digits of net sales derived from the sale of products developed from Fibrocell ECC 2, as defined in the agreement.

Fibrocell is responsible for conducting preclinical and clinical development of product candidates associated with Fibrocell ECC 2, as well as for other aspects of commercialization and manufacturing of the product candidates. The term of the ECC commenced in December 2015 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Fibrocell upon 90 days written notice to the Company.

All Fibrocell share data noted above reflect a 1-for-3 reverse stock split of Fibrocell's common stock effective March 10, 2017.

Genopaver Collaboration

In March 2013, the Company entered into an ECC with Genopaver, LLC ("Genopaver"), an affiliate of Third Security and a related party. Genopaver was formed for the purpose of entering into the ECC and developing and commercializing products in the field of the fermentative production of alkaloids through genetically modified cell-lines and substrate feeds for use as active pharmaceutical ingredients or as commercially sold intermediates in the manufacture of active pharmaceutical ingredients. Upon execution of the ECC, the Company received a technology access fee of $3,000 as upfront consideration. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC. Genopaver will pay the Company royalties as a percentage in the lower-double digits on the quarterly gross profits of product sales from products developed under the ECC, as defined in the agreement. Genopaver is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in March 2013 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Genopaver upon 90 days written notice to the Company.

AquaBounty Collaboration

In February 2013, the Company entered into an ECC with AquaBounty, a majority-owned consolidated subsidiary. The Company will be reimbursed for research and development services as provided for in the ECC agreement. In the event of product sales from a product developed from the ECC, the Company will receive 16.66% of quarterly gross profits for each product, as defined in the agreement. All revenues and expenses related to this ECC are eliminated in consolidation.

S & I Ophthalmic Collaboration

In September 2013, the Company entered into an ECC with S & I Ophthalmic, a joint venture between the Company and Sun Pharmaceutical Subsidiary, an indirect subsidiary of Sun Pharmaceutical, an international specialty pharmaceutical company focused on chronic diseases, and a related party. The ECC granted S & I Ophthalmic an exclusive license to the Company's technology platform to develop and commercialize therapies in humans for the treatment of ocular diseases defined more specifically in the agreement. The Company was reimbursed for research and development services pursuant to the agreement and manufacturing services for Company materials provided to S & I Ophthalmic during the ECC. The term of the ECC commenced in September 2013. In December 2017, the Company and Sun Pharmaceutical Subsidiary mutually agreed to terminate the ECC and dissolve the joint venture.

OvaXon Collaboration

In December 2013, the Company entered into an ECC with OvaXon, a joint venture between the Company and OvaScience, a life sciences company focused on infertility treatments, and a related party. The ECC grants OvaXon an exclusive license to the Company's technology platform to create new applications for improving human and animal health. OvaScience also licensed certain technology to OvaXon pursuant to a separate license agreement. The Company will be reimbursed for research and development services and manufacturing services as provided for in the ECC agreement. The term of the ECC commenced in December 2013 and continues until terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by OvaXon upon 90 days written notice to the Company. See additional discussion in Note 22.

Intrexon Energy Partners Collaboration

In March 2014, the Company entered into an ECC with Intrexon Energy Partners, a joint venture between the Company and certain investors and a related party. The ECC grants Intrexon Energy Partners an exclusive license to the Company's technology platform to optimize and scale-up the Company's methane bioconversion platform for the production of certain fuels and lubricants. Upon execution of the ECC, the Company received a technology access fee of $25,000 as upfront consideration. The Company will be reimbursed for research and development services as provided for in the ECC agreement. The term of the ECC commenced in March 2014 and continues until March 2034 unless terminated prior to that date by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Intrexon Energy Partners upon 90 days written notice to the Company.

Persea Bio Collaboration

In December 2014, the Company entered into an ECC with Persea Bio, LLC ("Persea Bio"), an affiliate of Third Security and a related party. Persea Bio was formed for the purpose of entering into the ECC and developing and commercializing a food program, as defined in the agreement. Upon effectiveness of the ECC, the Company received a technology access fee of $5,000 as upfront consideration. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC. Persea Bio will pay the Company royalties as a percentage in the lower-double digits on the quarterly gross profits of product sales from products derived from the ECC, as defined in the agreement. Persea Bio is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in December 2014 and continues until terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Persea Bio upon 90 days written notice to the Company.

Merck Licensing Agreement

In March 2015, the Company signed the Merck Agreement with Ares Trading and ZIOPHARM through which the parties established a collaboration for the research and development and commercialization of certain products for the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans. Pursuant to the Merck Agreement, the Company received a technology access fee of $115,000 as upfront consideration, of which $57,500 was paid to ZIOPHARM in accordance with the terms of the agreement. Upon the selection of the first two targets by Ares Trading, the Company received $10,000 in equal quarterly installments over two years. The Company is entitled to receive a further $5,000 for each additional target selected by Ares Trading. The Company is also entitled to up to $413,000 of potential payments for substantive and non-substantive development and commercial milestones for each product, and royalties ranging from the lower-single digits to the low-teens of the net sales derived from the sale of products developed under the Merck Agreement. The Company may also receive up to $50,000 of further cash fees upon certain technical milestones as provided for in the agreement. The term of the Merck Agreement commenced in May 2015 and may be terminated by either party in the event of a material breach as defined in the agreement and may be terminated voluntarily by Ares Trading upon 90 days written notice to the Company. The Company will pay to ZIOPHARM 50% of all payments received for upfront fees, milestones, and royalties under the Merck Agreement.

Thrive Agrobiotics Collaboration

In September 2015, the Company entered into an ECC with Thrive Agrobiotics, Inc. ("Thrive Agrobiotics"), an affiliate of Harvest and a related party. Thrive Agrobiotics was formed for the purpose of entering into the ECC and developing and commercializing products to improve the overall growth and feed efficiency in piglets. Upon execution of the ECC, the Company received a technology access fee in the form of equity in Thrive Agrobiotics valued at $1,667 as upfront consideration. The Company is also entitled to up to $5,500 of potential payments for development and commercial milestones for each product developed under the ECC. The Company receives reimbursement payments for research and development services provided pursuant to the agreement during the ECC. Thrive Agrobiotics will pay the Company royalties as a percentage in the lower-double digits on the quarterly gross profits of product sales from products developed under the ECC, as defined in the agreement. Thrive Agrobiotics is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in September 2015 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Thrive Agrobiotics upon 90 days written notice to the Company.

Intrexon Energy Partners II Collaboration

In December 2015, the Company entered into an ECC with Intrexon Energy Partners II, a joint venture between the Company and certain investors and a related party. Pursuant to the ECC, Intrexon Energy Partners II received an exclusive license to the Company's technology platform to optimize and scale-up the Company's methane bioconversion platform for the production of 1,4-butanediol (BDO), a key chemical intermediate that is used to manufacture spandex, polyurethane, plastics, and polyester. Upon execution of the ECC, the Company received a technology access fee of $18,000 and is entitled to reimbursement of research and development services as provided for in the ECC agreement. The term of the ECC commenced in December 2015 and continues until December 2035; termination prior to that date may be initiated (i) by either party in the event of certain material breaches defined in the agreement or (ii) may be terminated voluntarily by Intrexon Energy Partners II upon 90 days written notice to the Company.

Exotech Bio Collaboration

In March 2016, the Company entered into an ECC with Exotech Bio, Inc. ("Exotech Bio"), an affiliate of Harvest and a related party. Exotech Bio was formed for the purpose of entering into the ECC and developing and commercializing products using exosomes carrying a RNA payload designed to kill, suppress, or render immune-visible a cancer cell. Upon execution of the ECC, the Company received a technology access fee in the form of equity in Exotech Bio valued at $5,000 as upfront consideration. The Company is also entitled to up to $52,500 of potential payments for substantive and non-substantive development and commercial milestones for each product developed under the ECC. The Company receives reimbursement payments for research and development services provided pursuant to the ECC. Exotech Bio will pay the Company royalties as a percentage in the lower double-digits on the quarterly net sales of products developed under the ECC, as defined in the agreement. Exotech Bio is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in March 2016 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Exotech Bio upon 90 days written notice to the Company.

Relieve Genetics Collaboration

In March 2016, the Company entered into an ECC with Relieve Genetics, Inc. ("Relieve Genetics"), an affiliate of Harvest and a related party. Relieve Genetics was formed for the purpose of entering into the ECC and developing and commercializing products using a viral vector expressing interleukin-10 for the treatment of chronic neuropathic pain resultant from cancer in humans. Upon execution of the ECC, the Company received a technology access fee in the form of equity in Relieve Genetics valued at $4,333 as upfront consideration. The Company is also entitled to up to $52,500 of potential payments for substantive and non-substantive development and commercial milestones for each product developed under the ECC. The Company receives reimbursement payments for research and development services provided pursuant to the ECC. Relieve Genetics will pay the Company royalties as a percentage in the lower double-digits on the quarterly net sales of products developed under the ECC, as defined in the agreement. Relieve Genetics is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in March 2016 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Relieve Genetics upon 90 days written notice to the Company.

Intrexon T1D Partners Collaboration

In March 2016, the Company entered into an ECC with Intrexon T1D Partners, a joint venture between the Company and certain investors and a related party. Pursuant to the ECC, Intrexon T1D Partners received an exclusive license to the Company's technology platform to develop and commercialize products to treat type 1 diabetes. Upon execution of the ECC, the Company received a technology access fee of $10,000 and is entitled to reimbursement of research and development services as provided for in the ECC agreement. The term of the ECC commenced in March 2016 and continues until March 2036; termination prior to that date may be initiated (i) by either party in the event of certain material breaches defined in the agreement or (ii) may be terminated Intrexon T1D Partners upon 90 days written notice to the Company.

AD Skincare Collaboration

In June 2016, the Company entered into an ECC with AD Skincare, Inc. ("AD Skincare"), an affiliate of Harvest and a related party. AD Skincare was formed for the purpose of entering into the ECC and developing an advanced topical delivery system to improve the efficacy of biologically active ingredients aimed at improving signs of aging human skin. Upon execution of the ECC, the Company received a technology access fee in the form of equity in AD Skincare valued at $4,333 as upfront consideration. The Company is also entitled to up to $2,000 of potential payments for substantive and non-substantive development milestones for each product developed under the ECC, as well as up to $17,000 in one-time commercial milestones. The Company receives reimbursement payments for research and development services provided pursuant to the ECC. AD Skincare will pay the Company royalties as a percentage in the low double-digits on the quarterly net sales of products developed under the ECC, as defined in the agreement. AD Skincare is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in June 2016 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by AD Skincare upon 90 days written notice to the Company.

Genten Therapeutics Collaboration

In September 2016, the Company entered into an ECC with Genten Therapeutics, Inc. ("Genten Therapeutics"), an affiliate of Harvest and a related party. Genten Therapeutics was formed for the purpose of entering into the ECC and developing and commercializing products using the Company's technology for expression of gluten peptides, alone or in combination with immunomodulatory cytokines, to reestablish immune tolerance for patients with celiac disease. Upon execution of the ECC, the Company received a technology access fee in the form of a $1,500 cash payment and equity in Genten Therapeutics valued at $3,000 as upfront consideration. The Company is entitled to receive additional equity interests in Genten Therapeutics upon the first instance of the achievement of a certain non-substantive development milestone. The Company is also entitled to up to $82,000 of potential payments for substantive and non-substantive development and commercial milestones for each product developed under the ECC. The Company receives reimbursement payments for research and development services provided pursuant to the ECC. Genten Therapeutics will pay the Company royalties as a percentage in the lower double-digits on the quarterly net sales of products developed under the ECC, as defined in the agreement. Genten Therapeutics is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in September 2016 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by Genten Therapeutics upon 90 days written notice to the Company.

CRS Bio Collaboration

In September 2016, the Company entered into an ECC with CRS Bio, Inc. ("CRS Bio"), an affiliate of Harvest and a related party. CRS Bio was formed for the purpose of entering into the ECC and developing and commercializing products through targeted delivery of antibodies for treatment of chronic rhinosinusitis with and without nasal polyps, by utilizing the Company's technology to block inflammatory mediators in the nasal passage, leading to improved breathing and, importantly, patients' quality of life. Upon execution of the ECC, the Company received a technology access fee in the form of equity in CRS Bio valued at $2,100. The Company is entitled to receive additional equity interests in CRS Bio upon the first instance of the achievement of a certain non-substantive development milestone. The Company is also entitled to up to $75,000 of potential payments for substantive and non-substantive development and commercial milestones for each product developed under the ECC. The Company receives reimbursement payments for research and development services provided pursuant to the ECC. CRS Bio will pay the Company royalties as a percentage in the lower double-digits on the quarterly net sales of products developed under the ECC, as defined in the agreement. CRS Bio is responsible for the development and commercialization of the product candidates. The term of the ECC commenced in September 2016 and continues until terminated pursuant to the ECC agreement. The ECC may be terminated by either party in the event of certain material breaches defined in the agreement and may be terminated voluntarily by CRS Bio upon 90 days written notice to the Company.

Deferred Revenue

Deferred revenue primarily consists of consideration received for upfront and milestone payments in connection with the Company's collaborations and licensing agreements, prepayments for research and development services performed for collaborators and licensees, and prepayments for product and service revenues. Deferred revenue consists of the following:



	December 31,
	2017		2016
Upfront and milestone payments	$	230,531	$	297,867
Prepaid research and development services	1,052		6,015
Prepaid product and service revenues	4,681		5,554
Other	133		706
Total	$	236,397	$	310,142
Current portion of deferred revenue	$	42,870	$	53,364
Long-term portion of deferred revenue	193,527		256,778
Total	$	236,397	$	310,142

The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement.



	December 31,
	2017		2016
ZIOPHARM Oncology, Inc.	$	90,496	$	138,809
Oragenics, Inc.	6,719		7,766
Fibrocell Science, Inc.	16,607		19,026
Genopaver, LLC	1,704		1,977
Intrexon Energy Partners, LLC	15,625		18,125
Persea Bio, LLC	3,500		4,000
Ares Trading S.A.	40,789		47,178
Intrexon Energy Partners II, LLC	13,833		15,833
Intrexon T1D Partners, LLC	8,435		8,653
Harvest start-up entities (1)	18,400		20,208
Other	14,423		16,292
Total	$	230,531	$	297,867


(1)	As of December 31, 2017 and December 31, 2016, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.

Short-term and Long-term Investments

12 Months Ended

Dec. 31, 2017

Investments, Debt and Equity Securities [Abstract]

Short-term and Long-term Investments

The Company's investments are classified as available-for-sale. The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of December 31, 2017:



	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Aggregate Fair Value
U.S. government debt securities	$	6,000	$	—	$	(2	)	$	5,998
Certificates of deposit	275		—		—			275
Total	$	6,275	$	—	$	(2	)	$	6,273

The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of December 31, 2016:



	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Aggregate Fair Value
U.S. government debt securities	$	180,412	$	5	$	(94	)	$	180,323
Certificates of deposit	272		—		—			272
Total	$	180,684	$	5	$	(94	)	$	180,595

For more information on the Company's method for determining the fair value of its assets, see Note 2 – "Fair Value of Financial Instruments".

As of December 31, 2017, all of the available-for-sale investments were due within one year based on their contractual maturities.

Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. The unrealized losses of the Company's investments were primarily a result of unfavorable changes in interest rates subsequent to the initial purchase of these investments and are not significant as of December 31, 2017.

As of December 31, 2017 and 2016, the Company did not consider any of its investments to be other-than-temporarily impaired. When evaluating its investments for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer, the Company's ability and intent to hold the security and whether it is more likely than not that it will be required to sell the investment before recovery of its cost basis.

Investments in Preferred Stock

12 Months Ended

Dec. 31, 2017

Investment in Preferred Stock [Abstract]

Investments In Preferred Stock

Investments in Preferred Stock

Investment in ZIOPHARM Preferred Stock

In June 2016, the Company received 100,000 shares of Series 1 Preferred Stock (the "Preferred Shares") of ZIOPHARM with a per share stated value of $1,200, as consideration for amending their two previously existing ECC agreements (Note 5). A summary of the terms of the Preferred Shares follows.

Conversion. The Preferred Shares shall automatically convert into shares of ZIOPHARM common stock upon the date the first approval in the United States of (i) a ZIOPHARM product, as defined in and developed under one of the ECC agreements, or (ii) a product, as defined and developed under the License and Collaboration Agreement with Ares Trading and ZIOPHARM, is publicly announced (the "Conversion Event Date"). The Preferred Shares shall convert into a number of shares of ZIOPHARM common stock equal to the stated value of such Preferred Share, divided by the greater of: (i) the volume weighted average closing price of ZIOPHARM's common stock over the twenty trading days ending on the Conversion Event Date or (ii) $1.00. The number of converted shares is subject to certain limitations defined in the amended and restated Certificate of Designation, Preferences, and Rights of Series 1 Preferred Stock (the "A&R Certificate of Designation").

Dividend Rights. The Company shall receive a monthly dividend, payable in additional Preferred Shares, equal to $12.00 per Preferred Share held per month divided by the stated value of the Preferred Shares, which is referred to as the PIK Dividend. For any Preferred Shares that are not converted on the Conversion Event Date, the rate of PIK Dividend on these unconverted Preferred Shares will automatically increase from $12.00 to $24.00 per Preferred Share per month.

Voting Rights. The Preferred Shares do not have any voting rights except for certain protective voting rights defined in the A&R Certificate of Designation.

Liquidation Rights. In the event of any voluntary or involuntary liquidation, dissolution or winding up of ZIOPHARM or a deemed liquidation event, as defined in the A&R Certificate of Designation, including a change of control or the sale, lease transfer, or exclusive license of all or substantially all of ZIOPHARM's assets, the holders of the Preferred Shares shall be entitled to receive a portion of all funds to be distributed in proportion to the holders' proportionate share of ZIOPHARM's common stock on an as-converted to common stock basis (the "Series 1 Liquidation Amount"). For purposes of calculating the Series 1 Liquidation Amount, if such liquidation event occurs prior to the Conversion Event Date, each Preferred Share shall be deemed to be convertible into the number of shares of ZIOPHARM's common stock equal to (i) the stated value of each Preferred Share, divided by (ii) the volume weighted average price of ZIOPHARM's common stock for the twenty day period ending on the date of the public announcement of the liquidation event. In addition, ZIOPHARM may elect to redeem the Preferred Shares in connection with or following a deemed liquidation event at a price per share equal to the Series 1 Liquidation Amount.

The investment in ZIOPHARM preferred stock is categorized as Level 3 as there are significant unobservable inputs and the Preferred Shares are not traded on a public exchange. The fair value of the investment in ZIOPHARM preferred stock is estimated using a probability-weighted expected return ("PWERM") model. The key inputs used in the PWERM model are (i) estimating the future returns for conversion of the Preferred Shares for both product approval and a change in control of ZIOPHARM (the "conversion events") using market data of the change in value for guideline companies as a result of these conversion events; (ii) estimating the expected date and likelihood of each conversion event; and (iii) discounting these estimated future returns using a discount rate for the Preferred Shares considering industry debt issuances originated by public funds and venture capital rates of return. A significant change in unobservable inputs discussed above could result in a significant impact on the fair value of the Company's investment in ZIOPHARM preferred stock. The fair value of the Company's investment in ZIOPHARM preferred stock, including additional Preferred Shares received as dividends, was $160,832 and $129,545 as of December 31, 2017 and 2016, respectively. During the years ended December 31, 2017 and 2016, the Company received 13,460 shares and 6,184 shares, respectively, of additional Preferred Shares and recognized $16,717 and $7,421, respectively, of dividend income in the accompanying consolidated statements of operations.

Investment in Fibrocell Preferred Stock

In March 2017, Fibrocell sold Series A Convertible Preferred Stock (the "Convertible Preferred Shares") convertible into shares of Fibrocell common stock and warrants to purchase shares of Fibrocell common stock to certain institutional and accredited investors, including the Company and affiliates of Third Security. The Company paid $1,161 in exchange for 1,161 Convertible Preferred Shares and warrants to acquire 498,843 shares of Fibrocell common stock, reflective of the 1-for-3 reverse stock split of Fibrocell's common stock effective March 10, 2017. The Convertible Preferred Shares are convertible at any time at the election of the Company and accrue dividends at 4% per annum, compounded quarterly, increasing the stated value of the shares. The investment in Fibrocell preferred stock is categorized as Level 3 as there are significant unobservable inputs and the Convertible Preferred Shares are not traded on a public exchange. The fair value of the investment in Fibrocell preferred stock is estimated using a conversion plus dividend approach utilizing the trading value of the underlying common stock and an estimated premium for the preferred stock dividend and other preferences. Market price volatility of Fibrocell's common stock and a significant change in the estimated preferred stock premium could result in a significant impact to the fair value of the investment in Fibrocell preferred stock. As of December 31, 2017, the fair value of the Company's investment in Fibrocell preferred stock was $393. See Note 18 for additional discussion of the warrants.

Investment in Oragenics Preferred Stock

In November 2017, concurrent with Oragenics closing a preferred stock private placement, the Company exchanged a promissory note, including accrued interest, purchased from Oragenics in May 2017 and receivables due from Oragenics totaling $3,385 for Oragenics Series C preferred stock ("Series C Preferred Stock"). The Series C Preferred Stock is non-voting and non-convertible and is redeemable in whole or part at any time by Oragenics in cash. The Series C Preferred Stock accrues an annual 12% dividend payable in additional Series C Preferred Stock through May 10, 2019, and after such date, the annual dividend increases to 20%. Additionally, the Company and Oragenics amended certain future payment terms under its ECCs (Note 5). As of December 31, 2017, based on the most recent financial information available on Oragenics, the Company concluded that there was no value to its investment in Oragenics preferred stock.

Changes in the Fair Value of Investments in Preferred Stock

The following table summarizes the changes in the Level 3 investments in preferred stock during the years ended December 31, 2017 and 2016.



	2017		2016
Beginning balance	$	129,545	$	—
Receipt of preferred stock as consideration for amendments to collaboration agreements	—		120,000
Purchase of preferred stock	766		—
Conversion of receivables to preferred stock	3,385		—
Dividend income from investments in preferred stock	16,756		7,421
Net unrealized appreciation in the fair value of the investments in preferred stock	10,773		2,124
Ending balance	$	161,225	$	129,545

Fair Value Measurements

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Fair Value Measurements

The carrying amount of cash and cash equivalents, restricted cash, receivables, prepaid expenses and other current assets, accounts payable, accrued compensation and benefits, other accrued liabilities, and related party payables approximate fair value due to the short maturity of these instruments.

The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis, including the items for which the fair value option has been elected, as of December 31, 2017:



	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		December 31, 2017
Assets
U.S. government debt securities	$	—	$	5,998	$	—	$	5,998
Equity securities	10,537		4,563		—		15,100
Preferred stock	—		—		161,225		161,225
Other	—		850		—		850
Total	$	10,537	$	11,411	$	161,225	$	183,173



	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		December 31, 2016
Assets
U.S. government debt securities	$	—	$	180,323	$	—	$	180,323
Equity securities	15,544		7,978		—		23,522
Preferred stock	—		—		129,545		129,545
Other	—		1,917		—		1,917
Total	$	15,544	$	190,218	$	129,545	$	335,307

The method used to estimate the fair value of the Level 1 assets in the tables above is based on observable market data as these equity securities are publicly-traded. The method used to estimate the fair value of the Level 2 short-term and long-term investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets. The method used to estimate the fair value of the Level 2 equity securities in the tables above is based on the quoted market price of the publicly-traded security, adjusted for a discount for lack of marketability. The methods used to estimate the fair value of the Level 3 assets are discussed in Note 7.

There were no transfers between levels of the fair value hierarchy during the year ended December 31, 2017.

The carrying values of the Company's long term debt approximates fair value due to the length of time to maturity and/or the existence of interest rates that approximate prevailing market rates. The Company's contingent consideration liabilities (Notes 3 and 4) are measured on a recurring basis and were $585 and $2,081 as of December 31, 2017 and 2016, respectively. These fair value measurements were based on significant inputs not observable in the market and thus represented a Level 3 measurement. A significant change in unobservable inputs could result in a significant impact on the fair value of the Company's contingent consideration liabilities. The contingent consideration liabilities are remeasured to fair value at each reporting date until the contingency is resolved, and those changes in fair value are recognized in earnings. The changes in the fair value of the Level 3 liabilities during the years ended December 31, 2017 and 2016 were as follows:



	2017			2016
Beginning balance	$	2,081		$	—
Acquisition date fair value of contingent consideration liability	585			3,660
Payment of contingent consideration (Note 4)	—			(1,583		)
Change in fair value of contingent consideration recognized in selling, general and administrative expenses	(2,081		)	4
Ending balance	$	585		$	2,081

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Inventory

12 Months Ended

Dec. 31, 2017

Inventory Disclosure [Abstract]

Inventory

Inventory consists of the following:



	December 31,
	2017		2016
Supplies, embryos and other production materials	$	2,673	$	1,835
Work in process	4,767		5,466
Livestock	11,040		11,752
Feed	2,013		2,086
Total inventory	$	20,493	$	21,139

Property, Plant and Equipment, Net

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment, Net

Property, plant and equipment consist of the following:



	December 31,
	2017			2016
Land and land improvements	$	11,767		$	10,904
Buildings and building improvements	18,183			8,123
Furniture and fixtures	2,515			2,176
Equipment	65,863			44,392
Leasehold improvements	25,277			15,105
Breeding stock	3,832			3,893
Computer hardware and software	10,128			6,844
Trees	6,642			2,772
Construction and other assets in progress	14,113			4,513
	158,320			98,722
Less: Accumulated depreciation and amortization	(45,646		)	(34,050		)
Property, plant and equipment, net	$	112,674		$	64,672

Depreciation expense was $11,951, $9,387 and $7,872 for the years ended December 31, 2017, 2016 and 2015, respectively.

Included in the table above is $14,219 of land, buildings, and equipment related to a 2017 asset acquisition of a land-based aquaculture facility to be used in the production of AquAdvantage salmon in Indiana.

Goodwill and Intangible Assets, Net

12 Months Ended

Dec. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets, Net

The changes in the carrying amount of goodwill for the years ended December 31, 2017 and 2016, are as follows:



	2017			2016
Beginning balance	$	157,175		$	165,169
Acquisitions	4,850			—
Impairment	(13,823		)	—
Foreign currency translation adjustments	5,087			(7,994		)
Ending balance	$	153,289		$	157,175

For the year ended December 31, 2017, the Company recorded a $13,823 goodwill impairment charge, which primarily relates to AquaBounty. During the Company's annual goodwill impairment test, the Company determined, based on the price per share received by AquaBounty in its recent underwritten public offering (Note 22), it was more-likely-than-not that the fair value of the AquaBounty reporting unit was less than its carrying amount. As a result, the Company compared the carrying amount of the AquaBounty reporting unit to the fair value and determined the carrying amount exceeded the fair value resulting in a $13,001 goodwill impairment charge for the excess carrying value. The Company did not recognize any goodwill impairment charges during the years ended December 31, 2016 or 2015, and there were no accumulated impairment charges as of December 31, 2016.

Intangible assets consist of the following as of December 31, 2017:



	Weighted Average Useful Life (Years)	Gross Carrying Amount		Accumulated Amortization			Net
Patents, developed technologies and know-how	15.9	$	263,615	$	(44,954	)	$	218,661
Customer relationships	6.5	10,700		(6,383		)	4,317
Trademarks	9.3	6,800		(2,567		)	4,233
In-process research and development		5,666		—			5,666
Total		$	286,781	$	(53,904	)	$	232,877

Intangible assets consist of the following as of December 31, 2016:



	Gross Carrying Amount		Accumulated Amortization			Net
Patents, developed technologies and know-how	$	236,401	$	(29,748	)	$	206,653
Customer relationships	10,700		(4,672		)	6,028
Trademarks	6,800		(1,792		)	5,008
Covenant not to compete	370		(339		)	31
In-process research and development	7,895		—			7,895
Total	$	262,166	$	(36,551	)	$	225,615

The balance of in-process research and development includes certain in-process research and development technology acquired in the Company's acquisition of Oxitec in September 2015, and amortization will begin once certain regulatory approvals have been obtained for the in-process programs. In 2017, the Company decided to forgo further development for certain of its in-process research and development assets and, as a result, recorded an impairment charge of $2,950.

Amortization expense was $19,194, $15,185 and $9,871 for the years ended December 31, 2017, 2016 and 2015, respectively. Estimated aggregate amortization expense for definite lived intangible assets is expected to be as follows:



2018	$	19,258
2019	18,935
2020	18,833
2021	18,645
2022	17,646
Thereafter	133,894
Total	$	227,211

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Lines of Credit and Long Term Debt

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Lines of Credit and Long Term Debt

Lines of Credit

Trans Ova has a $5,000 revolving line of credit with First National Bank of Omaha which matures on May 1, 2018. The line of credit bears interest at the greater of 2.95% above the London Interbank Offered Rate or 3.00% and the actual rate was 4.32% as of December 31, 2017. As of December 31, 2017, there was no outstanding balance. The amount available under the line of credit is based on eligible accounts receivable and inventory up to the maximum principal amount. The line of credit is collateralized by certain of Trans Ova's assets and contains certain restricted covenants that include maintaining minimum tangible net worth and working capital and maximum allowable annual capital expenditures. Trans Ova was in compliance with these covenants as of December 31, 2017.

Exemplar has a $700 revolving line of credit with American State Bank which matures on October 30, 2018. The line of credit bears interest at 5.25% per annum. As of December 31, 2017, there was an outstanding balance of $233.

Long Term Debt

Long term debt consists of the following:



	December 31,
	2017		2016
Notes payable	$	5,010	$	5,453
Royalty-based financing	2,132		1,896
Other	895		599
Long term debt	8,037		7,948
Less current portion	502		386
Long term debt, less current portion	$	7,535	$	7,562

Trans Ova has a note payable to American State Bank which matures in April 2033 and has an outstanding principal balance of $4,872 as of December 31, 2017. Trans Ova pays monthly installments of $39, which includes interest at 3.95%. The note payable is collateralized by certain of Trans Ova's real estate and non-real estate assets.

AquaBounty has a royalty-based financing grant from the Atlantic Canada Opportunities Agency, a Canadian government agency, to provide funding of a research and development project. The total amount available under the award was $2,288, which AquaBounty claimed over a five year period. All amounts claimed by AquaBounty must be repaid in the form of a 10% royalty on any products commercialized out of this research and development project until fully paid. Because the timing of commercialization is subject to additional regulatory considerations, the timing of repayment is uncertain. As of the date of the acquisition by Intrexon in March 2013, AquaBounty had claimed $1,952 of the available funds and this amount was recorded at its acquisition date fair value of $1,107. The Company accretes the difference of $845 between the face value of amounts drawn and the acquisition date fair value over the expected period of repayment. Subsequent to the acquisition date, AquaBounty claimed the remaining balance available under the grant, resulting in total long term debt of $2,132 as of December 31, 2017.

Future maturities of long term debt are as follows:



2018	$	502
2019	401
2020	372
2021	832
2022	360
Thereafter	3,438
Total	$	5,905

The AquaBounty royalty-based financing grant is not included in the table above due to the uncertainty of the timing of repayment.

Income Taxes

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Income Taxes

The components of loss before income taxes are presented below:



	Year Ended December 31,
	2017			2016			2015
Domestic	$	(71,343	)	$	(157,067	)	$	(69,287	)
Foreign	(58,357		)	(37,084		)	(17,691		)
Loss before income taxes	$	(129,700	)	$	(194,151	)	$	(86,978	)

The components of income tax expense (benefit) are presented below:



	Year Ended December 31,
	2017			2016			2015
U.S. federal income taxes:
Current	$	27		$	(17	)	$	22
Deferred	(523		)	1,396			1,732
Foreign income taxes:
Current	(379		)	(393		)	(123		)
Deferred	(2,269		)	(5,177		)	(1,003		)
State income taxes:
Deferred	264			314			388
Income tax expense (benefit)	$	(2,880	)	$	(3,877	)	$	1,016

Income tax expense (benefit) for the years ended December 31, 2017, 2016 and 2015 differed from amounts computed by applying the applicable U.S. federal corporate income tax rate of 34% to loss before income taxes as a result of the following:



	2017			2016			2015
Computed statutory income tax benefit	$	(44,098	)	$	(66,011	)	$	(29,573	)
State and provincial income tax benefit, net of federal income taxes	(3,294		)	(7,905		)	(3,157		)
Nondeductible stock based compensation	4,147			3,321			3,182
Nondeductible officer compensation	476			—			2,433
Gain on dividend distribution of AquaBounty common stock	3,965			—			—
Impairment of goodwill	4,700			—			—
Research and development tax incentives	(1,166		)	(6,350		)	(348		)
Acquisition and internal restructuring transaction costs	354			571			883
Provisional impact of the Tax Act	85,288			—			—
Enacted changes in foreign tax rates and foreign tax reforms	2,138			—			(961		)
U.S.-foreign rate differential	5,410			3,463			620
Other, net	(64		)	1,485			(98		)
	57,856			(71,426		)	(27,019		)
Change in valuation allowance for deferred tax assets	(60,736		)	67,549			28,035
Total income tax expense (benefit)	$	(2,880	)	$	(3,877	)	$	1,016

The tax effects of temporary differences that comprise the deferred tax assets and liabilities as of December 31, 2017 and 2016, are as follows:



	2017			2016
Deferred tax assets
Allowance for doubtful accounts	$	1,300		$	1,676
Inventory	489			447
Equity securities and investments in affiliates	17,510			31,729
Accrued liabilities and long-term debt	3,131			4,168
Stock-based compensation	26,936			8,460
Deferred revenue	61,785			68,056
Research and development tax credits	11,385			10,396
Net operating and capital loss carryforwards	111,453			144,502
Total deferred tax assets	233,989			269,434
Less: Valuation allowance	215,582			256,165
Net deferred tax assets	18,407			13,269
Deferred tax liabilities
Property, plant and equipment	237			406
Intangible assets	33,790			29,870
Total deferred tax liabilities	34,027			30,276
Net deferred tax liabilities	$	(15,620	)	$	(17,007	)

Activity within the valuation allowance for deferred tax assets during the years ended December 31, 2017, 2016 and 2015 was as follows:



	2017			2016			2015
Valuation allowance at beginning of year	$	256,165		$	190,174		$	161,660
Increase (decrease) in valuation allowance as a result of
Mergers and acquisitions, net	—			(1,416		)	1,228
Current year operations	26,619			67,549			28,035
Adoption of ASU 2016-09	17,843			—			—
Provisional impact of the Tax Act	(87,473		)	—			—
Changes in foreign tax rates and foreign tax reforms	1,327			—			—
Foreign currency translation adjustment	1,101			(142		)	(749		)
Valuation allowance at end of year	$	215,582		$	256,165		$	190,174

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Due to the Company and its subsidiaries' histories of net losses incurred from inception, any corresponding net domestic and certain foreign deferred tax assets have been fully reserved as the Company and its subsidiaries cannot sufficiently be assured that these deferred tax assets will be realized. The components of the deferred tax assets and liabilities as of the date of the mergers and acquisitions by the Company prior to consideration of the valuation allowance are substantially similar to the components of deferred tax assets presented herein.

The Company's past issuances of stock and mergers and acquisitions have resulted in ownership changes as defined in Section 382 of the Internal Revenue Code of 1986, as amended ("Section 382"). As a result, utilization of portions of the net operating losses may be subject to annual limitations, however as of December 31, 2017, all such limited losses applicable to Intrexon, other than losses inherited via acquisition, have been fully utilized. As of December 31, 2017, approximately $33,590 of the Company's domestic net operating losses were inherited via acquisition, including $13,376 acquired via the acquisition of GenVec, and are limited based on the value of the target at the time of the transaction.

As of December 31, 2017, the Company has loss carryforwards for U.S. federal income tax purposes of approximately $244,274 available to offset future taxable income and federal and state research and development tax credits of $7,737, prior to consideration of annual limitations that may be imposed under Section 382. These carryforwards will begin to expire in 2022. The Company's direct foreign subsidiaries have foreign loss carryforwards of approximately $151,423, most of which do not expire.

The Company does not record deferred taxes on the undistributed earnings of its direct foreign subsidiaries because it does not expect the temporary differences related to those unremitted earnings to reverse in the foreseeable future. As of December 31, 2017, the Company's direct foreign subsidiaries had accumulated deficits of approximately $65,052. Future distributions of accumulated earnings of the Company's direct foreign subsidiaries may be subject to U.S. income and foreign withholding taxes. The Company is evaluating this accounting assertion in light of the Tax Act.

The Company does not file a consolidated income tax return with AquaBounty. As of December 31, 2017, AquaBounty has loss carryforwards for federal and foreign income tax purposes of approximately $28,209 and $15,653, respectively, and foreign tax credits of approximately $2,832 available to offset future taxable income, prior to consideration of annual limitations that may be imposed under Section 382 or analogous foreign provisions. These carryforwards will begin to expire in 2018. As a result of the Company's ownership in AquaBounty passing 50% in 2013, an annual Section 382 of approximately $900 per year will apply to domestic losses and credits carried forward by AquaBounty from prior years, which are also subject to prior Section 382 limitations.

The Company recorded a net provisional income tax benefit of $2,185 upon enactment of the Tax Act, which is comprised of several items. Amounts related to the remeasurement of most of the Company's domestic deferred tax assets as a result of the U.S. corporate rate change to 21% as part of the Tax Act are $87,473, which was fully offset by a reduction in the Company's valuation allowance. The Company's net U.S. deferred tax liability that is not offset by a valuation allowance was similarly written down, and the Company recorded a provisional deferred tax benefit of $1,730. The Company also recorded a provisional current tax benefit of $455 related to the expected refundability of accumulated corporate alternative minimum tax credits. The Company has provisionally estimated its transition tax exposure to be zero, as any accumulated earnings in foreign subsidiaries are offset by accumulated deficits in other foreign subsidiaries.

The provisional amounts recorded are subject to further refinement within the measurement period prescribed by SAB 118. As a result, the recorded amounts are subject to change, possibly materially, due to, among other things, changes in interpretations of the Tax Act, any legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates the Company utilized to provisionally compute the transition impact.

Additionally, in December 2017, Belgium enacted significant tax reform measures, the most significant of which to the Company is the limitation on the utilization of accumulated losses in years after 2017. After that date, loss carryforwards can only be used to offset 70% of taxable income that exceeds a certain threshold. As a result, the Company recorded adjustments to its net deferred tax assets and valuation allowances. These adjustments resulted in a net deferred tax liability of $2,307, which was recorded as a component of deferred tax expense for the year ended December 31, 2017.

The Company and its subsidiaries do not have material unrecognized tax benefits as of December 31, 2017. The Company does not anticipate significant changes in the amount of unrecognized tax benefits in the next 12 months. The Company's tax returns for years 2004 and forward are subject to examination by federal or state tax authorities due to the carryforward of unutilized net operating losses and research and development tax credits.

Shareholders' Equity

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Shareholders' Equity

Issuances of Common Stock

In December 2017, the Company entered into a securities purchase agreement with an affiliate of Third Security for the private placement of 1,207,980 shares of the Company's common stock for gross proceeds of $13,686.

In August 2015, the Company closed a public offering of 5,609,756 shares of its common stock, the net proceeds of which were $218,193, after deducting underwriting discounts of $11,500 and offering expenses paid by the Company of approximately $306, all of which were capitalized.

In January 2015, the Company closed a public offering of 4,312,500 shares of its common stock, including 555,556 shares of common stock purchased by affiliates of Third Security. The net proceeds of the offering were $110,041, after deducting underwriting discounts and commissions of $6,086 and offering expenses paid by the Company of approximately $311, all of which were capitalized.

Dividends to Shareholders

In January 2017, the Company distributed to its shareholders 1,776,557 shares of AquaBounty common stock valued at $22,385. The distribution constituted a dividend to shareholders of record as of January 9, 2017. In connection with the distribution and pursuant to the terms of the Company's equity incentive plans, the conversion terms of all outstanding options for shares of the Company's common stock as of January 9, 2017 were adjusted to reflect the value of the distribution with respect to shares of the Company's common stock by decreasing the exercise prices and increasing the number outstanding options. This adjustment resulted in 46,766 additional outstanding options at a weighted average exercise price of $31.11.

In June 2015, the Company distributed to its shareholders 17,830,305 shares of ZIOPHARM common stock, representing all of the equity interests of ZIOPHARM held by the Company at the time of the distribution and resulting in a realized gain of $81,401. The distribution constituted a dividend to shareholders of record as of June 4, 2015. In connection with the distribution, pursuant to the terms of the Company's equity incentive plans, the conversion terms of all outstanding options for shares of the Company's common stock as of June 4, 2015 were adjusted to reflect the value of the distribution with respect to shares of the Company's common stock by decreasing the exercise prices and increasing the number of shares. This adjustment resulted in 312,795 additional outstanding options at a weighted average exercise price of $25.40.

Components of Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows:



	December 31,
	2017			2016
Unrealized loss on investments	$	(2	)	$	(89	)
Loss on foreign currency translation adjustments	(15,552		)	(36,113		)
Total accumulated other comprehensive loss	$	(15,554	)	$	(36,202	)

Share-Based Payments

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Payments

The Company records the fair value of stock options issued to employees and non-employees as of the grant date as stock-based compensation expense. Stock-based compensation expense for employees and non-employees is recognized over the requisite service period, which is typically the vesting period. Stock-based compensation costs included in the consolidated statements of operations are presented below:



	Year Ended December 31,
	2017		2016		2015
Cost of products	$	116	$	81	$	95
Cost of services	322		274		354
Research and development	9,336		9,251		8,614
Selling, general and administrative	31,802		32,596		29,604
Total	$	41,576	$	42,202	$	38,667

Intrexon Stock Option Plans

In April 2008, Intrexon adopted the 2008 Equity Incentive Plan (the "2008 Plan") for employees and nonemployees pursuant to which Intrexon's board of directors granted share based awards, including stock options, to officers, key employees and nonemployees. Upon the effectiveness of the 2013 Omnibus Incentive Plan (the "2013 Plan"), no new awards may be granted under the 2008 Plan. As of December 31, 2017, there were 453,371 stock options outstanding under the 2008 Plan.

Intrexon adopted the 2013 Plan for employees and nonemployees pursuant to which Intrexon's board of directors may grant share-based awards, including stock options, shares of common stock, and other share-based awards, to employees, officers, consultants, advisors, and nonemployee directors. The 2013 Plan became effective upon the closing of the Company's initial public offering in August 2013, and as of December 31, 2017, there were 18,000,000 shares authorized for issuance under the 2013 Plan, of which 10,929,376 stock options were outstanding and 4,747,496 shares were available for grant.

Stock options may be granted with an exercise price equal to or greater than the stock's fair market value at the date of grant. Stock options may be granted with an exercise price less than the stock's fair market value at the date of grant if the stock options are replacement options in accordance with certain U.S. Treasury regulations. Virtually all stock options have ten-year terms and vest four years from the date of grant.

Stock option activity was as follows:



	Number of Shares		Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (Years)
Balances at December 31, 2014	8,323,544		$	22.59		8.64
Granted	5,051,500		45.82
Adjustment due to dividend (Note 14)	312,795		25.40
Exercised	(1,029,291	)	(15.16		)
Forfeited	(1,610,335	)	(26.75		)
Expired	(4,685	)	(28.29		)
Balances at December 31, 2015	11,043,528		32.66			8.49
Granted	4,644,860		29.39
Exercised	(1,210,840	)	(15.83		)
Forfeited	(2,760,809	)	(40.34		)
Expired	(76,356	)	(37.81		)
Balances at December 31, 2016	11,640,383		31.25			8.21
Granted	3,920,950		21.47
Adjustment due to dividend (Note 14)	46,766		31.11
Exercised	(149,429	)	(6.37		)
Forfeited	(3,797,105	)	(28.37		)
Expired	(278,818	)	(33.18		)
Balances at December 31, 2017	11,382,747		28.99			7.32
Exercisable at December 31, 2017	5,306,697		29.96			6.14

Total unrecognized compensation costs related to unvested awards as of December 31, 2017 were $68,999, and are expected to be recognized over a weighted-average period of approximately two years.

The weighted average grant date fair value of options granted during 2017, 2016 and 2015 was $12.19, $16.28 and $25.96, respectively. The aggregate intrinsic value of options exercised during 2017, 2016 and 2015 was $2,429, $22,704 and $24,675, respectively. The aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the fair value of Intrexon's common stock for those shares where the exercise price was lower than the fair value of Intrexon's common stock on the date of exercise.

The following table summarizes additional information about stock options outstanding as of December 31, 2017:



					Options Outstanding						Options Exercisable
Range of Exercise Prices					Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value		Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value
$	2.64	—	$	9.30	453,371	$	7.06	3.94	$	2,020	453,371	$	7.06	3.94	$	2,020
$	12.50	—	$	21.38	3,158,121	20.58		8.74	—		456,942	19.52		7.13	—
$	21.43	—	$	28.81	3,399,721	25.55		6.91	—		1,804,401	25.86		5.69	—
$	28.88	—	$	40.99	2,751,716	32.07		6.70	—		1,732,250	31.51		6.32	—
$	41.41	—	$	65.08	1,619,818	53.52		7.42	—		859,733	53.07		7.38	—
					11,382,747	$	28.99	7.32	$	2,020	5,306,697	$	29.96	6.14	$	2,020

The following table summarizes additional information about stock options outstanding as of December 31, 2016:



					Options Outstanding						Options Exercisable
Range of Exercise Prices					Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value		Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value
$	2.65	—	$	9.34	562,951	$	6.23	4.13	$	10,172	525,755	$	6.01	3.97	$	9,615
$	15.21	—	$	27.19	2,785,705	23.47		8.54	4,797		684,704	21.07		7.29	2,237
$	27.21	—	$	29.68	3,147,242	29.30		7.53	—		1,400,707	29.35		7.31	—
$	29.70	—	$	42.22	3,590,423	32.89		9.09	—		345,274	37.06		6.85	—
$	43.99	—	$	65.34	1,554,062	54.40		8.43	—		461,595	53.06		8.33	—
					11,640,383	$	31.25	8.21	$	14,969	3,418,035	$	28.09	6.88	$	11,852

Intrexon currently uses authorized and unissued shares to satisfy share award exercises.

In October 2015, the compensation committee and the independent members of Intrexon's board of directors approved a compensation arrangement whereby the Company's Chief Executive Officer ("CEO") would receive a monthly salary. Previously, the CEO did not receive compensation for his services as an employee of the Company other than through his participation in the Company's Annual Executive Incentive Plan which became effective January 1, 2015. Pursuant to the compensation agreement, the CEO receives a base salary of $200 per month payable in fully vested shares of Intrexon common stock with such shares subject to a three-year lock-up on resale. The monthly number of shares of common stock is calculated based on the closing price on the last trading day of each month and the shares are issued pursuant to the terms of a Restricted Stock Unit Agreement ("RSU Agreement") which was executed between Intrexon and the CEO pursuant to the terms of the 2013 Plan. The RSU Agreement became effective in November 2015 and had an initial term of twelve months. The independent members of Intrexon's board of directors, with the recommendation of the compensation committee of the board of directors, subsequently approved extensions of the RSU Agreement through March 31, 2018, all of which are on the same terms as the original RSU Agreement. The fair value of the shares issued as compensation for services is included in selling, general, and administrative expenses in the Company's consolidated statements of operations for the years ended December 31, 2017, 2016 and 2015, and totaled $1,908, $1,861, and $314, respectively.

AquaBounty Stock Option Plans

In March 2016, AquaBounty's board of directors adopted the AquaBounty 2016 Equity Incentive Plan ("AquaBounty 2016 Plan") to replace the AquaBounty 2006 Equity Incentive Plan ("AquaBounty 2006 Plan"). The AquaBounty 2016 Plan provides for the issuance of incentive stock options, non-qualified stock options and awards of restricted and direct stock purchases to directors, officers, employees, and consultants of AquaBounty. The AquaBounty 2016 Plan was approved by AquaBounty's shareholders at its annual meeting in April 2016. Upon the effectiveness of the AquaBounty 2016 Plan, no new awards may be granted under the AquaBounty 2006 Plan.

As of December 31, 2017, there were 227,203 options outstanding under both AquaBounty plans, of which 192,748 were exercisable, at a weighted average exercise price of $9.39 per share. As of December 31, 2016, there were 185,591 options outstanding under these plans, of which 181,766 were exercisable, at a weighted average exercise price of $7.89 per share.

License Agreement	12 Months Ended
License Agreement	Dec. 31, 2017
License Agreement [Abstract]
License Agreement	License Agreement In January 2015, the Company and ZIOPHARM jointly entered into a license agreement with the University of Texas System Board of Regents on behalf of the University of Texas MD Anderson Cancer Center ("MD Anderson") whereby the Company received an exclusive license to certain research and development technologies owned and licensed by MD Anderson, including technologies relating to novel chimeric antigen receptor (CAR) T-cell therapies, as well as co-licenses and non-exclusive licenses to certain other related technologies. ZIOPHARM received access to these technologies pursuant to the terms of the Company's ECC with ZIOPHARM. The Company issued 2,100,085 shares of its common stock valued at $59,579 to MD Anderson as consideration, which is included in research and development expenses in the accompanying consolidated statement of operations for the year ended December 31, 2015. Subject to certain exceptions, the license agreement expires on the last to occur of (i) the expiration of all patents licensed thereunder, or (ii) the twentieth anniversary of the date of the license agreement. In connection with the license agreement, the Company, ZIOPHARM, and MD Anderson entered into a research and development agreement which governs certain operational activities between the parties and pursuant to which ZIOPHARM provided funding for certain research and development activities of MD Anderson for a period of three years, in an amount between $15,000 and $20,000 per year. The Company and ZIOPHARM reimburse MD Anderson for out of pocket expenses for maintaining patents covering the licensed technologies.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Operating Leases

The Company leases certain facilities and equipment under noncancelable operating leases. The equipment leases are renewable at the option of the Company. As of December 31, 2017, future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows:



2018	$	7,964
2019	9,115
2020	9,186
2021	8,299
2022	7,279
Thereafter	26,044
Total	$	67,887

Rent expense, including other facility expenses, was $11,064, $8,593 and $8,610 in 2017, 2016 and 2015, respectively.

The Company maintains subleases for certain of its facilities. Rental income under sublease agreements was $137, $1,051 and $1,486 for the years ended December 31, 2017, 2016 and 2015, respectively. Future rental income is expected to be $104 in 2018, $120 in 2019, $55 in 2020, $56 in 2021, $58 in 2022, and $310 thereafter.

Purchase Commitments

As of December 31, 2017, the Company had outstanding contractual purchase commitments of $15,802, which primarily relate to amounts that will be paid in 2018, 2019, and 2020 upon delivery of commercial non-browning apple trees.

Contingencies

In March 2012, Trans Ova was named as a defendant in a licensing and patent infringement suit brought by XY, LLC ("XY") alleging that certain of Trans Ova's activities breached a 2004 licensing agreement and infringed on patents that XY allegedly owned. Trans Ova filed a number of counterclaims in the case. In Colorado District Court, the matter proceeded to a jury trial in January 2016. The jury determined that XY and Trans Ova had each breached the licensing agreement and that Trans Ova had infringed XY's patents. In April 2016, the court issued its post-trial order, awarding $528 in damages to Trans Ova and $6,066 in damages to XY. The order also provided Trans Ova with a compulsory license to XY's technology, subject to an ongoing royalty obligation. Both parties appealed the court's order, which appeal is pending before the Court of Appeals for Federal Circuit. Since the inception of the 2004 agreement, Trans Ova has remitted payments to XY pursuant to the terms of that agreement and has recorded these payments in cost of services in the consolidated statements of operations for the respective periods. For the period from inception of the 2004 agreement through the court's April 2016 order, aggregate royalty and license payments were $3,170, of which $2,759 had not yet been deposited by XY. For the year ended December 31, 2016, the Company recorded litigation expense of $4,228, which is included in selling, general and administrative expenses on the accompanying consolidated statement of operations and represents the excess of the net damages awarded to XY, including prejudgment interest, over the liability previously recorded by Trans Ova for uncashed checks previously remitted to XY. In August 2016, Trans Ova deposited the net damages amount, including prejudgment interest, into the court's treasury, to be held until the appeals process is complete and final judgment amounts are determined. As of December 31, 2017, this amount is included in restricted cash on the accompanying consolidated balance sheet. In December 2016, Trans Ova elected to void the outstanding checks discussed above, and these amounts have been reclassified to other accrued liabilities on the accompanying consolidated balance sheets as of December 31, 2017 and 2016. Depending on the outcome of an appeal decision, the damages awarded to either party could decrease, increase, or be eliminated. The appeal decision may also remand to the Colorado District Court all, or a portion, of the issues being appealed. In December 2016, XY filed a complaint for patent infringement and trade secret misappropriation against Trans Ova in the District Court of Waco, Texas. Since the claims in this 2016 complaint directly relate to the 2012 licensing dispute and patent issues, Trans Ova filed and was granted a motion for change of venue to Colorado District Court. Trans Ova also filed a motion to dismiss, from which the Court recently dismissed nine of the twelve counts of the complaint. Presently, three counts for patent infringement remain pending. Trans Ova and the Company could elect to enter into a settlement agreement in order to avoid the further costs and uncertainties of litigation, to modify the court-ordered license to XY's technologies, or to recover monetary damages stemming from Trans Ova's counterclaims for antitrust violations by XY and its parent company, Inguran.

In May 2016, two putative shareholder class action lawsuits, captioned Hoffman v. Intrexon Corporation et al. and Gibrall v. Intrexon Corporation et al., were filed in the U.S. District Court for the Northern District of California on behalf of purchasers of Intrexon's common stock between May 12, 2015 and April 20, 2016 (the "Class Period"). In July 2016, the court consolidated the lawsuits and appointed a lead plaintiff. The consolidated amended complaint names as defendants Intrexon and certain of Intrexon's current and former officers (the "Defendants"). It alleges, among other things, that the Defendants made materially false and/or misleading statements during the Class Period with respect to the Company's business, operations, and prospects in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended. The plaintiffs' claims are based in part upon allegations in a report published in April 2016 on the Seeking Alpha financial blog. The plaintiffs seek compensatory damages, interest and an award of reasonable attorneys' fees and costs. The Defendants moved to dismiss the case. On February 24, 2017, the court granted the Defendants' motion to dismiss the lawsuit on the grounds that the plaintiff failed to state a claim, while granting the plaintiff leave to amend. The plaintiff subsequently notified the court that it would seek to appeal the court's ruling rather than amend its complaint. On April 26, 2017, the court entered final judgment in the case. Notice of appeal was filed by the plaintiff on May 26, 2017. On October 26, 2017, the plaintiff filed a voluntary motion to dismiss the case, which the court of appeals granted on November 1, 2017.

In July 2016, a putative shareholder derivative action captioned Basile v. Kirk et al. was filed in the Circuit Court of Fairfax County, Virginia, against certain of the Company's directors, the Company's CEO, and Third Security, and naming the Company as a nominal defendant. The complaint alleges causes of action for breaches of fiduciary duty and unjust enrichment relating to the entry by the Company into the Services Agreement with Third Security. The plaintiff seeks, among other things, damages in an unspecified amount, disgorgement of improper benefits, appropriate equitable relief, and an award of attorney fees and other costs and expenses. The complaint is substantially similar to two separate demands made by shareholders concerning the Services Agreement and Mr. Kirk's compensation. The board of directors of the Company appointed a Special Litigation Committee ("SLC") consisting of independent directors to investigate the claims and allegations made in the derivative action and in the two shareholder demands and to decide on behalf of the Company whether the claims and allegations should be pursued. The Basile case was stayed pending the report of the SLC. In November 2016, the SLC completed its review and evaluation and unanimously determined that the claims were without merit because the compensation arrangements were the result of an informed and disinterested decision-making process and were fair to the Company, and that prosecution of the asserted claims was not in the best interest of Intrexon or its shareholders. Based upon the determination of the SLC, on February 24, 2017, the Company moved to dismiss the court action pursuant to Virginia statute. On June 8, 2017, the court granted the Company's motion to dismiss while granting the plaintiff leave to amend. On August 30, 2017, the plaintiff filed a consent motion for leave to amend along with the amended shareholder derivative complaint. The Company moved to dismiss the amended complaint on October 6, 2017. On January 25, 2018, the court granted the Company's motion and dismissed the plaintiff's amended complaint with prejudice.

In addition to the shareholder demands above, in June and July 2016, two shareholders made separate demands under Virginia law demanding that the Company file suit against certain of its current officers and directors for alleged breaches of fiduciary duty and other claims. The demands were based upon and asserted the allegations previously published in April 2016 in the Seeking Alpha financial blog. In July 2016, the Company's board of directors authorized the SLC to expand its review to include all such allegations. In February 2017, the SLC completed its review and evaluation and unanimously determined that there was no basis for any of the allegations, that the Company's officers and directors did not breach their fiduciary duties or any other applicable law, and that prosecution of the asserted claims was not in the best interest of Intrexon or its shareholders. Following the SLC's determination, in March 2017, one of the putative shareholders filed a derivative complaint captioned Luger v. Kirk et al. in the Circuit Court of Fairfax County, Virginia. The Company is a nominal defendant in this action, and other defendants include certain of the Company's directors, the Company's CEO, and Third Security. The complaint alleges causes of action for breaches of fiduciary duty and unjust enrichment relating to the entry by the Company into the Services Agreement with Third Security, Mr. Kirk's compensation, and certain allegations contained in the April 2016 Seeking Alpha financial blog piece. Based on the determination of the SLC and a review of applicable law, the Company intends to defend the lawsuit vigorously; however, there can be no assurance regarding the ultimate outcome of this case.

The Division of Enforcement of the U.S. Securities and Exchange Commission ("SEC") is conducting an investigation which the Company believes concerns certain issues raised by the foregoing matters. The Company has met with the SEC staff and is voluntarily cooperating with their investigation. The Company's board of directors has authorized the SLC to monitor the Company's interaction with the SEC staff.

The Company may become subject to other claims and assessments from time to time in the ordinary course of business. Such matters are subject to many uncertainties and outcomes are not predictable with assurance. The Company accrues liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of December 31, 2017 and 2016, the Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company's business, financial condition, results of operations, or cash flows.

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Third Security and Affiliates The Company's CEO and Chairman of the board of directors is also the Senior Managing Director and CEO of Third Security and owns 100% of the equity interests of Third Security. In November 2015, the independent members of Intrexon's board of directors, with the recommendation of the audit committee of the board of directors, approved the execution of a Services Agreement ("Services Agreement") with Third Security pursuant to which Third Security provides the Company with certain professional, legal, financial, administrative, and other support services necessary to support the Company and its CEO. As consideration for providing these services, Third Security is entitled to a fee of $800 per month to be paid in the form of fully-vested shares of the Company's common stock. The number of shares of common stock is calculated based on the closing price of the Company's common stock on the 15th day of each month. The payments made by the Company under the Services Agreement constitute, in the aggregate, an award under the 2013 Plan and are subject to the terms of the 2013 Plan (Note 15). The Services Agreement had a term of one year, can be terminated by the Company at any time, and may be extended only by agreement of the parties, including approval of a majority of the independent members of Intrexon's board of directors. The independent members of Intrexon's board of directors, with the recommendation of the audit committee of the board of directors, subsequently approved extensions of the Services Agreement through January 1, 2019. For the years ended December 31, 2017, 2016 and 2015, the Company issued 500,650 shares, 337,163 shares, and 48,678 shares, respectively, with values of $8,704, $8,571, and $1,375, respectively, to Third Security as payment for services pursuant to the Services Agreement. In addition to the foregoing Services Agreement, the Company reimburses Third Security for certain out-of-pocket expenses incurred on the Company's behalf, and the total expenses incurred by the Company under this arrangement was $409, $309, and $428 for the years ended December 31, 2017, 2016 and 2015, respectively. See also Note 15 regarding compensation arrangements between the Company and its CEO. In October 2017, the Company entered into a Preferred Stock Equity Facility ("Preferred Stock Facility") with an affiliate of Third Security ("Third Security Affiliate"). Under the Preferred Stock Facility, the Company may, from time to time at its sole and exclusive option, issue and sell to the Third Security Affiliate, up to $100,000 of newly issued Series A Redeemable Preferred Stock ("Series A Preferred Stock"). Any issued Series A Preferred Stock is non-voting, accrues dividends of 8% per annum and, subject to limited exceptions, is senior to Intrexon's common stock with respect to the rights to the payment of dividends and on parity with the common stock with respect to the distribution of assets in the event of any liquidation, dissolution or winding up or change of control of Intrexon. Any issued Series A Preferred Stock is convertible into common stock only following receipt of shareholder approval by the Company, including a majority of the shares voted by those shareholders unaffiliated with Mr. Kirk (the "Shareholder Approval"), subject to any necessary regulatory approvals. Following receipt of the Shareholder Approval and receipt of any necessary regulatory approvals, any issued Series A Preferred Stock is convertible into Intrexon common stock based on a conversion price using the 20-day volume-weighted average market price as of market closing on the fifth business day prior to the mailing of the proxy statement soliciting the Shareholder Approval, subject to adjustment for certain stock splits and similar events. The Company has agreed to take all reasonable steps necessary to seek Shareholder Approval on or before the date of its annual meeting of shareholders in 2019. Any issued Series A Preferred Stock is redeemable at the election of the Company at any time, or at the election of the Third Security Affiliate after December 31, 2020. The Preferred Stock Facility will expire on the earliest to occur of: (i) the date on which the Third Security Affiliate has purchased shares of Series A Preferred Stock in the aggregate amount of $100,000, (ii) April 30, 2019, (iii) the date of the Shareholder Approval, and (iv) the mutual agreement of the parties. To date, the Company has not utilized the Preferred Stock Facility. See additional discussion regarding Third Security's participation in the Company's equity offerings at Notes 14 and 22. The Company also subleases certain administrative offices to Third Security. The significant terms of the lease mirror the terms of the Company's lease with the landlord, and the Company recorded sublease income of $43 for each of the years ended December 31, 2017, 2016 and 2015. Transactions with ECC Parties In addition to entities controlled by Third Security, any entity in which the Company holds equity securities, including securities received as upfront or milestone consideration, and which also are party to a collaboration with the Company are considered to be related parties. In December 2017, the Company purchased certain property and equipment comprising the pilot plant production facility for its energy programs for $2,812 from Intrexon Energy Partners. The Company intends to use the pilot plant to support the collaborations with Intrexon Energy Partners and Intrexon Energy Partners II and its own research programs. The Company holds a promissory note convertible into shares of Fibrocell common stock ("convertible note") and warrants to purchase shares of Fibrocell common stock. As of December 31, 2017 and 2016, the value of the convertible note and warrants totaled $575 and $1,642, respectively, and is included in other assets on the accompanying consolidated balance sheets. In July 2015, the Company purchased 125,290 shares of common stock of Fibrocell at $17.40 per share. The share data reflect a 1-for-3 reverse stock split of Fibrocell's common stock effective March 10, 2017. In June 2016, the Company purchased 226,142 shares of Oragenics common stock at $5.20 per share. The share data reflect a 1-for-10 reverse stock split of Oragenics' common stock effective January 19, 2018. In March 2015, the Company purchased 27,879 shares of common stock of AmpliPhi Biosciences Corporation ("AmpliPhi") and 6,969 warrants for $2,300. The share and warrant data reflect a 1-for-10 reverse stock split of AmpliPhi's common stock effective April 24, 2017. Of the total purchase price, $1,979 was allocated to the value of the shares of common stock and $321 was allocated to the value of the warrants. In December 2016, the Company sold all of its investment in AmpliPhi common stock, resulting in a realized loss of $4,098, which is included in unrealized and realized depreciation in fair value of equity securities on the consolidated statement of operations for the year ended December 31, 2016. In February 2015, the Company purchased $12,600 of ZIOPHARM common stock. See Note 14 for additional discussion related to the Company's investment in ZIOPHARM. Other Related Parties In June 2015, the Company entered into an agreement with Harvest, an investment fund sponsored by Harvest Capital Strategies, LLC, and a related party based on ownership in the fund by affiliates of Third Security. Harvest was established to invest in life science research and development start-up opportunities that the Company offered to Harvest with exclusive rights of first-look and first negotiation. Based on this agreement, Harvest established six new collaboration entities, each of which entered into an ECC with the Company in a designated field. The terms of such ECCs were negotiated between the Company and Harvest. As consideration for providing exclusive rights of first-look and first negotiation for start-up opportunities, the Company received a portion of the management fee collected by the fund sponsor of Harvest. These fees are included in other income in the accompanying consolidated statements of operations and totaled $1,839, $2,483, and $1,349 for the years ended December 31, 2017, 2016 and 2015, respectively. In September 2017, the commitment period for Harvest was terminated and, as a result, the agreement with Harvest terminated. The termination of the agreement had no effect on the existing collaborations with Harvest-controlled entities.

Net Loss per Share

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Net Loss per Share

The following table presents the computation of basic and diluted net loss per share:



	2017			2016			2015
Historical net loss per share:
Numerator:
Net loss attributable to Intrexon	$	(117,018	)	$	(186,612	)	$	(84,493	)
Denominator:
Weighted average shares outstanding, basic and diluted	119,998,826			117,983,836			111,066,352
Net loss attributable to Intrexon per share, basic and diluted	$	(0.98	)	$	(1.58	)	$	(0.76	)

The following potentially dilutive securities as of December 31, 2017, 2016, and 2015, have been excluded from the above computations of diluted weighted average shares outstanding for the years then ended as they would have been anti-dilutive:



	December 31,
	2017	2016	2015
Options	11,382,747	11,640,383	11,043,528
Warrants	133,264	—	194,719
Total	11,516,011	11,640,383	11,238,247

Quarterly Financial Information (Unaudited)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Information (Unaudited)

The following information has been derived from unaudited consolidated statements that, in the opinion of management, include all recurring adjustments necessary for a fair statement of such information.



	Three Months Ended
	March 31, 2017			June 30, 2017			September 30, 2017			December 31, 2017 (1)
Total revenues	$	53,504		$	54,433		$	46,016		$	77,028
Operating loss	(31,381		)	(35,270		)	(44,747		)	(26,492		)
Net loss	(32,377		)	(19,662		)	(40,836		)	(33,945		)
Net loss attributable to Intrexon	(31,399		)	(18,664		)	(39,689		)	(27,266		)
Net loss attributable to Intrexon per share, basic and diluted	$	(0.26	)	$	(0.16	)	$	(0.33	)	$	(0.23	)



	Three Months Ended
	March 31, 2016			June 30, 2016			September 30, 2016			December 31, 2016
Total revenues	$	43,438		$	52,501		$	48,985		$	46,002
Operating loss	(40,533		)	(23,222		)	(28,821		)	(32,590		)
Net loss	(65,320		)	(50,031		)	(30,011		)	(44,912		)
Net loss attributable to Intrexon	(64,429		)	(49,064		)	(28,982		)	(44,137		)
Net loss attributable to Intrexon per share, basic and diluted	$	(0.55	)	$	(0.42	)	$	(0.24	)	$	(0.37	)


(1)	During the fourth quarter of 2017, the Company recognized the remaining balance of deferred revenue associated with ZIOPHARM ECC2 upon the parties' mutual agreement to terminate (Note 5). The Company also recorded goodwill impairment charges primarily related to the AquaBounty reporting unit and an impairment charge related to certain of its in-process research and development assets (Note 11).

Defined Contribution Plans	12 Months Ended
Defined Contribution Plans	Dec. 31, 2017
Retirement Benefits [Abstract]
Defined Contribution Plans	Defined Contribution Plans The Company sponsors defined contribution plans covering employees who meet certain eligibility requirements. The Company makes contributions to the plans in accordance with terms specified in the plan agreement. The Company's contributions to the plans were $2,367, $1,857 and $1,157 in 2017, 2016 and 2015, respectively.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events In January 2018, the Company closed a public offering of 6,900,000 shares of its common stock, including 1,000,000 shares of common stock purchased by affiliates of Third Security. The net proceeds of the offering were $82,242, after deducting underwriting discounts of $3,688 and estimated offering expenses of approximately $320, all of which were capitalized. In January 2018, Intrexon purchased $5,000 of additional AquaBounty common stock through an underwritten public offering, reducing its ownership stake from approximately 58% to approximately 53%. In February 2018, OvaScience provided their notice of termination of the ECC between them and the Company, to be effective in May 2018 in accordance with the ECC agreement. As a result, the Company will recognize the remaining balance of the deferred revenue associated with this ECC agreement totaling $3,183 in 2018. The Company and OvaScience are in discussions regarding dissolving the OvaXon joint venture and terminating the related ECC agreement.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Principles of Consolidation

The accompanying consolidated financial statements reflect the operations of the Company and its subsidiaries. All intercompany accounts and transactions have been eliminated.

Revenue Recognition


(1)	The consideration is commensurate with either the entity's performance to achieve the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from the entity's performance to achieve the milestone;


(2)	The consideration relates solely to past performance; and


(3)	The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.

In the event that a milestone is not considered substantive, the Company recognizes the milestone consideration as revenue using the same method applied to upfront payments.

Research and Development

Cash and Cash Equivalents

Restricted Cash

Restricted cash represents funds deposited with the U.S. Treasury, as required by a court decision resulting from litigation against Trans Ova (Note 17).

Short-term and Long-term Investments

Equity Securities

Investment in Preferred Stock

Investments in Preferred Stock

The Company is entitled to monthly dividends and records dividend income as described in Note 7.

Fair Value of Financial Instruments



Level 1:	Quoted prices in active markets for identical assets and liabilities;

Level 2:	Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly; and

Level 3:	Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available.

Concentrations of Risk

Equity Method Investments

The Company accounts for its investment in Oragenics, Inc. ("Oragenics"), one of its collaborators, using the fair value option.

Variable Interest Entities

Trade Receivables

Inventory

Property, Plant and Equipment



	Years
Land improvements	4–20
Buildings and building improvements	3–25
Furniture and fixtures	1–10
Equipment	1–10
Breeding stock	1–4
Computer hardware and software	1–7

Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally one to twenty years

Goodwill

The Company performs its annual impairment review of goodwill in the fourth quarter, or sooner if a triggering event occurs prior to the annual impairment review.

Intangible Assets

Impairment of Long-Lived Assets

Self Insurance Reserves

Self-insurance Reserves

Foreign Currency Translation

Income Taxes

Share-Based Payments



	2017	2016	2015
Valuation assumptions
Expected dividend yield	0%	0%	0%
Expected volatility	57%—60%	59%—60%	59%—62%
Expected term (years)	6.25	6.25	6.25
Risk-free interest rate	1.89%—2.27%	1.23%—2.17%	1.56%—1.95%

Net Loss per Share

Segment Information

Use of Estimates

Recently Adopted and Issued Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements

Reclassifications

Certain insignificant reclassifications have been made to the prior year consolidated financial statements to conform to the current year presentation.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Summarized Financial Information of Equity Method Investments



	December 31,
	2017		2016
Current assets	$	61,086	$	77,761
Non-current assets	13,598		11,040
Total assets	74,684		88,801
Current liabilities	6,213		11,588
Net assets	$	68,471	$	77,213



	Year Ended December 31,
	2017			2016			2015
Revenues, net	$	254		$	417		$	1,176
Operating expenses	41,904			62,373			32,513
Operating loss	(41,650		)	(61,956		)	(31,337		)
Other, net	(8		)	1,535			(64		)
Net loss	$	(41,658	)	$	(60,421	)	$	(31,401	)

Rollforward of Allowance for Doubtful Receivable Accounts

The following table shows the activity in the allowance for doubtful receivable accounts for the years ended December 31, 2017, 2016, and 2015:



	2017			2016			2015
Beginning balance	$	3,703		$	2,081		$	565
Charged to operating expenses	1,217			1,963			1,757
Write offs of accounts receivable, net of recoveries	(289		)	(341		)	(241		)
Ending balance	$	4,631		$	3,703		$	2,081

Estimated Useful Lives of Property, Plant and Equipment

The estimated useful lives of these assets are as follows:



	Years
Land improvements	4–20
Buildings and building improvements	3–25
Furniture and fixtures	1–10
Equipment	1–10
Breeding stock	1–4
Computer hardware and software	1–7

Leasehold improvements are amortized over the shorter of the useful life of the asset or the applicable lease term, generally one to twenty years.

Summary of Assumptions Used in Option Pricing Model

The assumptions used in the Black-Scholes option pricing model for the years ended December 31, 2017, 2016 and 2015 are set forth in the table below:



	2017	2016	2015
Valuation assumptions
Expected dividend yield	0%	0%	0%
Expected volatility	57%—60%	59%—60%	59%—62%
Expected term (years)	6.25	6.25	6.25
Risk-free interest rate	1.89%—2.27%	1.23%—2.17%	1.56%—1.95%

Mergers and Acquisitions (Tables)

12 Months Ended

Dec. 31, 2017

GenVec, Inc.

Business Acquisition [Line Items]

Fair Value of Consideration Transferred

The fair value of the total consideration transferred was $17,582. The acquisition date fair value of each class of consideration transferred is presented below:



Common shares	$	15,616
Warrants	1,381
Contingent consideration	585
	$	17,582

Fair Value of Assets Acquired and Liabilities Assumed

The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:



Cash and cash equivalents	$	2,054
Short term investments	542
Trade receivables	75
Other receivables	97
Prepaid expenses and other	227
Property and equipment	250
Intangible assets	14,000
Other noncurrent assets	58
Total assets acquired	17,303
Accounts payable	2,158
Accrued compensation and benefits	1,226
Other accrued expenses	856
Other long term liabilities	92
Deferred tax liabilities	239
Total liabilities assumed	4,571
Net assets acquired	12,732
Goodwill	4,850
Total consideration	$	17,582

Condensed Pro forma Financial Information

The following unaudited condensed pro forma financial information for the years ended December 31, 2017 and 2016, is presented as if the acquisition had been consummated on January 1, 2016:



	Year Ended December 31,
	2017			2016
	Pro Forma
Revenues	$	231,213		$	191,437
Loss before income taxes	(136,966		)	(201,210		)
Net loss	(134,275		)	(197,144		)
Net loss attributable to the noncontrolling interests	9,802			3,662
Net loss attributable to Intrexon	(124,473		)	(193,482		)

Oxitec Limited

Business Acquisition [Line Items]

Fair Value of Consideration Transferred

The fair value of the total consideration transferred was $146,394. The acquisition date fair value of the Stock Consideration and Cash Consideration is presented below:



Cash	$	90,199
Common shares	56,195
	$	146,394

Fair Value of Assets Acquired and Liabilities Assumed

The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:



Cash	$	3,780
Trade receivables	125
Other receivables	7,395
Prepaid expenses and other	121
Property, plant, and equipment	1,198
Intangible assets	96,854
Total assets acquired	109,473
Accounts payable	1,187
Accrued compensation and benefits	246
Other accrued liabilities	210
Deferred revenue	120
Deferred tax liabilities	12,584
Total liabilities assumed	14,347
Net assets acquired	95,126
Goodwill	51,268
Total consideration	$	146,394

Okanagan Specialty Fruits Inc.

Business Acquisition [Line Items]

Fair Value of Consideration Transferred

The fair value of the total consideration transferred was $40,933. The acquisition date fair value of each class of consideration transferred is presented below:



Cash	$	10,000
Common shares	30,933
	$	40,933

Fair Value of Assets Acquired and Liabilities Assumed

The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:



Cash	$	58
Trade receivables	16
Other receivables	49
Property, plant, and equipment	32
Intangible assets	36,500
Total assets acquired	36,655
Accounts payable	181
Deferred revenue	181
Deferred tax liabilities	8,847
Total liabilities assumed	9,209
Net assets acquired	27,446
Goodwill	13,487
Total consideration	$	40,933

ActoGeniX NV

Business Acquisition [Line Items]

Fair Value of Consideration Transferred

The fair value of the total consideration transferred was $72,474. The acquisition date fair value of each class of consideration transferred is presented below:



Cash	$	32,739
Common shares	39,735
	$	72,474

Fair Value of Assets Acquired and Liabilities Assumed

The estimated fair value of assets acquired and liabilities assumed at the acquisition date is shown below:



Cash	$	3,180
Other receivables	305
Prepaid expenses and other	31
Property, plant and equipment	209
Intangible assets	68,100
Other noncurrent assets	23
Total assets acquired	71,848
Accounts payable	230
Accrued compensation and benefits	196
Other accrued liabilities	253
Deferred revenue	732
Deferred tax liabilities	612
Total liabilities assumed	2,023
Net assets acquired	69,825
Goodwill	2,649
Total consideration	$	72,474

2015 Business Acquisitions

Business Acquisition [Line Items]

Condensed Pro forma Financial Information

The following unaudited condensed pro forma financial information for the year ended December 31, 2015 is presented as if the 2015 acquisitions had been consummated on January 1, 2014:



	Year Ended December 31, 2015
	Pro Forma
Revenues	$	174,558
Loss before income taxes	(99,751		)
Net loss	(99,594		)
Net loss attributable to the noncontrolling interests	3,501
Net loss attributable to Intrexon	(96,093		)

Collaboration and Licensing Revenue (Tables)

12 Months Ended

Dec. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summarized Collaboration and Licensing Revenues

The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant collaboration or licensing agreement for the years ended December 31, 2017, 2016 and 2015.



	Year Ended December 31, 2017
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	48,313	$	21,499	$	69,812
Oragenics, Inc.	1,047		973		2,020
Fibrocell Science, Inc.	2,419		4,925		7,344
Genopaver, LLC	273		6,417		6,690
S & I Ophthalmic, LLC	—		755		755
OvaXon, LLC	—		1,966		1,966
Intrexon Energy Partners, LLC	2,500		8,165		10,665
Persea Bio, LLC	500		446		946
Ares Trading S.A.	6,389		4,349		10,738
Intrexon Energy Partners II, LLC	2,000		1,672		3,672
Intrexon T1D Partners, LLC	1,109		4,859		5,968
Harvest start-up entities (1)	2,442		12,790		15,232
Other	4,645		5,126		9,771
Total	$	71,637	$	73,942	$	145,579


(1)	For the year ended December 31, 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.



	Year Ended December 31, 2016
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	11,529	$	22,307	$	33,836
Oragenics, Inc.	1,047		1,705		2,752
Fibrocell Science, Inc.	2,419		3,523		5,942
Genopaver, LLC	273		5,844		6,117
S & I Ophthalmic, LLC	—		6,141		6,141
OvaXon, LLC	—		2,934		2,934
Intrexon Energy Partners, LLC	2,500		15,052		17,552
Persea Bio, LLC	500		778		1,278
Ares Trading S.A.	6,389		3,803		10,192
Intrexon Energy Partners II, LLC	2,000		1,169		3,169
Intrexon T1D Partners, LLC	821		1,087		1,908
Harvest start-up entities (1)	1,383		3,591		4,974
Other	5,572		7,504		13,076
Total	$	34,433	$	75,438	$	109,871


(1)	For the year ended December 31, 2016, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.



	Year Ended December 31, 2015
	Revenue Recognized From				Total
	Upfront and Milestone Payments		Research and Development Services		Total
ZIOPHARM Oncology, Inc.	$	2,855	$	16,451	$	19,306
Oragenics, Inc.	5,679		856		6,535
Fibrocell Science, Inc.	6,046		6,133		12,179
Genopaver, LLC	273		3,556		3,829
S & I Ophthalmic, LLC	—		4,115		4,115
OvaXon, LLC	—		2,540		2,540
Intrexon Energy Partners, LLC	2,500		10,947		13,447
Persea Bio, LLC	500		741		1,241
Ares Trading S.A.	3,933		795		4,728
Intrexon Energy Partners II, LLC	167		—		167
Harvest start-up entities (1)	46		220		266
Other	10,514		8,954		19,468
Total	$	32,513	$	55,308	$	87,821


(1)	For the year ended December 31, 2015, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.

Summary of Deferred Revenue

Deferred revenue consists of the following:



	December 31,
	2017		2016
Upfront and milestone payments	$	230,531	$	297,867
Prepaid research and development services	1,052		6,015
Prepaid product and service revenues	4,681		5,554
Other	133		706
Total	$	236,397	$	310,142
Current portion of deferred revenue	$	42,870	$	53,364
Long-term portion of deferred revenue	193,527		256,778
Total	$	236,397	$	310,142

Summary of Deferred Revenue by Collaborator

The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement.



	December 31,
	2017		2016
ZIOPHARM Oncology, Inc.	$	90,496	$	138,809
Oragenics, Inc.	6,719		7,766
Fibrocell Science, Inc.	16,607		19,026
Genopaver, LLC	1,704		1,977
Intrexon Energy Partners, LLC	15,625		18,125
Persea Bio, LLC	3,500		4,000
Ares Trading S.A.	40,789		47,178
Intrexon Energy Partners II, LLC	13,833		15,833
Intrexon T1D Partners, LLC	8,435		8,653
Harvest start-up entities (1)	18,400		20,208
Other	14,423		16,292
Total	$	230,531	$	297,867


(1)	As of December 31, 2017 and December 31, 2016, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.

Short-term and Long-term Investments (Tables)

12 Months Ended

Dec. 31, 2017

Investments, Debt and Equity Securities [Abstract]

Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Investments

The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of December 31, 2017:



	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Aggregate Fair Value
U.S. government debt securities	$	6,000	$	—	$	(2	)	$	5,998
Certificates of deposit	275		—		—			275
Total	$	6,275	$	—	$	(2	)	$	6,273

The following table summarizes the amortized cost, gross unrealized gains and losses and fair value of available-for-sale investments as of December 31, 2016:



	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Aggregate Fair Value
U.S. government debt securities	$	180,412	$	5	$	(94	)	$	180,323
Certificates of deposit	272		—		—			272
Total	$	180,684	$	5	$	(94	)	$	180,595

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Investments in Preferred Stock (Tables)

12 Months Ended

Dec. 31, 2017

Investment in Preferred Stock [Abstract]

Schedule of Changes in Level 3 Investments

The following table summarizes the changes in the Level 3 investments in preferred stock during the years ended December 31, 2017 and 2016.



	2017		2016
Beginning balance	$	129,545	$	—
Receipt of preferred stock as consideration for amendments to collaboration agreements	—		120,000
Purchase of preferred stock	766		—
Conversion of receivables to preferred stock	3,385		—
Dividend income from investments in preferred stock	16,756		7,421
Net unrealized appreciation in the fair value of the investments in preferred stock	10,773		2,124
Ending balance	$	161,225	$	129,545

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2017

Fair Value Disclosures [Abstract]

Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis



	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		December 31, 2017
Assets
U.S. government debt securities	$	—	$	5,998	$	—	$	5,998
Equity securities	10,537		4,563		—		15,100
Preferred stock	—		—		161,225		161,225
Other	—		850		—		850
Total	$	10,537	$	11,411	$	161,225	$	183,173



	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		December 31, 2016
Assets
U.S. government debt securities	$	—	$	180,323	$	—	$	180,323
Equity securities	15,544		7,978		—		23,522
Preferred stock	—		—		129,545		129,545
Other	—		1,917		—		1,917
Total	$	15,544	$	190,218	$	129,545	$	335,307

Schedule of Changes in Level 3 Liabilities

The changes in the fair value of the Level 3 liabilities during the years ended December 31, 2017 and 2016 were as follows:



	2017			2016
Beginning balance	$	2,081		$	—
Acquisition date fair value of contingent consideration liability	585			3,660
Payment of contingent consideration (Note 4)	—			(1,583		)
Change in fair value of contingent consideration recognized in selling, general and administrative expenses	(2,081		)	4
Ending balance	$	585		$	2,081

Inventory (Tables)

12 Months Ended

Dec. 31, 2017

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory consists of the following:



	December 31,
	2017		2016
Supplies, embryos and other production materials	$	2,673	$	1,835
Work in process	4,767		5,466
Livestock	11,040		11,752
Feed	2,013		2,086
Total inventory	$	20,493	$	21,139

Property, Plant and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2017

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment

Property, plant and equipment consist of the following:



	December 31,
	2017			2016
Land and land improvements	$	11,767		$	10,904
Buildings and building improvements	18,183			8,123
Furniture and fixtures	2,515			2,176
Equipment	65,863			44,392
Leasehold improvements	25,277			15,105
Breeding stock	3,832			3,893
Computer hardware and software	10,128			6,844
Trees	6,642			2,772
Construction and other assets in progress	14,113			4,513
	158,320			98,722
Less: Accumulated depreciation and amortization	(45,646		)	(34,050		)
Property, plant and equipment, net	$	112,674		$	64,672

Goodwill and Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Changes in Carrying Amount of Goodwill

The changes in the carrying amount of goodwill for the years ended December 31, 2017 and 2016, are as follows:



	2017			2016
Beginning balance	$	157,175		$	165,169
Acquisitions	4,850			—
Impairment	(13,823		)	—
Foreign currency translation adjustments	5,087			(7,994		)
Ending balance	$	153,289		$	157,175

Schedule of Intangible Assets

Intangible assets consist of the following as of December 31, 2017:



	Weighted Average Useful Life (Years)	Gross Carrying Amount		Accumulated Amortization			Net
Patents, developed technologies and know-how	15.9	$	263,615	$	(44,954	)	$	218,661
Customer relationships	6.5	10,700		(6,383		)	4,317
Trademarks	9.3	6,800		(2,567		)	4,233
In-process research and development		5,666		—			5,666
Total		$	286,781	$	(53,904	)	$	232,877

Intangible assets consist of the following as of December 31, 2016:



	Gross Carrying Amount		Accumulated Amortization			Net
Patents, developed technologies and know-how	$	236,401	$	(29,748	)	$	206,653
Customer relationships	10,700		(4,672		)	6,028
Trademarks	6,800		(1,792		)	5,008
Covenant not to compete	370		(339		)	31
In-process research and development	7,895		—			7,895
Total	$	262,166	$	(36,551	)	$	225,615

Schedule of Definite-Lived Intangible Assets, Estimated Future Amortization Expense

Estimated aggregate amortization expense for definite lived intangible assets is expected to be as follows:



2018	$	19,258
2019	18,935
2020	18,833
2021	18,645
2022	17,646
Thereafter	133,894
Total	$	227,211

Lines of Credit and Long Term Debt (Tables)

12 Months Ended

Dec. 31, 2017

Debt Disclosure [Abstract]

Schedule of Long Term Debt Instruments

Long term debt consists of the following:



	December 31,
	2017		2016
Notes payable	$	5,010	$	5,453
Royalty-based financing	2,132		1,896
Other	895		599
Long term debt	8,037		7,948
Less current portion	502		386
Long term debt, less current portion	$	7,535	$	7,562

Schedule of Maturities of Long Term Debt

Future maturities of long term debt are as follows:



2018	$	502
2019	401
2020	372
2021	832
2022	360
Thereafter	3,438
Total	$	5,905

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

+ Details

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2017

Income Tax Disclosure [Abstract]

Components of Loss Before Income Taxes

The components of loss before income taxes are presented below:



	Year Ended December 31,
	2017			2016			2015
Domestic	$	(71,343	)	$	(157,067	)	$	(69,287	)
Foreign	(58,357		)	(37,084		)	(17,691		)
Loss before income taxes	$	(129,700	)	$	(194,151	)	$	(86,978	)

Components of Income Tax Expense (Benefit)

The components of income tax expense (benefit) are presented below:



	Year Ended December 31,
	2017			2016			2015
U.S. federal income taxes:
Current	$	27		$	(17	)	$	22
Deferred	(523		)	1,396			1,732
Foreign income taxes:
Current	(379		)	(393		)	(123		)
Deferred	(2,269		)	(5,177		)	(1,003		)
State income taxes:
Deferred	264			314			388
Income tax expense (benefit)	$	(2,880	)	$	(3,877	)	$	1,016

Schedule of Effective Income Tax Rate Reconciliation



	2017			2016			2015
Computed statutory income tax benefit	$	(44,098	)	$	(66,011	)	$	(29,573	)
State and provincial income tax benefit, net of federal income taxes	(3,294		)	(7,905		)	(3,157		)
Nondeductible stock based compensation	4,147			3,321			3,182
Nondeductible officer compensation	476			—			2,433
Gain on dividend distribution of AquaBounty common stock	3,965			—			—
Impairment of goodwill	4,700			—			—
Research and development tax incentives	(1,166		)	(6,350		)	(348		)
Acquisition and internal restructuring transaction costs	354			571			883
Provisional impact of the Tax Act	85,288			—			—
Enacted changes in foreign tax rates and foreign tax reforms	2,138			—			(961		)
U.S.-foreign rate differential	5,410			3,463			620
Other, net	(64		)	1,485			(98		)
	57,856			(71,426		)	(27,019		)
Change in valuation allowance for deferred tax assets	(60,736		)	67,549			28,035
Total income tax expense (benefit)	$	(2,880	)	$	(3,877	)	$	1,016

Schedule of Deferred Tax Assets and Liabilities

The tax effects of temporary differences that comprise the deferred tax assets and liabilities as of December 31, 2017 and 2016, are as follows:



	2017			2016
Deferred tax assets
Allowance for doubtful accounts	$	1,300		$	1,676
Inventory	489			447
Equity securities and investments in affiliates	17,510			31,729
Accrued liabilities and long-term debt	3,131			4,168
Stock-based compensation	26,936			8,460
Deferred revenue	61,785			68,056
Research and development tax credits	11,385			10,396
Net operating and capital loss carryforwards	111,453			144,502
Total deferred tax assets	233,989			269,434
Less: Valuation allowance	215,582			256,165
Net deferred tax assets	18,407			13,269
Deferred tax liabilities
Property, plant and equipment	237			406
Intangible assets	33,790			29,870
Total deferred tax liabilities	34,027			30,276
Net deferred tax liabilities	$	(15,620	)	$	(17,007	)

Summary of Valuation Allowance

Activity within the valuation allowance for deferred tax assets during the years ended December 31, 2017, 2016 and 2015 was as follows:



	2017			2016			2015
Valuation allowance at beginning of year	$	256,165		$	190,174		$	161,660
Increase (decrease) in valuation allowance as a result of
Mergers and acquisitions, net	—			(1,416		)	1,228
Current year operations	26,619			67,549			28,035
Adoption of ASU 2016-09	17,843			—			—
Provisional impact of the Tax Act	(87,473		)	—			—
Changes in foreign tax rates and foreign tax reforms	1,327			—			—
Foreign currency translation adjustment	1,101			(142		)	(749		)
Valuation allowance at end of year	$	215,582		$	256,165		$	190,174

Shareholders' Equity (Tables)

12 Months Ended

Dec. 31, 2017

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss are as follows:



	December 31,
	2017			2016
Unrealized loss on investments	$	(2	)	$	(89	)
Loss on foreign currency translation adjustments	(15,552		)	(36,113		)
Total accumulated other comprehensive loss	$	(15,554	)	$	(36,202	)

Share-Based Payments (Tables)

12 Months Ended

Dec. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock-based Compensation Expense

Stock-based compensation costs included in the consolidated statements of operations are presented below:



	Year Ended December 31,
	2017		2016		2015
Cost of products	$	116	$	81	$	95
Cost of services	322		274		354
Research and development	9,336		9,251		8,614
Selling, general and administrative	31,802		32,596		29,604
Total	$	41,576	$	42,202	$	38,667

Schedule of Stock Option Activity

Stock option activity was as follows:



	Number of Shares		Weighted Average Exercise Price			Weighted Average Remaining Contractual Term (Years)
Balances at December 31, 2014	8,323,544		$	22.59		8.64
Granted	5,051,500		45.82
Adjustment due to dividend (Note 14)	312,795		25.40
Exercised	(1,029,291	)	(15.16		)
Forfeited	(1,610,335	)	(26.75		)
Expired	(4,685	)	(28.29		)
Balances at December 31, 2015	11,043,528		32.66			8.49
Granted	4,644,860		29.39
Exercised	(1,210,840	)	(15.83		)
Forfeited	(2,760,809	)	(40.34		)
Expired	(76,356	)	(37.81		)
Balances at December 31, 2016	11,640,383		31.25			8.21
Granted	3,920,950		21.47
Adjustment due to dividend (Note 14)	46,766		31.11
Exercised	(149,429	)	(6.37		)
Forfeited	(3,797,105	)	(28.37		)
Expired	(278,818	)	(33.18		)
Balances at December 31, 2017	11,382,747		28.99			7.32
Exercisable at December 31, 2017	5,306,697		29.96			6.14

Summary of Information About Stock Options Outstanding

The following table summarizes additional information about stock options outstanding as of December 31, 2017:



					Options Outstanding						Options Exercisable
Range of Exercise Prices					Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value		Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value
$	2.64	—	$	9.30	453,371	$	7.06	3.94	$	2,020	453,371	$	7.06	3.94	$	2,020
$	12.50	—	$	21.38	3,158,121	20.58		8.74	—		456,942	19.52		7.13	—
$	21.43	—	$	28.81	3,399,721	25.55		6.91	—		1,804,401	25.86		5.69	—
$	28.88	—	$	40.99	2,751,716	32.07		6.70	—		1,732,250	31.51		6.32	—
$	41.41	—	$	65.08	1,619,818	53.52		7.42	—		859,733	53.07		7.38	—
					11,382,747	$	28.99	7.32	$	2,020	5,306,697	$	29.96	6.14	$	2,020

The following table summarizes additional information about stock options outstanding as of December 31, 2016:



					Options Outstanding						Options Exercisable
Range of Exercise Prices					Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value		Number of Options	Weighted Average Exercise Price		Weighted Average Remaining Life (Years)	Aggregate Intrinsic Value
$	2.65	—	$	9.34	562,951	$	6.23	4.13	$	10,172	525,755	$	6.01	3.97	$	9,615
$	15.21	—	$	27.19	2,785,705	23.47		8.54	4,797		684,704	21.07		7.29	2,237
$	27.21	—	$	29.68	3,147,242	29.30		7.53	—		1,400,707	29.35		7.31	—
$	29.70	—	$	42.22	3,590,423	32.89		9.09	—		345,274	37.06		6.85	—
$	43.99	—	$	65.34	1,554,062	54.40		8.43	—		461,595	53.06		8.33	—
					11,640,383	$	31.25	8.21	$	14,969	3,418,035	$	28.09	6.88	$	11,852

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Future Minimum Lease Payments Under Noncancelable Operating Leases

As of December 31, 2017, future minimum lease payments under operating leases having initial or remaining noncancelable lease terms in excess of one year are as follows:



2018	$	7,964
2019	9,115
2020	9,186
2021	8,299
2022	7,279
Thereafter	26,044
Total	$	67,887

Net Loss per Share (Tables)

12 Months Ended

Dec. 31, 2017

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net Loss per Share

The following table presents the computation of basic and diluted net loss per share:



	2017			2016			2015
Historical net loss per share:
Numerator:
Net loss attributable to Intrexon	$	(117,018	)	$	(186,612	)	$	(84,493	)
Denominator:
Weighted average shares outstanding, basic and diluted	119,998,826			117,983,836			111,066,352
Net loss attributable to Intrexon per share, basic and diluted	$	(0.98	)	$	(1.58	)	$	(0.76	)

Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share



	December 31,
	2017	2016	2015
Options	11,382,747	11,640,383	11,043,528
Warrants	133,264	—	194,719
Total	11,516,011	11,640,383	11,238,247

Quarterly Financial Information (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information (Unaudited)



	Three Months Ended
	March 31, 2017			June 30, 2017			September 30, 2017			December 31, 2017 (1)
Total revenues	$	53,504		$	54,433		$	46,016		$	77,028
Operating loss	(31,381		)	(35,270		)	(44,747		)	(26,492		)
Net loss	(32,377		)	(19,662		)	(40,836		)	(33,945		)
Net loss attributable to Intrexon	(31,399		)	(18,664		)	(39,689		)	(27,266		)
Net loss attributable to Intrexon per share, basic and diluted	$	(0.26	)	$	(0.16	)	$	(0.33	)	$	(0.23	)



	Three Months Ended
	March 31, 2016			June 30, 2016			September 30, 2016			December 31, 2016
Total revenues	$	43,438		$	52,501		$	48,985		$	46,002
Operating loss	(40,533		)	(23,222		)	(28,821		)	(32,590		)
Net loss	(65,320		)	(50,031		)	(30,011		)	(44,912		)
Net loss attributable to Intrexon	(64,429		)	(49,064		)	(28,982		)	(44,137		)
Net loss attributable to Intrexon per share, basic and diluted	$	(0.55	)	$	(0.42	)	$	(0.24	)	$	(0.37	)


(1)	During the fourth quarter of 2017, the Company recognized the remaining balance of deferred revenue associated with ZIOPHARM ECC2 upon the parties' mutual agreement to terminate (Note 5). The Company also recorded goodwill impairment charges primarily related to the AquaBounty reporting unit and an impairment charge related to certain of its in-process research and development assets (Note 11).

Organization and Basis of Presentation - Additional Information (Details) $ in Thousands	1 Months Ended		12 Months Ended
	Mar. 31, 2017 USD ($) shares	Jan. 31, 2017 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($) shares
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Purchase of noncontrolling interest by parent, parent equity issued (in shares) \| shares					307,074
Purchase of noncontrolling interest by parent, parent equity issued			$ 913	$ 0	$ 1,566
Biological & Popular Culture, Inc.
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Purchase of noncontrolling interest by parent, percentage	0.49
Purchase of noncontrolling interest by parent, cash paid	$ 900
Purchase of noncontrolling interest by parent, parent equity issued (in shares) \| shares	221,743
Purchase of noncontrolling interest by parent, parent equity issued	$ 5,082
AquaBounty Technologies, Inc.
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Parent ownership interest			58.00%
Purchase of additional equity of majority-owned subsidiary		$ 25,000

Summary of Significant Accounting Policies - Additional Information (Details)
$ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2017

USD ($)

Sep. 30, 2017

USD ($)

Jun. 30, 2017

USD ($)

Mar. 31, 2017

USD ($)

Dec. 31, 2016

USD ($)

Sep. 30, 2016

USD ($)

Jun. 30, 2016

USD ($)

Mar. 31, 2016

USD ($)

Dec. 31, 2017

USD ($)

segment

Dec. 31, 2016

USD ($)

Dec. 31, 2015

USD ($)

Jan. 01, 2018

USD ($)

Organization And Significant Accounting Policies [Line Items]

Research and development commitments with third parties not incurred

$ 10,682

$ 10,631

$ 10,682

$ 10,631

Maturity period of highly liquid investment

3 months

Cash equivalent investments in highly liquid money market accounts

43,012

43,808

$ 43,012

43,808

Fair value of financial assets measured at fair value on a recurring basis

183,173

335,307

183,173

335,307

Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock

2,586

(58,894)

$ 66,876

Maximum risk of loss related to the identified VIEs

185,261

159,115

$ 185,261

159,115

Number of segments | segment

Property, plant and equipment, net

112,674

64,672

$ 112,674

64,672

Revenues

$ 77,028

^[1]

$ 46,016

$ 54,433

$ 53,504

$ 46,002

$ 48,985

$ 52,501

$ 43,438

230,981

190,926

173,605

Cumulative effect of adoption of ASU 2016-09

Valuation allowance, deferred tax asset, change in amount due to adoption of accounting principle

$ 17,843

$ 0

Oragenics, Inc.

Organization And Significant Accounting Policies [Line Items]

Company's ownership percentage

29.40%

29.50%

29.40%

29.50%

ZIOPHARM Oncology, Inc.

Organization And Significant Accounting Policies [Line Items]

Realized investment gain

81,401

Equity securities

Organization And Significant Accounting Policies [Line Items]

Fair value of financial assets measured at fair value on a recurring basis

$ 15,100

$ 23,522

$ 15,100

$ 23,522

Equity securities | Oragenics, Inc.

Organization And Significant Accounting Policies [Line Items]

Fair value of financial assets measured at fair value on a recurring basis

3,085

7,244

3,085

7,244

Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock

(4,159)

(10,523)

4,863

Foreign Countries

Organization And Significant Accounting Policies [Line Items]

Property, plant and equipment, net

$ 21,837

$ 13,265

21,837

13,265

Revenues

$ 17,605

$ 11,969

$ 5,918

Minimum

Organization And Significant Accounting Policies [Line Items]

Expected useful life of intangible asset

3 years

Maximum

Organization And Significant Accounting Policies [Line Items]

Expected useful life of intangible asset

21 years

Intrexon Stock Option Plans

Organization And Significant Accounting Policies [Line Items]

Expected dividend yield

0.00%

Additional Paid-in Capital

Organization And Significant Accounting Policies [Line Items]

Cumulative effect of adoption of ASU 2016-09

$ 1,461

Subsequent Event | Accounting Standards Update 2014-09

Organization And Significant Accounting Policies [Line Items]

Cumulative effect of adoption of ASU 2014-09

$ 40,413

Subsequent Event | Ares Trading S.A. | Accounting Standards Update 2014-09

Organization And Significant Accounting Policies [Line Items]

Cumulative effect of adoption of ASU 2014-09

40,789

Subsequent Event | ZIOPHARM Oncology, Inc. | Accounting Standards Update 2014-09

Organization And Significant Accounting Policies [Line Items]

Cumulative effect of adoption of ASU 2014-09

$ 376

[1]

During the fourth quarter of 2017, the Company recognized the remaining balance of deferred revenue associated with ZIOPHARM ECC2 upon the parties' mutual agreement to terminate (Note 5). The Company also recorded goodwill impairment charges primarily related to the AquaBounty reporting unit and an impairment charge related to certain of its in-process research and development assets (Note 11).

Summary of Significant Accounting Policies - Summarized Financial Data of Equity Method Investments (Details) - USD ($)
$ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2017

Sep. 30, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Equity Method Investment, Summarized Financial Information, Gross Profit (Loss) [Abstract]

Operating expenses

$ 368,871

$ 316,092

$ 320,469

Operating loss

$ (26,492)

^[1]

$ (44,747)

$ (35,270)

$ (31,381)

$ (32,590)

$ (28,821)

$ (23,222)

$ (40,533)

(137,890)

(125,166)

(146,864)

Other, net

22,473

(47,865)

68,830

Equity Method Investments

Equity Method Investment, Summarized Financial Information, Assets [Abstract]

Current assets

61,086

77,761

61,086

77,761

Non-current assets

13,598

11,040

13,598

11,040

Total assets

74,684

88,801

74,684

88,801

Equity Method Investment, Summarized Financial Information, Liabilities [Abstract]

Current liabilities

6,213

11,588

6,213

11,588

Net assets

$ 68,471

$ 77,213

68,471

77,213

Equity Method Investment, Summarized Financial Information, Gross Profit (Loss) [Abstract]

Revenues, net

254

417

1,176

Operating expenses

41,904

62,373

32,513

Operating loss

(41,650)

(61,956)

(31,337)

Other, net

(8)

1,535

(64)

Net loss

$ (41,658)

$ (60,421)

$ (31,401)

[1]

Summary of Significant Accounting Policies - Rollforward of Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Allowance for Doubtful Accounts
Beginning balance	$ 3,703	$ 2,081	$ 565
Charged to operating expenses	1,217	1,963	1,757
Write offs of accounts receivable, net of recoveries	(289)	(341)	(241)
Ending balance	$ 4,631	$ 3,703	$ 2,081

Summary of Significant Accounting Policies - Estimated Useful Lives of Property, Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2017
Minimum \| Land improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	4 years
Minimum \| Building and building improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	3 years
Minimum \| Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Minimum \| Equipment
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Minimum \| Breeding stock
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Minimum \| Computer hardware and software
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Minimum \| Leasehold improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	1 year
Maximum \| Land improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	20 years
Maximum \| Building and building improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	25 years
Maximum \| Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	10 years
Maximum \| Equipment
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	10 years
Maximum \| Breeding stock
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	4 years
Maximum \| Computer hardware and software
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	7 years
Maximum \| Leasehold improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment, useful life	20 years

Summary of Significant Accounting Policies - Summary of Assumptions Used in Option Pricing Model (Details) - Intrexon Stock Option Plans	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%	0.00%
Expected volatility, minimum	57.00%	59.00%	59.00%
Expected volatility, maximum	60.00%	60.00%	62.00%
Expected term (years)	6 years 3 months	6 years 3 months	6 years 3 months
Risk-free interest rate, minimum	1.89%	1.23%	1.56%
Risk-free interest rate, maximum	2.27%	2.17%	1.95%

Mergers and Acquisitions - GenVec - Fair Value of Consideration Transferred (Details) - GenVec, Inc. $ in Thousands	1 Months Ended
	Jun. 30, 2017 USD ($)
Business Acquisition [Line Items]
Common shares	$ 15,616
Warrants	1,381
Contingent consideration	585
Total consideration transferred	$ 17,582

Mergers and Acquisitions - GenVec - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill	$ 153,289		$ 157,175	$ 165,169
GenVec, Inc.
Business Acquisition [Line Items]
Cash and cash equivalents		$ 2,054
Short term investments		542
Trade receivables		75
Other receivables		97
Prepaid expenses and other		227
Property and equipment		250
Intangible assets		14,000
Other noncurrent assets		58
Total assets acquired		17,303
Accounts payable		2,158
Accrued compensation and benefits		1,226
Other accrued expenses		856
Other long term liabilities		92
Deferred tax liabilities		239
Total liabilities assumed		4,571
Net assets acquired		12,732
Goodwill		4,850
Total consideration		$ 17,582

Mergers and Acquisitions - GenVec - Additional Information (Details) - GenVec, Inc. - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Percentage of outstanding common stock acquired	100.00%
Business combination, consideration paid, shares issued	684,240
Collaboration agreement, percent of collaboration payments	50.00%
Business combination, period subsequent to acquisition during which a portion of collaboration payments received will be paid to former stockholders of acquired entity	3 years
Expected useful life of intangible asset	11 years
Business Combination, Consideration Transferred	$ 17,582
Selling, general and administrative
Business Acquisition [Line Items]
Business combination, acquisition related cost		$ 507	$ 12

Mergers and Acquisitions - Oxitec - Fair Value of Consideration Transferred (Details) - Oxitec Limited $ in Thousands	1 Months Ended
	Sep. 30, 2015 USD ($)
Business Acquisition [Line Items]
Cash	$ 90,199
Common shares	56,195
Total consideration transferred	$ 146,394

Mergers and Acquisitions - Oxitec - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Sep. 30, 2015
Business Acquisition [Line Items]
Goodwill	$ 153,289	$ 157,175	$ 165,169
Oxitec Limited
Business Acquisition [Line Items]
Cash				$ 3,780
Trade receivables				125
Other receivables				7,395
Prepaid expenses and other				121
Property, plant, and equipment				1,198
Intangible assets				96,854
Total assets acquired				109,473
Accounts payable				1,187
Accrued compensation and benefits				246
Other accrued liabilities				210
Deferred revenue				120
Deferred tax liabilities				12,584
Total liabilities assumed				14,347
Net assets acquired				95,126
Goodwill				51,268
Total consideration				$ 146,394

Mergers and Acquisitions - Oxitec - Additional Information (Details) - Oxitec Limited - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Nov. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Business Acquisition [Line Items]
Percentage of outstanding common stock acquired		100.00%
Business combination, consideration paid, shares issued		1,359,343
Cash		$ 90,199
Business combination, consideration transferred, cash and working capital adjustments		$ 9,449
Business combination, equity interest issued or issuable, number of shares withheld as escrow		480,422
Business combination, cash consideration withheld as escrow		$ 1,991
Expected useful life of intangible asset	18 years
Selling, general and administrative
Business Acquisition [Line Items]
Business combination, acquisition related cost			$ 1,675

Mergers and Acquisitions - Okanagan - Fair Value of Consideration Transferred (Details) - Okanagan Specialty Fruits Inc. $ in Thousands	1 Months Ended
	Apr. 30, 2015 USD ($)
Business Acquisition [Line Items]
Cash	$ 10,000
Common shares	30,933
Total consideration transferred	$ 40,933

Mergers and Acquisitions - Okanagan - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Apr. 30, 2015
Business Acquisition [Line Items]
Goodwill	$ 153,289	$ 157,175	$ 165,169
Okanagan Specialty Fruits Inc.
Business Acquisition [Line Items]
Cash				$ 58
Trade receivables				16
Other receivables				49
Property, plant, and equipment				32
Intangible assets				36,500
Total assets acquired				36,655
Accounts payable				181
Deferred revenue				181
Deferred tax liabilities				8,847
Total liabilities assumed				9,209
Net assets acquired				27,446
Goodwill				13,487
Total consideration				$ 40,933

Mergers and Acquisitions - Okanagan - Additional Information (Details) - Okanagan Specialty Fruits Inc. - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Apr. 30, 2015	Dec. 31, 2015
Business Acquisition [Line Items]
Percentage of outstanding common stock acquired	100.00%
Business combination, consideration paid, shares issued	707,853
Cash	$ 10,000
Expected useful life of intangible asset	14 years
Selling, general and administrative
Business Acquisition [Line Items]
Business combination, acquisition related cost		$ 267

Mergers and Acquisitions - ActoGeniX - Fair Value of Consideration Transferred (Details) - ActoGeniX NV $ in Thousands	1 Months Ended
	Feb. 28, 2015 USD ($)
Business Acquisition [Line Items]
Cash	$ 32,739
Common shares	39,735
Total consideration transferred	$ 72,474

Mergers and Acquisitions - ActoGeniX - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Feb. 28, 2015
Business Acquisition [Line Items]
Goodwill	$ 153,289	$ 157,175	$ 165,169
ActoGeniX NV
Business Acquisition [Line Items]
Cash				$ 3,180
Other receivables				305
Prepaid expenses and other				31
Property, plant, and equipment				209
Intangible assets				68,100
Other noncurrent assets				23
Total assets acquired				71,848
Accounts payable				230
Accrued compensation and benefits				196
Other accrued liabilities				253
Deferred revenue				732
Deferred tax liabilities				612
Total liabilities assumed				2,023
Net assets acquired				69,825
Goodwill				2,649
Total consideration				$ 72,474

Mergers and Acquisitions - ActoGeniX - Additional Information (Details) - ActoGeniX NV - USD ($) $ in Thousands	1 Months Ended		12 Months Ended
	Aug. 31, 2015	Feb. 28, 2015	Dec. 31, 2015
Business Acquisition [Line Items]
Percentage of outstanding common stock acquired		100.00%
Business combination, consideration paid, shares issued		965,377
Cash		$ 32,739
Expected useful life of intangible asset	18 years
Selling, general and administrative
Business Acquisition [Line Items]
Business combination, acquisition related cost			$ 381

Mergers and Acquisitions - GenVec - Pro Forma Financial Information (Details) - GenVec, Inc. - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition, Pro Forma Information, Nonrecurring Adjustment [Line Items]
Revenues	$ 231,213	$ 191,437
Loss before income taxes	(136,966)	(201,210)
Net loss	(134,275)	(197,144)
Net loss attributable to the noncontrolling interests	9,802	3,662
Net loss attributable to Intrexon	$ (124,473)	$ (193,482)

Mergers and Acquisitions - 2015 Acquisitions - Pro Forma Financial Information (Details) - 2015 Business Acquisitions $ in Thousands	12 Months Ended
	Dec. 31, 2015 USD ($)
Business Acquisition [Line Items]
Revenues	$ 174,558
Loss before income taxes	(99,751)
Net loss	(99,594)
Net loss attributable to the noncontrolling interests	3,501
Net loss attributable to Intrexon	$ (96,093)

Investments in Joint Ventures - S & I Ophthalmic - Additional Information (Details)	1 Months Ended	12 Months Ended
	Oct. 31, 2013 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2017 USD ($) board_seat	Dec. 31, 2016 USD ($)
Schedule Of Investments In Joint Venture [Line Items]
Due from related parties, current			$ 17,913,000	$ 16,793,000
Investment			$ 18,870,000	23,655,000
S & I Ophthalmic, LLC
Schedule Of Investments In Joint Venture [Line Items]
Capital contribution	$ 5,000,000	$ 5,000,000
Membership interest	50.00%
Total number of seats on the joint venture's governing board \| board_seat			4
Total number of seats on the joint venture's governing board, externally selected \| board_seat			2
Total number of seats on the joint venture's governing board, internally selected \| board_seat			2
S & I Opthalmic, LLC
Schedule Of Investments In Joint Venture [Line Items]
Due from related parties, current			$ 2,598,000
Investor \| S & I Ophthalmic, LLC
Schedule Of Investments In Joint Venture [Line Items]
Capital contribution	$ 5,000,000	$ 5,000,000
Membership interest	50.00%
Investments in affiliates \| S & I Ophthalmic, LLC
Schedule Of Investments In Joint Venture [Line Items]
Investment				$ 3,236,000

Investments in Joint Ventures - OvaXon - Additional Information (Details)	1 Months Ended	47 Months Ended
	Jan. 31, 2014 USD ($)	Dec. 31, 2017 USD ($) board_seat	Dec. 31, 2016 USD ($)
Schedule Of Investments In Joint Venture [Line Items]
Investment		$ 18,870,000	$ 23,655,000
OvaXon, LLC
Schedule Of Investments In Joint Venture [Line Items]
Capital contribution	$ 1,500,000	$ 4,350,000
Membership interest	50.00%
Total number of seats on the joint venture's governing board \| board_seat		4
Total number of seats on the joint venture's governing board, internally selected \| board_seat		2
Total number of seats on the joint venture's governing board, externally selected \| board_seat		2
OvaXon, LLC \| Investor
Schedule Of Investments In Joint Venture [Line Items]
Capital contribution	$ 1,500,000	$ 4,350,000
Membership interest	50.00%
Investments in affiliates \| OvaXon, LLC
Schedule Of Investments In Joint Venture [Line Items]
Investment		$ 146,000	$ 65,000

Investments in Joint Ventures - Intrexon Energy Partners - Additional Information (Details)	1 Months Ended
	Mar. 31, 2014 USD ($)	Dec. 31, 2017 USD ($) board_seat	Dec. 31, 2016 USD ($)
Schedule Of Investments In Joint Venture [Line Items]
Investment		$ 18,870,000	$ 23,655,000
Intrexon Energy Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest	50.00%
Maximum additional capital contributions committed	$ 25,000,000
Additional capital contributions committed, remaining commitment		$ 6,011,000
Total number of seats on the joint venture's governing board \| board_seat		5
Total number of seats on the joint venture's governing board, internally selected \| board_seat		2
Total number of seats on the joint venture's governing board, externally selected \| board_seat		3
Investor \| Intrexon Energy Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest	50.00%
Capital contribution	$ 25,000,000
Maximum additional capital contributions committed	25,000,000
Upfront and Milestone Payments \| Upfront \| Intrexon Energy Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Collaborative agreement, consideration received, value	$ 25,000,000
Other accrued liabilities \| Intrexon Energy Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Investment		$ (444,000)	$ (477,000)

Investments in Joint Ventures - Intrexon Energy Partners II - Additional Information (Details)	1 Months Ended
	Dec. 31, 2015 USD ($)	Dec. 31, 2017 USD ($) board_seat	Dec. 31, 2016 USD ($)
Schedule Of Investments In Joint Venture [Line Items]
Investment		$ 18,870,000	$ 23,655,000
Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest	50.00%
Maximum additional capital contributions committed	$ 10,000,000
Total number of seats on the joint venture's governing board \| board_seat		5
Total number of seats on the joint venture's governing board, internally selected \| board_seat		1
Total number of seats on the joint venture's governing board, externally selected \| board_seat		4
Intrexon Energy Partners II, LLC \| Upfront and Milestone Payments \| Upfront
Schedule Of Investments In Joint Venture [Line Items]
Collaborative agreement, consideration received, value	$ 18,000,000
Investor \| Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest	50.00%
Capital contribution	$ 18,000,000
Maximum additional capital contributions committed	10,000,000
All Investors \| Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Capital contribution	$ 4,000,000
Investments in affiliates \| Intrexon Energy Partners II, LLC
Schedule Of Investments In Joint Venture [Line Items]
Investment		$ 572,000	$ 1,414,000

Investments in Joint Ventures - EnviroFlight - Additional Information (Details) - USD ($)	1 Months Ended				12 Months Ended			47 Months Ended
	Oct. 31, 2016	Feb. 29, 2016	Jan. 31, 2014	Oct. 31, 2013	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2017
Schedule Of Investments In Joint Venture [Line Items]
Cash paid in asset acquisition					$ 14,219,000	$ 7,244,000	$ 0
Shares issued in asset acquisition					0	4,401,000	0
Contingent consideration assumed in asset acquisition					0	3,660,000	0
Shares issued as payment for contingent consideration					0	1,583,000	0
Investment					18,870,000	23,655,000		$ 18,870,000
S & I Ophthalmic, LLC
Schedule Of Investments In Joint Venture [Line Items]
Capital contribution				$ 5,000,000			5,000,000
Membership interest				50.00%
OvaXon, LLC
Schedule Of Investments In Joint Venture [Line Items]
Capital contribution			$ 1,500,000					4,350,000
Membership interest			50.00%
EnviroFlight, LLC
Schedule Of Investments In Joint Venture [Line Items]
Cash paid in asset acquisition		$ 4,244,000
Shares issued in asset acquisition, shares		136,340
Shares issued in asset acquisition		$ 4,401,000
Contingent consideration assumed in asset acquisition		3,660,000
Capital contribution		$ 3,000,000
Membership interest		50.00%
Maximum additional capital contributions committed		$ 5,000,000
Additional capital contributions committed, remaining commitment					250,000			250,000
Estimated fair value of investment		5,425,000
Shares issued as payment for contingent consideration, shares	59,337
Shares issued as payment for contingent consideration	$ 1,583,000
Contingent consideration for commercial milestones payable in common stock, maximum		$ 4,000,000
Investor \| S & I Ophthalmic, LLC
Schedule Of Investments In Joint Venture [Line Items]
Capital contribution				$ 5,000,000			$ 5,000,000
Membership interest				50.00%
Investor \| OvaXon, LLC
Schedule Of Investments In Joint Venture [Line Items]
Capital contribution			$ 1,500,000					4,350,000
Membership interest			50.00%
Investor \| EnviroFlight, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest		50.00%
Maximum additional capital contributions committed		$ 5,000,000
Patents, developed technologies and know-how \| EnviroFlight, LLC
Schedule Of Investments In Joint Venture [Line Items]
Estimated fair value of developed technology acquired		$ 9,880,000
Expected useful life of intangible asset		21 years
Investments in affiliates \| S & I Ophthalmic, LLC
Schedule Of Investments In Joint Venture [Line Items]
Investment						3,236,000
Investments in affiliates \| OvaXon, LLC
Schedule Of Investments In Joint Venture [Line Items]
Investment					146,000	65,000		146,000
Investments in affiliates \| EnviroFlight, LLC
Schedule Of Investments In Joint Venture [Line Items]
Investment					$ 7,092,000	$ 4,189,000		$ 7,092,000

Investments in Joint Ventures - Intrexon T1D Partners - Additional Information (Details)	1 Months Ended
	Mar. 31, 2016 USD ($)	Dec. 31, 2017 USD ($) board_seat	Dec. 31, 2016 USD ($)
Schedule Of Investments In Joint Venture [Line Items]
Investment		$ 18,870,000	$ 23,655,000
Intrexon T1D Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest	50.00%
Maximum additional capital contributions committed	$ 5,000,000
Additional capital contributions committed, remaining commitment		$ 2,900,000
Total number of seats on the joint venture's governing board \| board_seat		5
Total number of seats on the joint venture's governing board, internally selected \| board_seat		2
Total number of seats on the joint venture's governing board, externally selected \| board_seat		3
Upfront \| Intrexon T1D Partners, LLC \| Upfront and Milestone Payments
Schedule Of Investments In Joint Venture [Line Items]
Collaborative agreement, consideration received, value	$ 10,000,000
Investor \| Intrexon T1D Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Membership interest	50.00%
Capital contribution	$ 10,000,000
Maximum additional capital contributions committed	$ 5,000,000
Investments in affiliates \| Intrexon T1D Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Investment			$ 806,000
Other accrued liabilities \| Intrexon T1D Partners, LLC
Schedule Of Investments In Joint Venture [Line Items]
Investment		$ (943,000)

Collaboration and Licensing Revenue - Summary of Deferred Revenue (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred Revenue Arrangement [Line Items]
Current portion of deferred revenue	$ 42,870	$ 53,364
Long-term portion of deferred revenue	193,527	256,778
Deferred revenue	236,397	310,142
Upfront and milestone payments
Deferred Revenue Arrangement [Line Items]
Deferred revenue	230,531	297,867
Prepaid research and development services
Deferred Revenue Arrangement [Line Items]
Deferred revenue	1,052	6,015
Prepaid product and service revenues
Deferred Revenue Arrangement [Line Items]
Deferred revenue	4,681	5,554
Other
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 133	$ 706

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References + Details

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details

Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator (Details) - USD ($)
$ in Thousands

Dec. 31, 2017

Dec. 31, 2016

Summary of Deferred Revenue by Collaborator [Line Items]

Deferred revenue

$ 236,397

$ 310,142

Upfront and Milestone Payments

Summary of Deferred Revenue by Collaborator [Line Items]

Deferred revenue

230,531

297,867

ZIOPHARM Oncology, Inc. | Upfront and Milestone Payments

Summary of Deferred Revenue by Collaborator [Line Items]

Deferred revenue

90,496

138,809

Oragenics, Inc. | Upfront and Milestone Payments

Summary of Deferred Revenue by Collaborator [Line Items]

Deferred revenue

6,719

7,766

Fibrocell Science, Inc. | Upfront and Milestone Payments

Summary of Deferred Revenue by Collaborator [Line Items]

Deferred revenue

16,607

19,026

Genopaver, LLC | Upfront and Milestone Payments

Summary of Deferred Revenue by Collaborator [Line Items]

Deferred revenue

1,704

1,977

Intrexon Energy Partners, LLC | Upfront and Milestone Payments

Summary of Deferred Revenue by Collaborator [Line Items]

Deferred revenue

15,625

18,125

Persea Bio, LLC | Upfront and Milestone Payments

Summary of Deferred Revenue by Collaborator [Line Items]

Deferred revenue

3,500

4,000

Ares Trading S.A. | Upfront and Milestone Payments

Summary of Deferred Revenue by Collaborator [Line Items]

Deferred revenue

40,789

47,178

Intrexon Energy Partners II, LLC | Upfront and Milestone Payments

Summary of Deferred Revenue by Collaborator [Line Items]

Deferred revenue

13,833

15,833

Intrexon T1D Partners, LLC | Upfront and Milestone Payments

Summary of Deferred Revenue by Collaborator [Line Items]

Deferred revenue

8,435

8,653

Harvest Start-Up Entities | Upfront and Milestone Payments

Summary of Deferred Revenue by Collaborator [Line Items]

Deferred revenue

^[1]

18,400

20,208

Other | Upfront and Milestone Payments

Summary of Deferred Revenue by Collaborator [Line Items]

Deferred revenue

$ 14,423

$ 16,292

[1]	As of December 31, 2017 and December 31, 2016, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.

Collaboration and Licensing Revenue - Additional Information (Details)			1 Months Ended																				5 Months Ended	12 Months Ended
	Jan. 19, 2018	Mar. 10, 2017	Dec. 31, 2017 USD ($)	Nov. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($) shares	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($) shares	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	May 31, 2015 USD ($) target	Dec. 31, 2014 USD ($)	Mar. 31, 2014 USD ($)	Jan. 31, 2014 USD ($) shares	Dec. 31, 2013 shares	Sep. 30, 2013 USD ($) shares	Jun. 30, 2013 USD ($) shares	Mar. 31, 2013 USD ($)	Feb. 28, 2013	Oct. 31, 2012 USD ($) shares	Jun. 30, 2012 USD ($) shares	Jan. 31, 2011 USD ($) shares	May 31, 2016	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																								$ 145,579,000	$ 109,871,000	$ 87,821,000
Deferred revenue			$ 236,397,000																					236,397,000	310,142,000
Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																								71,637,000	34,433,000	32,513,000
Deferred revenue			230,531,000																					230,531,000	297,867,000
Prepaid research and development services
Collaboration Agreements [Line Items]
Deferred revenue			1,052,000																					1,052,000	6,015,000
ZIOPHARM ECC 1
Collaboration Agreements [Line Items]
Percentage of shares outstanding at the date of achievement of future milestone																						7.495%
Required notice period for voluntary termination of collaborative agreement																						90 days
ZIOPHARM ECC 1 \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received (in shares) \| shares																						3,636,926
Collaborative agreement, consideration received, value																						$ 17,457,000
ZIOPHARM ECC 1 \| Milestone One \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received (in shares) \| shares																				3,636,926
Collaborative agreement, consideration received, value																				$ 18,330,000
ZIOPHARM ECC 1 Separate Unit Of Accounting \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																						1,115,000
ZIOPHARM ECC 1 Unit of Accounting 1 \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Deferred revenue																						$ 16,342,000
ZIOPHARM Oncology, Inc.
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																								69,812,000	33,836,000	19,306,000
Royalty rate as a percentage of net profit						20.00%																	50.00%
ZIOPHARM Oncology, Inc. \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																								48,313,000	11,529,000	2,855,000
Deferred revenue			90,496,000																					90,496,000	138,809,000
ZIOPHARM Oncology, Inc. \| Other Contractual Payments \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value						$ 120,000,000
Collaborative arrangement consideration received, number of preferred shares (in shares) \| shares						100,000
Ares Trading S.A.
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																								10,738,000	10,192,000	4,728,000
Required notice period for voluntary termination of collaborative agreement											90 days
Collaborative agreement, additional target fee											$ 5,000,000
Ares Trading S.A. \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																								6,389,000	6,389,000	3,933,000
Deferred revenue			40,789,000																					40,789,000	47,178,000
Ares Trading S.A. \| Prepaid research and development services
Collaboration Agreements [Line Items]
Deferred revenue											$ 10,000,000
Collaborative agreement, consideration receivable, minimum targets required \| target											2
Collaborative agreement, consideration receivable, collection period											2 years
Ares Trading S.A. \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value											$ 115,000,000
ZIOPHARM ECC 2 \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value									$ 10,000,000
Collaboration and licensing revenues			28,943,000
Oragenics ECC 1
Collaboration Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement																					90 days
Royalty rate as a percentage of net profit																					25.00%
Oragenics ECC 1 \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received (in shares) \| shares																					439,243
Collaborative agreement, consideration received, value																					$ 6,588,000
Oragenics ECC 2 \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received (in shares) \| shares																134,800
Collaborative agreement, consideration received, value																$ 3,503,000
Collaborative agreement, consideration received, value of convertible promissory note																$ 1,956,000
Conversion of promissory note into common stock (in shares) \| shares															69,824
Oragenics ECC 3
Collaboration Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement										90 days
Oragenics ECC 3 \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value of convertible promissory note										$ 5,000,000
Conversion of promissory note into common stock (in shares) \| shares								338,100
Fibrocell ECC 1
Collaboration Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement																				90 days
Royalty rate as a percentage of net sales, tier 1																				7.00%
Level of net sales at which royalty rate changes to tier 2																				$ 25,000,000
Royalty rate as a percentage of net sales, tier 2																				14.00%
Royalty rate of savings from improvement																				33.00%
Fibrocell ECC 1 \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received (in shares) \| shares																				439,173
Collaborative agreement, consideration received, value																				$ 7,576,000
Fibrocell ECC 1 \| Supplemental Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received (in shares) \| shares														341,530			414,594
Collaborative agreement, consideration received, value														$ 5,225,000			$ 7,612,000
Fibrocell ECC 2
Collaboration Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement								90 days
Maximum milestone payments required upon successful achievement, first product								$ 30,000,000
Maximum milestone payments required upon successful achievement, per each additional product								30,000,000
Maximum milestone payments required for certain sales milestones, per product								22,500,000
Fibrocell ECC 2 \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value								$ 10,000,000
Genopaver, LLC
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																								6,690,000	6,117,000	3,829,000
Required notice period for voluntary termination of collaborative agreement																		90 days
Genopaver, LLC \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																								273,000	273,000	273,000
Deferred revenue			1,704,000																					1,704,000	1,977,000
Genopaver, LLC \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value																		$ 3,000,000
AquaBounty Technologies, Inc.
Collaboration Agreements [Line Items]
Royalty rate as a percentage of gross profit																			16.66%
S & I Ophthalmic, LLC
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																								755,000	6,141,000	4,115,000
S & I Ophthalmic, LLC \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																								0	0	0
OvaXon, LLC
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																								1,966,000	2,934,000	2,540,000
Required notice period for voluntary termination of collaborative agreement															90 days
OvaXon, LLC \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																								0	0	0
Intrexon Energy Partners, LLC
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																								10,665,000	17,552,000	13,447,000
Required notice period for voluntary termination of collaborative agreement													90 days
Intrexon Energy Partners, LLC \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																								2,500,000	2,500,000	2,500,000
Deferred revenue			15,625,000																					15,625,000	18,125,000
Intrexon Energy Partners, LLC \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value													$ 25,000,000
Persea Bio, LLC
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																								946,000	1,278,000	1,241,000
Required notice period for voluntary termination of collaborative agreement												90 days
Persea Bio, LLC \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																								500,000	500,000	500,000
Deferred revenue			3,500,000																					3,500,000	4,000,000
Persea Bio, LLC \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value												$ 5,000,000
Thrive Agrobiotics, Inc.
Collaboration Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement									90 days
Thrive Agrobiotics, Inc. \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value									$ 1,667,000
Intrexon Energy Partners II, LLC
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																								3,672,000	3,169,000	167,000
Required notice period for voluntary termination of collaborative agreement								90 days
Intrexon Energy Partners II, LLC \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																								2,000,000	2,000,000	$ 167,000
Deferred revenue			13,833,000																					13,833,000	15,833,000
Intrexon Energy Partners II, LLC \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value								$ 18,000,000
Exotech Bio, Inc.
Collaboration Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement							90 days
Exotech Bio, Inc. \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value							$ 5,000,000
Relieve Genetics, Inc.
Collaboration Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement							90 days
Relieve Genetics, Inc. \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value							$ 4,333,000
Intrexon T1D Partners, LLC
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																								5,968,000	1,908,000
Required notice period for voluntary termination of collaborative agreement							90 days
Intrexon T1D Partners, LLC \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaboration and licensing revenues																								1,109,000	821,000
Deferred revenue			$ 8,435,000																					$ 8,435,000	$ 8,653,000
Intrexon T1D Partners, LLC \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value							$ 10,000,000
AD Skincare, Inc.
Collaboration Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement						90 days
AD Skincare, Inc. \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value						$ 4,333,000
Genten Therapeutics, Inc.
Collaboration Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement					90 days
Genten Therapeutics, Inc. \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value					$ 3,000,000
Collaborative agreement, consideration received, cash					$ 1,500,000
CRS Bio, Inc.
Collaboration Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement					90 days
CRS Bio, Inc. \| Upfront \| Upfront and Milestone Payments
Collaboration Agreements [Line Items]
Collaborative agreement, consideration received, value					$ 2,100,000
ZIOPHARM Oncology, Inc. \| Ares Trading S.A.
Collaboration Agreements [Line Items]
Collaboration agreement, percent of collaboration payments																								50.00%
Payments to related parties											57,500,000
Maximum \| Ares Trading S.A.
Collaboration Agreements [Line Items]
Milestone payments required upon successful achievement, per product											413,000,000
Milestone payments required upon successful achievement, one-time											$ 50,000,000
Maximum \| Oragenics ECC 1
Collaboration Agreements [Line Items]
Milestone payments required upon successful achievement, one-time				$ 35,000,000
Maximum \| Oragenics ECC 3
Collaboration Agreements [Line Items]
Milestone payments required upon successful achievement, per product				$ 5,500,000						22,000,000
Milestone payments required upon successful achievement, one-time										$ 10,000,000
Maximum \| Thrive Agrobiotics, Inc.
Collaboration Agreements [Line Items]
Milestone payments required upon successful achievement, per product									$ 5,500,000
Maximum \| Exotech Bio, Inc.
Collaboration Agreements [Line Items]
Milestone payments required upon successful achievement, per product							52,500,000
Maximum \| Relieve Genetics, Inc.
Collaboration Agreements [Line Items]
Milestone payments required upon successful achievement, per product							$ 52,500,000
Maximum \| AD Skincare, Inc.
Collaboration Agreements [Line Items]
Milestone payments required upon successful achievement, per product						2,000,000
Milestone payments required upon successful achievement, one-time						$ 17,000,000
Maximum \| Genten Therapeutics, Inc.
Collaboration Agreements [Line Items]
Milestone payments required upon successful achievement, per product					82,000,000
Maximum \| CRS Bio, Inc.
Collaboration Agreements [Line Items]
Milestone payments required upon successful achievement, per product					$ 75,000,000
Fibrocell Science, Inc.
Collaboration Agreements [Line Items]
Stockholders' equity, reverse stock split		1-for-3
Stockholders' equity reverse stock split conversion ratio		0.3333
Subsequent Event \| Oragenics, Inc.
Collaboration Agreements [Line Items]
Stockholders' equity, reverse stock split	1-for-10
Stockholders' equity reverse stock split conversion ratio	0.1

Short-term and Long-term Investments - Summary of Amortized Cost, Gross Unrealized Gains and Losses and Fair Value of Short-term and Long-term Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 6,275	$ 180,684
Gross Unrealized Gains	0	5
Gross Unrealized Losses	(2)	(94)
Aggregate Fair Value	6,273	180,595
U.S. government debt securities
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	6,000	180,412
Gross Unrealized Gains	0	5
Gross Unrealized Losses	(2)	(94)
Aggregate Fair Value	5,998	180,323
Certificates of deposit
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	275	272
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Aggregate Fair Value	$ 275	$ 272

Investments in Preferred Stock - Additional Information (Details) $ / shares in Units, $ in Thousands		1 Months Ended			12 Months Ended
	Mar. 10, 2017	Nov. 30, 2017 USD ($)	Mar. 31, 2017 USD ($) shares	Jun. 30, 2016 $ / shares shares	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) shares	Dec. 31, 2015 USD ($)
Schedule of Investments [Line Items]
Noncash dividend income on preferred shares					$ 16,756	$ 7,421	$ 0
Purchase of preferred stock					1,161	2,308	17,080
Fair value of financial assets measured at fair value on a recurring basis					183,173	335,307
Receivables converted to preferred stock					$ 3,385	$ 0	$ 0
Fibrocell Science, Inc.
Schedule of Investments [Line Items]
Convertible preferred shares, shares issued \| shares			1,161
Number of common shares into which warrants are convertible (in shares) \| shares			498,843
Stockholders' equity reverse stock split conversion ratio	0.3333
Preferred stock, dividend rate, percentage					4.00%
Stockholders' equity, reverse stock split	1-for-3
ZIOPHARM Oncology, Inc.
Schedule of Investments [Line Items]
Preferred shares, stated value (in usd per share) \| $ / shares				$ 1,200
Threshold consecutive trading days, conversion in shares					20 days
Preferred shares, dividend rate (in usd per share) \| $ / shares					$ 12.00
Preferred shares, dividend rate, for unconverted shares after conversion event (in usd per share) \| $ / shares					24.00
Minimum \| ZIOPHARM Oncology, Inc.
Schedule of Investments [Line Items]
Preferred shares, conversion calculation, divisor (in usd per share) \| $ / shares					$ 1.00
ZIOPHARM Oncology, Inc.
Schedule of Investments [Line Items]
Dividend income, number of preferred shares received (in shares) \| shares					13,460	6,184
Other Contractual Payments \| Upfront and Milestone Payments \| ZIOPHARM Oncology, Inc.
Schedule of Investments [Line Items]
Collaborative arrangement consideration received, number of preferred shares (in shares) \| shares				100,000
ZIOPHARM Oncology, Inc.
Schedule of Investments [Line Items]
Noncash dividend income on preferred shares					$ 16,717	$ 7,421
Fibrocell Science, Inc.
Schedule of Investments [Line Items]
Purchase of preferred stock			$ 1,161
Preferred stock
Schedule of Investments [Line Items]
Fair value of financial assets measured at fair value on a recurring basis					161,225	129,545
Preferred stock \| ZIOPHARM Oncology, Inc.
Schedule of Investments [Line Items]
Fair value of financial assets measured at fair value on a recurring basis					160,832	$ 129,545
Preferred stock \| Oragenics, Inc.
Schedule of Investments [Line Items]
Fair value of financial assets measured at fair value on a recurring basis					$ 0
Receivables converted to preferred stock		$ 3,385
Preferred stock, initial dividend rate					12.00%
Preferred stock, subsequent dividend rate					20.00%
Preferred stock \| Fibrocell Science, Inc.
Schedule of Investments [Line Items]
Fair value of financial assets measured at fair value on a recurring basis					$ 393

Investments in Preferred Stock - Schedule of Changes in Level 3 Investments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Receipt of preferred stock as consideration for amendments to collaboration agreements	$ 0	$ 120,000	$ 0
Purchase of preferred stock	1,161	2,308	17,080
Conversion of receivables to preferred stock	3,385	0	0
Dividend income from investments in preferred stock	16,756	7,421	0
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance	129,545	0
Receipt of preferred stock as consideration for amendments to collaboration agreements	0	120,000
Purchase of preferred stock	766	0
Conversion of receivables to preferred stock	3,385	0
Dividend income from investments in preferred stock	16,756	7,421
Net unrealized appreciation in the fair value of the investments in preferred stock	10,773	2,124
Ending balance	$ 161,225	$ 129,545	$ 0

Fair Value Measurements - Summary of Placement in the Fair Value Hierarchy of Financial Assets that are Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Assets
Fair value of assets	$ 183,173	$ 335,307
US government debt securities
Assets
Fair value of assets	5,998	180,323
Equity securities
Assets
Fair value of assets	15,100	23,522
Preferred stock
Assets
Fair value of assets	161,225	129,545
Other
Assets
Fair value of assets	850	1,917
Quoted Prices in Active Markets (Level 1)
Assets
Fair value of assets	10,537	15,544
Quoted Prices in Active Markets (Level 1) \| US government debt securities
Assets
Fair value of assets	0	0
Quoted Prices in Active Markets (Level 1) \| Equity securities
Assets
Fair value of assets	10,537	15,544
Quoted Prices in Active Markets (Level 1) \| Preferred stock
Assets
Fair value of assets	0	0
Quoted Prices in Active Markets (Level 1) \| Other
Assets
Fair value of assets	0	0
Significant Other Observable Inputs (Level 2)
Assets
Fair value of assets	11,411	190,218
Significant Other Observable Inputs (Level 2) \| US government debt securities
Assets
Fair value of assets	5,998	180,323
Significant Other Observable Inputs (Level 2) \| Equity securities
Assets
Fair value of assets	4,563	7,978
Significant Other Observable Inputs (Level 2) \| Preferred stock
Assets
Fair value of assets	0	0
Significant Other Observable Inputs (Level 2) \| Other
Assets
Fair value of assets	850	1,917
Significant Unobservable Inputs (Level 3)
Assets
Fair value of assets	161,225	129,545
Significant Unobservable Inputs (Level 3) \| US government debt securities
Assets
Fair value of assets	0	0
Significant Unobservable Inputs (Level 3) \| Equity securities
Assets
Fair value of assets	0	0
Significant Unobservable Inputs (Level 3) \| Preferred stock
Assets
Fair value of assets	161,225	129,545
Significant Unobservable Inputs (Level 3) \| Other
Assets
Fair value of assets	$ 0	$ 0

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	$ 585	$ 2,081

Fair Value Measurements - Schedule of Changes in Level 3 Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Contingent consideration assumed in asset acquisition	$ 0	$ 3,660	$ 0
Payment of contingent consideration	0	(1,583)	0
Significant Unobservable Inputs (Level 3)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	2,081	0
Contingent consideration assumed in asset acquisition	585	3,660
Payment of contingent consideration	0	(1,583)
Change in fair value of contingent consideration	(2,081)	4
Ending Balance	$ 585	$ 2,081	$ 0

Inventory - Schedule of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Inventory [Line Items]
Inventory	$ 20,493	$ 21,139
Supplies, embryos and other production materials
Inventory [Line Items]
Inventory	2,673	1,835
Work in process
Inventory [Line Items]
Inventory	4,767	5,466
Livestock
Inventory [Line Items]
Inventory	11,040	11,752
Feed
Inventory [Line Items]
Inventory	$ 2,013	$ 2,086

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Land and land improvements	$ 11,767	$ 10,904
Buildings and building improvements	18,183	8,123
Furniture and fixtures	2,515	2,176
Equipment	65,863	44,392
Leasehold improvements	25,277	15,105
Breeding stock	3,832	3,893
Computer hardware and software	10,128	6,844
Trees	6,642	2,772
Construction and other assets in progress	14,113	4,513
Property, plant and equipment, gross	158,320	98,722
Less: Accumulated depreciation and amortization	(45,646)	(34,050)
Property, plant and equipment, net	$ 112,674	$ 64,672

Property, Plant and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 11,951	$ 9,387	$ 7,872
Cash paid in asset acquisition	$ 14,219	$ 7,244	$ 0

Goodwill and Intangible Assets, Net - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Goodwill [Line Items]
Goodwill impairment charge	$ (13,823,000)	$ 0
Accumulated impairment losses		0
Impairment charge	2,950,000
Amortization expense	19,194,000	$ 15,185,000	$ 9,871,000
AquaBounty Technologies, Inc.
Goodwill [Line Items]
Goodwill impairment charge	$ (13,001,000)

Goodwill and Intangible Assets, Net - Schedule of Changes in Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Goodwill
Beginning Balance	$ 157,175	$ 165,169
Acquisitions	4,850	0
Impairment	(13,823)	0
Foreign currency translation adjustments	5,087	(7,994)
Ending Balance	$ 153,289	$ 157,175

Goodwill and Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 286,781	$ 262,166
Accumulated Amortization	(53,904)	(36,551)
Net	232,877	225,615
Patents, developed technologies and know-how
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	263,615	236,401
Accumulated Amortization	(44,954)	(29,748)
Net	218,661	206,653
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	10,700	10,700
Accumulated Amortization	(6,383)	(4,672)
Net	4,317	6,028
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	6,800	6,800
Accumulated Amortization	(2,567)	(1,792)
Net	4,233	5,008
Covenant not to compete
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount		370
Accumulated Amortization		(339)
Net		31
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	5,666	7,895
Net	$ 5,666	$ 7,895
Weighted Average \| Patents, developed technologies and know-how
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (Years)	15 years 10 months 24 days
Weighted Average \| Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (Years)	6 years 6 months
Weighted Average \| Trademarks
Finite-Lived Intangible Assets [Line Items]
Weighted Average Useful Life (Years)	9 years 3 months 18 days

Goodwill and Intangible Assets, Net - Schedule of Definite-Lived Intangible Assets, Estimated Future Amortization Expense (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2018	$ 19,258
2019	18,935
2020	18,833
2021	18,645
2022	17,646
Thereafter	133,894
Total	$ 227,211

Lines of Credit and Long Term Debt - Lines of Credit - Additional Information (Details) - Revolving Credit Facility	12 Months Ended
	Dec. 31, 2017 USD ($)
Trans Ova Genetics, LC \| First National Bank of Omaha
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 5,000,000
Line of credit facility, interest rate at period end	4.32%
Line of credit outstanding	$ 0
Trans Ova Genetics, LC \| First National Bank of Omaha \| London Interbank Offered Rate (LIBOR)
Line of Credit Facility [Line Items]
Debt instrument, basis spread on variable rate	2.95%
Exemplar Genetics, LLC \| American State Bank
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 700,000
Debt instrument, interest rate, stated percentage	5.25%
Line of credit outstanding	$ 233,000
Minimum \| Trans Ova Genetics, LC \| First National Bank of Omaha
Line of Credit Facility [Line Items]
Debt instrument, interest rate, stated percentage	3.00%

Lines of Credit and Long Term Debt - Components of Long Term Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Long term debt	$ 8,037	$ 7,948
Less current portion	502	386
Long term debt, less current portion	7,535	7,562
Notes payable
Debt Instrument [Line Items]
Long term debt	5,010	5,453
Royalty-based financing
Debt Instrument [Line Items]
Long term debt	2,132	1,896
Other
Debt Instrument [Line Items]
Long term debt	$ 895	$ 599

Lines of Credit and Long Term Debt - Long Term Debt - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2013
Debt Instrument [Line Items]
Long term debt	$ 8,037	$ 7,948
Notes payable to banks \| Trans Ova Genetics, LC \| American State Bank
Debt Instrument [Line Items]
Long term debt	4,872
Debt instrument, periodic payment	$ 39
Debt instrument, interest rate, stated percentage	3.95%
Notes payable
Debt Instrument [Line Items]
Long term debt	$ 5,010	5,453
Other
Debt Instrument [Line Items]
Long term debt	895	599
Royalty-based financing
Debt Instrument [Line Items]
Long term debt	2,132	$ 1,896
Royalty-based financing \| AquaBounty Technologies, Inc. \| Atlantic Canada Opportunities Agency
Debt Instrument [Line Items]
Long term debt	2,132
Amount available under the grant for research and development	$ 2,288
Claims period	5 years
Royalty on products	10.00%
Amount claimed			$ 1,952
Long term debt			1,107
Accreted difference between face value of amount drawn and acquisition date fair value			$ 845

Lines of Credit and Long Term Debt - Schedule of Future Maturities of Long Term Debt (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Debt Disclosure [Abstract]
2018	$ 502
2019	401
2020	372
2021	832
2022	360
Thereafter	3,438
Total	$ 5,905

Income Taxes - Components of Loss Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax [Line Items]
Loss before income taxes	$ (129,700)	$ (194,151)	$ (86,978)
Domestic
Income Tax [Line Items]
Loss before income taxes	(71,343)	(157,067)	(69,287)
Foreign
Income Tax [Line Items]
Loss before income taxes	$ (58,357)	$ (37,084)	$ (17,691)

Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
U.S. federal income taxes:
Current	$ 27	$ (17)	$ 22
Deferred	(523)	1,396	1,732
Foreign income taxes:
Current	(379)	(393)	(123)
Deferred	(2,269)	(5,177)	(1,003)
State income taxes:
Deferred	264	314	388
Total income tax expense (benefit)	$ (2,880)	$ (3,877)	$ 1,016

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Computed statutory income tax benefit	$ (44,098)	$ (66,011)	$ (29,573)
State and provincial income tax benefit, net of federal income taxes	(3,294)	(7,905)	(3,157)
Nondeductible stock based compensation	4,147	3,321	3,182
Nondeductible officer compensation	476	0	2,433
Gain on dividend distribution of AquaBounty common stock	3,965	0	0
Impairment of goodwill	4,700	0	0
Research and development tax incentives	(1,166)	(6,350)	(348)
Acquisition and internal restructuring transaction costs	354	571	883
Provisional impact of the Tax Act	85,288	0	0
Enacted changes in foreign tax rates and foreign tax reforms	2,138	0	(961)
U.S.-foreign rate differential	5,410	3,463	620
Other, net	(64)	1,485	(98)
Income tax reconciliation income tax benefit before valuation allowance, total	57,856	(71,426)	(27,019)
Change in valuation allowance for deferred tax assets	(60,736)	67,549	28,035
Total income tax expense (benefit)	$ (2,880)	$ (3,877)	$ 1,016

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets
Allowance for doubtful accounts	$ 1,300	$ 1,676
Inventory	489	447
Equity securities and investments in affiliates	17,510	31,729
Accrued liabilities and long-term debt	3,131	4,168
Stock-based compensation	26,936	8,460
Deferred revenue	61,785	68,056
Research and development tax credits	11,385	10,396
Net operating and capital loss carryforwards	111,453	144,502
Total deferred tax assets	233,989	269,434
Less: Valuation allowance	215,582	256,165	$ 190,174	$ 161,660
Net deferred tax assets	18,407	13,269
Deferred tax liabilities
Property, plant and equipment	237	406
Intangible assets	33,790	29,870
Total deferred tax liabilities	34,027	30,276
Net deferred tax liabilities	$ (15,620)	$ (17,007)

Income Taxes - Summary of Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Valuation Allowance
Valuation allowance at beginning of year	$ 256,165	$ 190,174	$ 161,660
Mergers and acquisitions, net	0	(1,416)	1,228
Current year operations	26,619	67,549	28,035
Adoption of ASU 2016-09	17,843	0	0
Provisional impact of the Tax Act	(87,473)	0	0
Changes in foreign tax rates and foreign tax reforms	1,327	0	0
Foreign currency translation adjustment	1,101	(142)	(749)
Valuation allowance at end of year	$ 215,582	$ 256,165	$ 190,174

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2013
Operating Loss Carryforwards [Line Items]
Federal corporate income tax rate	34.00%	34.00%	34.00%
Federal and state research and development tax credits	$ 11,385	$ 10,396
Retained earnings (accumulated deficit)	(847,820)	(729,341)
Estimated tax benefit upon enactment of Tax Act	2,185
Change in deferred tax assets resulting from enactment of Tax Act	87,473
Estimated tax benefit due to changes in deferred tax liabilities upon enactment of Tax Act	1,730
Estimated current tax benefit upon enactment of Tax Act	455
Provisional transition tax amount	0
Additional deferred tax liabilities recorded due to enacted foreign tax changes	15,620	$ 17,007
AquaBounty Technologies, Inc.
Operating Loss Carryforwards [Line Items]
Annual usage limit of operating loss carryforwards	$ 900
Expiration date of Federal income tax loss carryforwards	2018
Ownership percentage in AquaBounty (more than)				50.00%
Foreign Subsidiaries
Operating Loss Carryforwards [Line Items]
Retained earnings (accumulated deficit)	$ 65,052
Domestic
Operating Loss Carryforwards [Line Items]
Net operating losses inherited via acquisition	33,590
Operating loss carryforwards	244,274
Federal and state research and development tax credits	$ 7,737
Expiration date of Federal income tax loss carryforwards	2022
Domestic \| GenVec, Inc.
Operating Loss Carryforwards [Line Items]
Net operating losses inherited via acquisition	$ 13,376
Domestic \| AquaBounty Technologies, Inc.
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	28,209
Foreign
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	151,423
Foreign \| AquaBounty Technologies, Inc.
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	15,653
Tax credit	2,832
BELGIUM
Operating Loss Carryforwards [Line Items]
Additional deferred tax liabilities recorded due to enacted foreign tax changes	$ 2,307

Shareholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended					12 Months Ended
	Dec. 31, 2017	Jan. 31, 2017	Aug. 31, 2015	Jun. 30, 2015	Jan. 31, 2015	Dec. 31, 2017	Dec. 31, 2015
Class of Stock [Line Items]
Shares issued in public or private offerings, net of issuance costs, shares	1,207,980		5,609,756		4,312,500
Value of shares issued in public or private offerings	$ 13,686		$ 218,193		$ 110,041	$ 13,686	$ 328,234
Underwriting discounts and commissions			11,500		6,086
Capitalized offering expenses			$ 306		$ 311
Noncash dividend to shareholders						$ 0	172,419
Affiliates Of Third Security
Class of Stock [Line Items]
Shares issued in public or private offerings, net of issuance costs, shares					555,556
AquaBounty Technologies, Inc.
Class of Stock [Line Items]
Noncash dividend, shares		1,776,557
Noncash dividend to shareholders		$ 22,385
ZIOPHARM Oncology, Inc.
Class of Stock [Line Items]
Noncash dividend, shares				17,830,305
Realized investment gain							$ 81,401
Intrexon Stock Option Plans
Class of Stock [Line Items]
Adjustment due to dividend (in shares)						46,766	312,795
Adjustment due to dividend (in usd per share)						$ 31.11	$ 25.40

Shareholders' Equity - Components of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrexon shareholders' equity	$ 533,631	$ 560,237
Unrealized loss on investments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrexon shareholders' equity	(2)	(89)
Loss on foreign currency translation adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrexon shareholders' equity	(15,552)	(36,113)
Total accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Intrexon shareholders' equity	$ (15,554)	$ (36,202)

Share-Based Payments - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation cost	$ 41,576	$ 42,202	$ 38,667
Cost of products
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation cost	116	81	95
Cost of services
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation cost	322	274	354
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation cost	9,336	9,251	8,614
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation cost	$ 31,802	$ 32,596	$ 29,604

Share-Based Payments - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Nov. 30, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Mar. 31, 2016	Dec. 31, 2014	Aug. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as payment for services		$ 11,118	$ 10,777	$ 2,169
Intrexon Stock Option Plan - 2008 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)							0
Options outstanding (in shares)		453,371
Intrexon Stock Option Plan - 2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)		4,747,496
Options outstanding (in shares)		10,929,376
Number of authorized awards (in shares)		18,000,000
Intrexon Stock Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)		11,382,747	11,640,383	11,043,528		8,323,544
Term at issuance of option		10 years
Vesting period of option		4 years
Unrecognized compensation costs related to unvested awards		$ 68,999
Recognized over weighted-average period		2 years
Weighted average grant date fair value of options granted (in usd per share)		$ 12.19	$ 16.28	$ 25.96
Aggregate intrinsic value of options exercised		$ 2,429	$ 22,704	$ 24,675
Options outstanding, weighted average exercise price (in usd per share)		$ 28.99	$ 31.25	$ 32.66		$ 22.59
Options exercisable (in shares)		5,306,697
Aqua Bounty 2006 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining shares available to grant (in shares)					0
Aqua Bounty Stock Option Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)		227,203	185,591
Options outstanding, weighted average exercise price (in usd per share)		$ 9.39	$ 7.89
Options exercisable (in shares)		192,748	181,766
Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Monthly base salary		$ 200
Lock-up period		3 years
Term of compensation arrangement	12 months
Selling, general and administrative \| Chief Executive Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as payment for services		$ 1,908	$ 1,861	$ 314

Share-Based Payments - Intrexon Stock Option Plans - Schedule of Stock Option Activity (Details) - Intrexon Stock Option Plans - $ / shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Number of Shares
Balances at beginning of period (in shares)	11,640,383	11,043,528	8,323,544
Granted (in shares)	3,920,950	4,644,860	5,051,500
Adjustment due to dividend (in shares)	46,766		312,795
Exercised (in shares)	(149,429)	(1,210,840)	(1,029,291)
Forfeited (in shares)	(3,797,105)	(2,760,809)	(1,610,335)
Expired (in shares)	(278,818)	(76,356)	(4,685)
Balances at period end (in shares)	11,382,747	11,640,383	11,043,528	8,323,544
Weighted Average Exercise Price (usd per share)
Balances at beginning of period (in usd per share)	$ 31.25	$ 32.66	$ 22.59
Granted (in usd per share)	21.47	29.39	45.82
Adjustment due to dividend (in usd per share)	31.11		25.40
Exercised (in usd per share)	(6.37)	(15.83)	(15.16)
Forfeited (in usd per share)	(28.37)	(40.34)	(26.75)
Expired (in usd per share)	(33.18)	(37.81)	(28.29)
Balances at period end (in usd per share)	$ 28.99	31.25	$ 32.66	$ 22.59
Additional Disclosures
Exercisable at period end (in shares)	5,306,697
Options exercisable, weighted average exercise price (in usd per share)	$ 29.96	$ 28.09
Balances at period end, weighted average remaining contractual period	7 years 3 months 25 days	8 years 2 months 15 days	8 years 5 months 27 days	8 years 7 months 21 days
Exercisable at period end, weighted average remaining contractual period	6 years 1 month 20 days

Share-Based Payments - Intrexon Stock Option Plans - Summary of Information About Stock Options Outstanding (Details) - Intrexon Stock Option Plans - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options outstanding, number of options (in shares)	11,382,747	11,640,383
Options outstanding, weighted average exercise price (in usd per share)	$ 28.99	$ 31.25	$ 32.66	$ 22.59
Options outstanding, weighted average remaining life (in years)	7 years 3 months 25 days	8 years 2 months 15 days
Options outstanding, aggregate intrinsic value	$ 2,020	$ 14,969
Options exercisable, number of options (in shares)	5,306,697	3,418,035
Options exercisable, weighted average exercise price (in usd per share)	$ 29.96	$ 28.09
Options exercisable, weighted average remaining life (in years)	6 years 1 month 20 days	6 years 10 months 17 days
Options exercisable, aggregate intrinsic value	$ 2,020	$ 11,852
Price range 1
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 2.64	$ 2.65
Stock options, exercise price range, upper limit (in usd per share)	$ 9.30	$ 9.34
Options outstanding, number of options (in shares)	453,371	562,951
Options outstanding, weighted average exercise price (in usd per share)	$ 7.06	$ 6.23
Options outstanding, weighted average remaining life (in years)	3 years 11 months 10 days	4 years 1 month 18 days
Options outstanding, aggregate intrinsic value	$ 2,020	$ 10,172
Options exercisable, number of options (in shares)	453,371	525,755
Options exercisable, weighted average exercise price (in usd per share)	$ 7.06	$ 6.01
Options exercisable, weighted average remaining life (in years)	3 years 11 months 10 days	3 years 11 months 20 days
Options exercisable, aggregate intrinsic value	$ 2,020	$ 9,615
Price range 2
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 12.50	$ 15.21
Stock options, exercise price range, upper limit (in usd per share)	$ 21.38	$ 27.19
Options outstanding, number of options (in shares)	3,158,121	2,785,705
Options outstanding, weighted average exercise price (in usd per share)	$ 20.58	$ 23.47
Options outstanding, weighted average remaining life (in years)	8 years 8 months 25 days	8 years 5 months 45 days
Options outstanding, aggregate intrinsic value	$ 0	$ 4,797
Options exercisable, number of options (in shares)	456,942	684,704
Options exercisable, weighted average exercise price (in usd per share)	$ 19.52	$ 21.07
Options exercisable, weighted average remaining life (in years)	7 years 1 month 18 days	7 years 3 months 15 days
Options exercisable, aggregate intrinsic value	$ 0	$ 2,237
Price range 3
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 21.43	$ 27.21
Stock options, exercise price range, upper limit (in usd per share)	$ 28.81	$ 29.68
Options outstanding, number of options (in shares)	3,399,721	3,147,242
Options outstanding, weighted average exercise price (in usd per share)	$ 25.55	$ 29.30
Options outstanding, weighted average remaining life (in years)	6 years 10 months 28 days	7 years 5 months 42 days
Options outstanding, aggregate intrinsic value	$ 0	$ 0
Options exercisable, number of options (in shares)	1,804,401	1,400,707
Options exercisable, weighted average exercise price (in usd per share)	$ 25.86	$ 29.35
Options exercisable, weighted average remaining life (in years)	5 years 7 months 38 days	7 years 3 months 22 days
Options exercisable, aggregate intrinsic value	$ 0	$ 0
Price range 4
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 28.88	$ 29.70
Stock options, exercise price range, upper limit (in usd per share)	$ 40.99	$ 42.22
Options outstanding, number of options (in shares)	2,751,716	3,590,423
Options outstanding, weighted average exercise price (in usd per share)	$ 32.07	$ 32.89
Options outstanding, weighted average remaining life (in years)	6 years 8 months 12 days	9 years 33 days
Options outstanding, aggregate intrinsic value	$ 0	$ 0
Options exercisable, number of options (in shares)	1,732,250	345,274
Options exercisable, weighted average exercise price (in usd per share)	$ 31.51	$ 37.06
Options exercisable, weighted average remaining life (in years)	6 years 3 months 25 days	6 years 10 months 6 days
Options exercisable, aggregate intrinsic value	$ 0	$ 0
Price range 5
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock options, exercise price range, lower limit (in usd per share)	$ 41.41	$ 43.99
Stock options, exercise price range, upper limit (in usd per share)	$ 65.08	$ 65.34
Options outstanding, number of options (in shares)	1,619,818	1,554,062
Options outstanding, weighted average exercise price (in usd per share)	$ 53.52	$ 54.40
Options outstanding, weighted average remaining life (in years)	7 years 5 months 2 days	8 years 4 months 35 days
Options outstanding, aggregate intrinsic value	$ 0	$ 0
Options exercisable, number of options (in shares)	859,733	461,595
Options exercisable, weighted average exercise price (in usd per share)	$ 53.07	$ 53.06
Options exercisable, weighted average remaining life (in years)	7 years 4 months 18 days	8 years 3 months 30 days
Options exercisable, aggregate intrinsic value	$ 0	$ 0

License Agreement - Additional Information (Details)	1 Months Ended
License Agreement - Additional Information (Details)	Jan. 31, 2015 USD ($) shares
Other Commitments [Line Items]
Shares issued as consideration for licensing agreement, shares \| shares	2,100,085
Research and development
Other Commitments [Line Items]
Payment of license fees	$ 59,579,000
ZIOPHARM Oncology, Inc.
Other Commitments [Line Items]
Annual funding commitment, term	3 years
Minimum \| ZIOPHARM Oncology, Inc.
Other Commitments [Line Items]
Annual funding commitment, amount	$ 15,000,000
Maximum \| ZIOPHARM Oncology, Inc.
Other Commitments [Line Items]
Annual funding commitment, amount	$ 20,000,000

Commitments and Contingencies - Future Minimum Lease Payments Under Noncancelable Operating Leases (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2018	$ 7,964
2019	9,115
2020	9,186
2021	8,299
2022	7,279
Thereafter	26,044
Future minimum lease payments under operating leases, total	$ 67,887

Commitments and Contingencies - Operating Leases - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Leases [Abstract]
Rent expense, including other facility expenses	$ 11,064	$ 8,593	$ 8,610
Rental income under sublease agreement	137	$ 1,051	$ 1,486
Expected future rental income under sublease agreement, 2018	104
Expected future rental income under sublease agreement, 2019	120
Expected future rental income under sublease agreement, 2020	55
Expected future rental income under sublease agreement, 2021	56
Expected future rental income under sublease agreement, 2022	58
Expected future rental income under sublease agreement, thereafter	$ 310

Commitments and Contingencies - Purchase Commitments (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Outstanding contractual purchase commitments	$ 15,802

Commitments and Contingencies - Additional Information (Details) $ in Thousands	1 Months Ended				2 Months Ended	12 Months Ended		50 Months Ended
	Mar. 31, 2017 claim	Jul. 31, 2016 claim	May 31, 2016 claim	Apr. 30, 2016 USD ($)	Jul. 31, 2016 claim	Dec. 31, 2017 claim	Dec. 31, 2016 USD ($)	Apr. 30, 2016 USD ($)
Licensing and patent infringement suit
Loss Contingencies [Line Items]
Damages awarded to TransOva \| $				$ 528
Cumulative payments for royalties \| $								$ 3,170
Royalty payments not yet deposited \| $				2,759				$ 2,759
Hoffman v Intrexon Corporation et al. and Gibrall v. Intrexon Corporation et al.
Loss Contingencies [Line Items]
Number of lawsuits			2
Shareholder demand regarding Third Security Services Agreement and CEO Compensation
Loss Contingencies [Line Items]
Number of similar lawsuits		2
Shareholder demand regarding allegations made by Seeking Alpha financial blog
Loss Contingencies [Line Items]
Number of lawsuits	1				2
XY, LLC \| Licensing and patent infringement suit
Loss Contingencies [Line Items]
Damages awarded against TransOva \| $				$ 6,066
Claims dismissed						9
Total claims						12
Claims pending resolution						3
Selling, general and administrative \| Licensing and patent infringement suit
Loss Contingencies [Line Items]
Litigation settlement expense \| $							$ 4,228

Related Party Transactions - Additional Information (Details)				1 Months Ended								12 Months Ended
	Jan. 19, 2018	Apr. 24, 2017	Mar. 10, 2017	Dec. 31, 2017 USD ($)	Oct. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Jun. 30, 2016 $ / shares shares	Nov. 30, 2015 USD ($)	Jul. 31, 2015 $ / shares shares	Mar. 31, 2015 USD ($) shares	Feb. 28, 2015 USD ($)	Dec. 31, 2017 USD ($) shares	Dec. 31, 2016 USD ($) shares	Dec. 31, 2015 USD ($) shares
Related Party Transaction [Line Items]
Sublease rental income												$ 137,000	$ 1,051,000	$ 1,486,000
Purchases of property and equipment												46,666,000	31,629,000	12,749,000
Shares issued as payment for services												11,118,000	10,777,000	2,169,000
Fair value of assets				$ 183,173,000		$ 335,307,000						183,173,000	335,307,000
Purchase of preferred stock												1,161,000	2,308,000	17,080,000
Other nonoperating income												1,013,000	1,700,000	1,314,000
ZIOPHARM Oncology, Inc.
Related Party Transaction [Line Items]
Common stock purchased from collaborative partners, value											$ 12,600,000
AmpliPhi Biosciences Corp
Related Party Transaction [Line Items]
Common stock purchased from collaborative partners, shares \| shares										27,879
Warrants purchased from collaborative partners, shares \| shares										6,969
Purchase of preferred stock										$ 2,300,000
Oragenics, Inc.
Related Party Transaction [Line Items]
Common stock purchased from collaborative partners, shares \| shares							226,142
Price per share of common shares (in usd per share) \| $ / shares							$ 5.20
Intrexon Energy Partners, LLC
Related Party Transaction [Line Items]
Purchases of property and equipment				2,812,000
Third Security
Related Party Transaction [Line Items]
Expense for services												409,000	309,000	428,000
Sublease rental income												$ 43,000	$ 43,000	$ 43,000
Services agreement, term								1 year
Shares issued as compensation for services, shares \| shares												500,650	337,163	48,678
Shares issued as payment for services												$ 8,704,000	$ 8,571,000	$ 1,375,000
Harvest Intrexon Enterprise Fund I, LP
Related Party Transaction [Line Items]
Other nonoperating income												1,839,000	2,483,000	$ 1,349,000
Fibrocell Science, Inc.
Related Party Transaction [Line Items]
Common stock purchased from collaborative partners, shares \| shares									125,290
Price per share of common shares (in usd per share) \| $ / shares									$ 17.4
Series A Preferred Shares
Related Party Transaction [Line Items]
Convertible Preferred Shares, Conversion Price, Consecutive Trading Days					20 days
Series A Preferred Shares \| Affiliates Of Third Security
Related Party Transaction [Line Items]
Convertible Preferred Stock, Amount Authorized					$ 100,000,000
Preferred stock, dividend rate, percentage					8.00%
Common Stock \| Third Security
Related Party Transaction [Line Items]
Expense for services								$ 800,000
Warrants \| AmpliPhi Biosciences Corp
Related Party Transaction [Line Items]
Purchase of preferred stock										321,000
Common Stock \| AmpliPhi Biosciences Corp
Related Party Transaction [Line Items]
Purchase of preferred stock										$ 1,979,000
Other assets \| Convertible note and warrants \| Fibrocell Science, Inc.
Related Party Transaction [Line Items]
Fair value of assets				$ 575,000		1,642,000						$ 575,000	$ 1,642,000
AmpliPhi Biosciences Corp
Related Party Transaction [Line Items]
Stockholders' equity, reverse stock split		1-for-10
Stockholders' equity reverse stock split conversion ratio		0.1
Fibrocell Science, Inc.
Related Party Transaction [Line Items]
Preferred stock, dividend rate, percentage												4.00%
Stockholders' equity, reverse stock split			1-for-3
Stockholders' equity reverse stock split conversion ratio			0.3333
Third Security \| Chief Executive Officer
Related Party Transaction [Line Items]
Ownership interest				100.00%								100.00%
AmpliPhi Biosciences Corp
Related Party Transaction [Line Items]
Realized investment (gain) loss						$ 4,098,000
Subsequent Event \| Oragenics, Inc.
Related Party Transaction [Line Items]
Stockholders' equity, reverse stock split	1-for-10
Stockholders' equity reverse stock split conversion ratio	0.1

Net Loss per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2017

^[1]

Sep. 30, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Numerator:

Net loss attributable to Intrexon

$ (27,266)

$ (39,689)

$ (18,664)

$ (31,399)

$ (44,137)

$ (28,982)

$ (49,064)

$ (64,429)

$ (117,018)

$ (186,612)

$ (84,493)

Denominator:

Weighted average shares outstanding, basic and diluted

119,998,826

117,983,836

111,066,352

Net loss attributable to Intrexon per share, basic and diluted

$ (0.23)

$ (0.33)

$ (0.16)

$ (0.26)

$ (0.37)

$ (0.24)

$ (0.42)

$ (0.55)

$ (0.98)

$ (1.58)

$ (0.76)

[1]

Net Loss per Share - Potentially Dilutive Securities Excluded from Calculation of Net Loss per Share (Details) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	11,516,011	11,640,383	11,238,247
Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	11,382,747	11,640,383	11,043,528
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	133,264	0	194,719

Quarterly Financial Information (Unaudited) - Schedule of Quarterly Financial Information (Details) - USD ($)
$ / shares in Units, $ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2017

^[1]

Sep. 30, 2017

Jun. 30, 2017

Mar. 31, 2017

Dec. 31, 2016

Sep. 30, 2016

Jun. 30, 2016

Mar. 31, 2016

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Quarterly Financial Information Disclosure [Abstract]

Total revenues

$ 77,028

$ 46,016

$ 54,433

$ 53,504

$ 46,002

$ 48,985

$ 52,501

$ 43,438

$ 230,981

$ 190,926

$ 173,605

Operating loss

(26,492)

(44,747)

(35,270)

(31,381)

(32,590)

(28,821)

(23,222)

(40,533)

(137,890)

(125,166)

(146,864)

Net loss

(33,945)

(40,836)

(19,662)

(32,377)

(44,912)

(30,011)

(50,031)

(65,320)

(126,820)

(190,274)

(87,994)

Net loss attributable to Intrexon

$ (27,266)

$ (39,689)

$ (18,664)

$ (31,399)

$ (44,137)

$ (28,982)

$ (49,064)

$ (64,429)

$ (117,018)

$ (186,612)

$ (84,493)

Net loss attributable to Intrexon per share, basic and diluted

$ (0.23)

$ (0.33)

$ (0.16)

$ (0.26)

$ (0.37)

$ (0.24)

$ (0.42)

$ (0.55)

$ (0.98)

$ (1.58)

$ (0.76)

[1]

Defined Contribution Plans - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Retirement Benefits [Abstract]
Defined contribution plans, cost recognized	$ 2,367	$ 1,857	$ 1,157

Subsequent Events - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended					2 Months Ended	12 Months Ended
	Jan. 31, 2018	Dec. 31, 2017	Jan. 31, 2017	Aug. 31, 2015	Jan. 31, 2015	Mar. 01, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Subsequent Event [Line Items]
Shares issued in public offering		1,207,980		5,609,756	4,312,500
Proceeds from shares issued in public offering							$ 0	$ 0	$ 328,234
Underwriting discounts and commissions				$ 11,500	$ 6,086
Capitalized offering expenses				$ 306	$ 311
Collaboration and licensing revenues							$ 145,579	109,871	$ 87,821
Subsequent Event
Subsequent Event [Line Items]
Proceeds from shares issued in public offering	$ 82,242
Underwriting discounts and commissions	3,688
Capitalized offering expenses	320
Affiliates Of Third Security
Subsequent Event [Line Items]
Shares issued in public offering					555,556
AquaBounty Technologies, Inc.
Subsequent Event [Line Items]
Purchase of additional equity of majority-owned subsidiary			$ 25,000
Parent ownership interest		58.00%					58.00%
AquaBounty Technologies, Inc. \| Subsequent Event
Subsequent Event [Line Items]
Purchase of additional equity of majority-owned subsidiary	$ 5,000
Parent ownership interest	53.00%
Common Stock
Subsequent Event [Line Items]
Shares issued in public offering							1,207,980		9,922,256
Common Stock \| Subsequent Event
Subsequent Event [Line Items]
Shares issued in public offering	6,900,000
Common Stock \| Affiliates Of Third Security \| Subsequent Event
Subsequent Event [Line Items]
Shares issued in public offering	1,000,000
Upfront and Milestone Payments
Subsequent Event [Line Items]
Collaboration and licensing revenues							$ 71,637	$ 34,433	$ 32,513
Upfront and Milestone Payments \| Upfront \| OvaScience, Inc. \| Subsequent Event
Subsequent Event [Line Items]
Collaboration and licensing revenues						$ 3,183